Role of acid sphingomyelinase in steatohepatitis by Fucho, Raquel
DEPARTMENT OF CELL DEATH AND PROLIFERATION, IIBB-CSIC 
UNIVERSITAT DE BARCELONA 
 
 
 
 
 
ROLE OF ACID SPHINGOMYELINASE 
IN STEATOHEPATITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raquel Fucho Salvador 
2013
?
DOCTORAL PROGRAM IN BIOMEDICINE 
 
 
 
 
 
ROLE OF ACID SPHINGOMYELINASE 
IN STEATOHEPATITIS 
 
A dissertation submitted to the Medical School of the University of Barcelona in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in Biology. 
 
 
 
 
By 
 
Raquel Fucho Salvador 
 
 
 
 
 
 
This thesis has been conducted under the supervision of Dra. Mª del Carmen García-
Ruiz and Dr. José Carlos Fernández-Checa Torres at the Department of Cell Death and 
Proliferation of the Institute of Biomedical Research of Barcelona (IIBB), Spanish 
National Research Council (CSIC). 
?
  
 
 
 
 
 
 
 
 
 
 
 
Als meus pares, 
al Trepi i al Quim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"Never, never, never give up" 
Winston Churchill 
?
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS
?
Sembla mentida que la tesi ja sigui una realitat. L'altre dia fent neteja a la meva antiga 
habitació de casa els pares vaig trobar el llibre de COU de Biologia i en obrir-lo, just vaig 
anar a petar a una pàgina que parlava dels esfingolípids! Això ve de lluny! No vaig poder 
evitar pensar en el llarg camí que m'ha dut a defensar la tesi. Ha estat un camí ple 
d'aventures, reptes i vivències compartides amb gent que m'estimo i que m'ha ajudat a 
créixer com a científic i sobretot, com a persona. És per això que abans de posar-me a 
parlar de lípids de noms impronunciables, voldria donar les gràcies a totes aquelles 
persones que m'han ajudat a arribar fins aquí. 
 
El camí de la meva tesi és una mica atípic i comença molt abans d'arribar al laboratori on 
sóc avui. Tornant al 2003, voldria agrair a tota la gent del Departament de Biologia 
Cel·lular de la Facultat de Medicina, grans i petits, per ser el meu primer contacte amb la 
investigació científica i donar-me una base sòlida com a investigadora que em va permetre 
accedir a la gran aventura que va ser Boston. En aquesta segona etapa, lluny de casa, és 
inevitable mencionar a en Gökhan. Gökhan, thanks for giving me a unic chance to live, 
breath and soak in your very special way of science making. Thanks for believing in this crazy 
Catalan girl! Katy and Masato San...there's a special thanks for you since my everyday in the lab 
is scented with your great scientific manners. Cem, your are an endless source of animal wisdom 
and always ready to share. MegGus... what can I say, I miss you! Specially our talks in the coffe 
room. Thanks to all G.S.H. lab for an amazing adventure and making me an appealing 
candidate for my PhD hunt! 
 
I ara sí, Checa lab! Voldria agrair als meus directors de tesi, la Carmen i en Carlos, per 
donar-me l'oportunitat d'entrar a formar part del seu gran laboratori. Per entendre la 
meva carrera atípica i donar-me llibertat suficient per créixer. A nivell personal m'heu 
donat suport sempre que l'he necessitat. Carmen, tothom sap que estàs feta un belluguet 
però ets una marassa i sé que si mai em passa res en podem parlar tot fent un cafetó. 
Gràcies també per donar-me una visió més amplia del que representa ser mare 
investigadora... A l'Albert, l'Anna i la Montse per mostrar-me la diversitat del grup i 
atendre les meves consultes. Als Post Docs del lab, començant per la Clàudia, em va 
ajudar molt parlar amb tu al principi del doctorat. A la Conde, pel seu "desparpajo" 
explicant les coses del dia a dia. I al Vicent, per escoltar-me, discutir sobre ciència i 
ajudar-me en aquesta última etapa sempre aportant bon humor. "Serà, s-QUIM milk"? 
?Als nou vinguts, Álvaro, Guille i Sandra. Molta sort en el vostre doctorat. No us adormiu 
però sobretot gaudiu d'aquests anys que passen molt ràpid! Dels principis del doctorat, a 
Laura Llacuna per fer-me riure fins a no poder més. A l'Anna Moles per ajudar-me, estar 
sempre a punt per ensenyar noves tècniques i portar-me a fer danses! A la Cris i a la 
Milica, ànims en la recta final. Milica, glamour girl... trobaré a faltar les nostres converses 
de "treinta-añeras" que dius tu. A la Bet, pel seu entusiasme en vers la ciència. A la Laura 
Martínez, la "Profeeeeeessional"... què vols que et digui "equipo ceramidas"... t'he de 
donar les gràcies per saltar en aquesta última etapa i estirar juntes del carro. "Señorita! 
Puedo subir al estrado? tarariiiii-rora!" Admiro la teva voluntat i decisió a l'hora de fer les 
coses que de ben segur et portarà lluny. Molta sort en la recta final i salutacions al 
Summers, que mai se sap ;).  
 
A la Ferni, perquè és tota una institució! I de ben segur tothom sabrà qui ets en les 
futures generacions Checa lab! Merci per cuidar-me amb pometes àcides i orxates de lo 
tió Che en plena etapa "antojil". A la Mati, perquè sense saber quina cara feia, ja 
m'ajudava des de Boston per poder-me matricular del màster. I com que no en vas tenir 
prou, em vas seguir aguantant durant tot el doctorat. Ai... Mati-Mati... merci per 
ensenyar-me a domar el confocal i agafar perspectiva quan les coses sembla que no van 
ben encarrilades. Crec que això és el que més li agrada al Quim de tu... que li dones 
molta pau :) Estic super contenta de veure't tan feliç amb el nou rumb que has triat tot i 
que perdem una gran científica. A la Natalia, que tot i venir uns mesos d'estada des de 
Mèxic, es va fer un lloc només arribar. A ver cuando vienes de visita y nos cocinas unas tingas 
y compramos unas camisetas que no se enchuequen! A la Bau... per ser la barreja perfecta de 
passió, coneixement i aptitud experimental i portar-ho amb elegància i humilitat. Merci 
per ajudar amb les meves <<Preguntes de Biòloga a Química Orgànica>>. Per les 
converses d'ascensor, per estar sempre a punt per escoltar, ajudar i ser tan detallista. Així 
un si que se sent estimat!  A la meva Nunu... Nuns... la persona més resolutiva i amb més 
capacitat de treball del món. Nuns, give me a 3! Des del primer dia de doctorat hem estat 
juntes. I quan més liada he estat, has aparegut no res i t'has quedat amb mi fins les tantes 
acabant coses. Quan passen aquestes coses te n'adones de la gent que de veritat compta. 
Si fins i tot m'has fet de revisora! Sense demanar res sempre m'ho has donat tot. Tinc 
molta sort d'haver-te conegut i de comptar amb la teva amistat. Dra. Tarrats, que no se't 
quedin aquests anglesos que et volem de tornada! Suuuuuuuuuu... Suuuu... Suuuu! A que 
te gasto el nombre! Un trosset d'aquesta tesi és teu. Com totes les tesis que es fan al 
laboratori. El més important que he après de tu és... que els hepatòcits de ratolí surten 
millor si t'has pres un cafè abans. Això no surt als protocols! No aconsegueixo visualitzar 
aquest lab sense tu.  A nivell organitzatiu i experimental. No hi ha tècnica del lab que no 
hagis fet i puguis ensenyar, i si se n'han de posar noves a punt, ets a la primera voluntària. 
D'aquella gent que deia que realment compta... dels que no et fallen mai... doncs la peti-
Su. I fora del lab... no conec dona més forta i noble. Que vals un imperi i és un honor 
tenir-te com a amiga. I la Ireneeee guapa! Guapa! Guapa! Una menció especial a totes les 
tietes científiques del Quim, perquè ell també té molta sort de tenir unes tietes que se 
l'estimen tant! Nenes, sóc molt afortunada d'haver-vos conegut i us trobaré molt a faltar, 
sobretot els nostres esmorzars en família, però això només és una etapa que tanquem per 
començar-ne una altre on seguirem trobant-nos i compartint noves vivències tot i que 
estiguem dispersades pel món ara mateix. Us estimo molt! 
 
Als amics que tot i no entendre massa el que vol dir treballar tantes hores, anar a veure 
ratolins en cap de setmana i tot per amor a l'art... sempre sou aquí per animar i distreure, 
que la vida és molt més que el lab! A les noies de danses amb les que cada dimarts 
desconnecto de tot.  A la Cheles, que des de Bio Cel·lular no hem perdut el contacte i 
sempre ets a prop per xerrar del que sigui tot fent una coke. A la Julie i el Galleguiño, la 
meva família Bostoniana. Galleguiño, Fuxiña vai ser Doutora! Jules, thanks for always caring 
and helping with silly English questions. I miss you guys and love you tons! A les Fenícies que 
tot i veure'ns poc, les nostres trobades són explosives com si no hagués passat el temps. Al 
Ten, la Marina, en Ruls, l'Olga, la Xaiet i en Katur pels "fungols" i les cases rurals 
compartides. A Sa Doctora pel Guyton. Al meu germanet postís, en Joan, per preguntar 
sempre com va tot i interessar-se genuïnament. A la Telli, per ser una marona i no 
abandonar-me quan he estat més immersa en la tesi. Merci per mantenir-me connectada! 
A la Carol i la Cris, pel seu suport incondicional i per uns esmorzars que han fet història. 
M'encanta saber que en 30 anys probablement farem el mateix però serem unes velletes! 
 
A la meva família, per saber qui sóc, estimar-me i valorar-me. Al Tòfol i a la Montse, pel 
seu suport i pels cangurs durant aquests últims mesos de tesi. Als millors avis del món, el 
Ramon, la Maria, el Nicanor i la Rosita... en breu tindreu el primer Doctor de la família. 
Al Dani, per mostrar-me la importància de ser meticulós i per seguir els "ups and downs" 
?de la tesi. Al Ramon i la Maria Rosa, per estimar-me i fer-me sentir estimada. Per donar-
me la possibilitat de dedicar-me estudiar i mostrar-me sempre el seu suport 
incondicional. Us estimo! 
 
Finalment, a les dues persones que més han viscut aquesta tesi. Els dos homes de la meva 
vida que em donen noves forces cada dia per enfrontar-me al que sigui. Quim, sens dubte 
el millor resultat de tota la tesi. Gràcies per esborrar amb somriure qualsevol cabòria i 
fer-me veure la vida amb uns altres ulls. La teva arribada ha estat el millor regal que he 
tingut mai. T'estimo boleta... Finalment, al Trepi, per donar-me fortalesa i tendresa. Per 
creure en mi. Per no deixar-me conformar amb el que és suficient i fer-me buscar 
l’excel·lència en el que faig. Gràcies per aguantar els moments més durs de la tesi i 
celebrar els més emocionants. Ets el millor company per a qualsevol viatge. T'estimo. 
 
 
 
Barcelona, Febrer 2013. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDEX
?
??
INDEX 
ABBREVIATIONS 
INTRODUCTION  (1) 
1.  THE LIVER (3) 
1.1. Microscopic organization of the liver (3) 
1.2. Liver cell types (5) 
1.3. Liver functions (7) 
2. FROM OBESITY TO NON-ALCOHOLIC FATTY LIVER DISEASE (12) 
2.1. Obesity (12) 
2.2. Adipose tissue during obesity  (13) 
2.2.1. Adipose tissue plasticity (13) 
2.2.2. Adipose tissue dysfunction (14) 
2.2.2.1. Inflammation (14) 
2.2.2.2. Macrophage infiltration (15) 
2.2.2.3.  Insulin resistance (16) 
2.3. Systemic implications of adipose tissue dysfunction (17) 
2.4. Non-Alcoholic Fatty Liver Disease (17) 
2.4.1. Natural history of NAFLD (17) 
2.4.2. Epidemiology of NAFLD (18) 
2.4.3. Hepatic lipid metabolism in NAFLD (20) 
2.4.3.1. FA uptake (21) 
2.4.3.2. de novo hepatic lipogenesis (23) 
2.4.3.3. FA oxidation (24) 
2.5. Hepatic lipotoxicity (25) 
2.5.1. FFAs (27) 
2.5.2. Ceramide (30) 
2.5.3. Free Cholesterol (32) 
2.6. NAFLD management (33) 
2.6.1. Lifestyle intervention (33)  
2.6.2. Insulin sensitizers (33) 
2.6.3. Antioxidants (33) 
2.6.4. PPAR agonists (34) 
?3. FROM ALCOHOLISM TO ALCOHOLIC LIVER DISEASE (35) 
3.1. Alcohol absorption, distribution and metabolism (36) 
3.1.1. Alcohol absorption (36) 
3.1.2. Alcohol tissue distribution (36) 
3.1.3. Hepatic alcohol metabolism (37) 
3.2. Natural history of Alcoholic Liver Disease (39) 
3.3. Epidemiology of ALD (40) 
3.4. Pathogenesis of ALD (40) 
3.4.1. Steatosis (40) 
3.4.1.1. Increased adipose tissue lipolysis (41) 
3.4.1.2. Altered redox state (41) 
3.4.1.3. PPAR? inhibition (41) 
3.4.1.4. TG export inhibition (41) 
3.4.2. Ethanol hepatotoxicity (42) 
3.4.2.1. Inhibition of methionine cycle (42) 
3.4.2.2. ER stress (43) 
3.4.2.3. Acetaldehyde (44) 
3.4.2.4. Oxidative stress (45) 
3.4.2.5. Mitochondrial cholesterol (46) 
3.4.2.6. Endotoxin activation of innate immunity (47) 
3.4.2.7. TNF-ASMase-Ceramide axis in ALD (48) 
3.5. Management of ALD (50) 
3.5.1. Abstinence (50) 
3.5.2. Corticosteroids (50) 
3.5.3. TNF-? blockage (51) 
3.5.4. SAMe (51) 
3.5.5. Antioxidants (51) 
3.5.6. Liver transplantation (52) 
4. ENDOPLASMATIC RETICULUM STRESS IN LIVER DISEASE (53) 
4.1. ER stress, inflammation and cell death (55) 
4.2. ER stress and lipogenesis (57) 
4.3. ER stress and fatty liver disease (57) 
??
5. AUTOPHAGY IN LIVER DISEASE (60) 
5.1. Autophagic machinery (62) 
5.2. Autophagy regulation (63) 
5.3. Macrolipophagy and NAFLD (65) 
5.4. Autophagy and lysosomal storage disorders (66) 
6. CERAMIDE & ACID SPHINGOMYELINASE IN METABOLIC DISEASES (68) 
6.1. Sphingolipids (68) 
6.2. Ceramide metabolism (69) 
6.3. Ceramide and disease (72) 
6.4. Acid sphingomyelinase (73) 
6.5. ASMase in hepatic injury and metabolic disorders (75)   
 
AIMS (79) 
METHODS AND MATERIALS (83) 
1. MOUSE MODELS (85) 
1.1. ASMase knockout mice (85) 
1.1.1. Breeding (85) 
1.1.2. DNA extraction (85) 
1.1.3. ASMase genotyping (86) 
1.2. TNFR1, TNFR2 and TNFR1/R2 knockout mice (87) 
1.3. Wild type mice (87) 
2. IN VIVO EXPERIMENTAL MODELS (88) 
2.1. Diet models of steatohepatitis (88) 
2.1.1. Diet-induced obesity model (88) 
2.1.2. MCD diet-induced NASH model (89) 
2.1.3. Hypercholesterolemic diet-induced steatohepatitis model (89) 
2.1.4. Alcohol-induced ASH model (90) 
2.2. In vivo treatment models (91) 
2.2.1. ASMase inhibition models (91) 
2.2.1.1. Amitriptyline in drinking water (92) 
2.2.1.2. Amitriptyline intra-peritoneal injection (92) 
2.2.2. Acute liver damage models (92) 
2.2.2.1. Lipopolisaccharide (92) 
?2.2.2.2. Concanavalin A (93) 
2.2.3. ER stress-induction model (93) 
2.3. Liver regeneration-Partial hepatectomy model (93) 
3. IN VIVO METABOLIC STUDIES (94) 
3.1. Blood glucose levels (94) 
3.2. Glucose tolerance test (94) 
3.3. Insulin tolerance test (94) 
3.4. Insulin portal vein infusion (95) 
4. SERUM ANALYSIS (95) 
4.1. Total cholesterol, HDL and LDL (95) 
4.2. Alanine transaminase (95) 
5. HISTOLOGY (96) 
5.1. Tissue harvesting and preservation (96) 
5.2. Stainings (96) 
5.2.1. Hematoxylin and Eosin staining (96) 
5.2.2. Oil-Red staining (98) 
5.2.3. Filipin staining (98) 
5.2.4. PCNA immuno staining (99) 
6. MITOCHONDRIAL ANALYSIS (102) 
6.1. Mitochondrial isolation (102) 
6.2. Mitochondrial free cholesterol quantification (103) 
6.3. Mitochondrial total GSH quantification (104) 
7. HEPATIC LIPID ANALYSIS (107) 
7.1. Hepatic triglycerides, free fatty acid and total cholesterol content (107) 
7.2. Hepatic total ceramide and S1P quantification by HPLC (107) 
7.3. Hepatic total sphingomyelin (108) 
7.4. Hepatic lipidomic analysis of ceramide fatty acid chains (109) 
8. HEPATIC ASMase ACTIVITY (110) 
9. METHIONINE METABOLISM (111) 
9.1. Serum homocysteine quantification (111) 
9.2. Hepatic SAM and SAH quantification (111) 
10. PROTEIN EXPRESSION ANALYSIS (112) 
10.1. Homogenization and lysis (112) 
??
10.2. Protein quantification (113) 
10.3. Sample preparation (114) 
10.4. Western blotting (115) 
10.5. Immunodetection- Primary and secondary antibodies (116) 
10.6. Development, image capturing and analysis (117) 
11. GENE EXPRESSION ANALYSIS (117) 
11.1. mRNA isolation and quantification (117) 
11.2. cDNA synthesis (129) 
11.3. Real time PCR (120) 
11.4. RT-PCR primers (122) 
12. CELL CULTURE (123) 
12.1. Primary mouse hepatocytes (123) 
12.1.1. Isolation (123) 
12.1.2. Culture (125) 
12.1.3. Treatments (127) 
12.1.3.1. Insulin stimulation (127) 
12.1.3.2. ER stress induction (127) 
12.1.3.3. Autophagic flux (127) 
12.1.3.4. Lysosomal membrane permeabilization (128) 
12.1.3.5. TNF-? stimulation (129) 
12.2. Hep G2 cell line (129) 
12.2.1. Culture (129) 
12.2.2. Treatments (130) 
12.2.2.1. Exogenous sphingomyelinases (130) 
12.2.2.2. Thapsigargin-induced Ca2+ release (130) 
12.2.2.3. Tunicamycin-TUDCA treatment (131) 
13. CELL DEATH (131) 
13.1. MTT (131) 
13.2. Trypan blue (132) 
14. CONFOCAL MICROSCOPY (132) 
14.1. Mitochondrial cholesterol (132) 
14.2. Lysosomal cholesterol (133) 
14.3. Autophagosome formation (134) 
?14.4. ER Ca2+ release (135) 
15. HUMAN SAMPLES (136) 
16. STATISTICS (136)  
 
RESULTS (137) 
AIM 1. Role of acid sphingomyelinase in non-alcoholic steatohepatitis (137) 
AIM 2. Role of acid sphingomyelinase in alcoholic steatohepatitis (158) 
 
DISCUSSION (177) 
CONCLUSIONS (189) 
BIBLIOGRAPHY (193)
? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS
?
ABBREVIATIONS 
?
?
3KSn- 3-keto-sphinganine 
ABCA1- ATP-binding cassette transporter 
ACC- acetyl-CoA carboxylase 
ADH- alcohol dehydrogenase 
AIF- apoptosis inducing factor  
ALD- alcoholic liver disease 
ALDH- acetaldehyde dehydrogenase 
ALT- alanine transaminase 
AMP-adenosyl monophosphate 
AMPK- AMP-activated protein kinase 
ApoB- apolipoprotein B 
ASH- alcoholic steatohepatitis 
ASMase- acid sphingomyelinase 
ASMase-/-- acid sphingomyelinase knockout mice 
ATF- activating transcription factor 
ATG- autophagy-related gene 
ATM- adipose tissue resident macrophages 
ATP- adenosyl triphosphate 
Bcl-2- B-cell lymphoma 2 
BHMT- betaine-homocysteine methyltransferase 
BMI- body mass index 
BSA- bovine serum albumin 
C1P- ceramide-1-phosphate 
CBS- cystathionine-?-synthase 
CDases- ceramidases 
CerS- ceramide synthase 
CHOP- C/EBP (CCAAT/enhancer binding protein) 
homologous protein 
CHQ- chloroquine 
ChREBP- carbohydrate-responsive element binding protein 
CK- ceramide kinase  
CLS- crown-like structures 
CMA- chaperone-mediated autophagy 
Con A- concanavalin A 
CPT1- carnitine palmitoyl transferase 1 
Ct- cycle threshold 
CTRL- control 
CVD- cardiovascular disease 
CYP2E1- cytochrome P450 enzymes 2E1 
DALY- disability-adjusted life years 
db/db- leptin receptor deficient mice 
DGAT- diacylglycerol acyltransferase 
DIO- diet-induced obesity 
DNL- de novo lipogenesis 
DR5- TRAIL receptor 5 
EDEM- endoplasmatic reticulum degradation enhancer, 
monnosidase alpha-like 1 
eIF2?- eukariotic translation factor 2 alpha 
ER- endoplasmatic reticulum 
ERAD- endoplasmatic reticulum associated degradation 
EtOH- ethanol-containing Lieber-DeCarli diet 
EWAT- epididymal white adipose tissue 
FA(s)- fatty acid(s) 
FABP- fatty acid binding protein 
FAS- fatty acid synthase 
FAT/CD36- FA translocase  
FATP- fatty acid transporter protein 
FBS- fetal bovine serum 
FC- free cholesterol 
FFA(s)- free fatty acid(s) 
FXR- farnesoid X receptor 
GADD34- DNA damage-inducible protein 34 
GCS- galactosyl ceramide synthases 
GR- GSH reductase  
GRP78- glucose-regulated protein 78 
GSH- glutathione 
GSLs- glycosphingolipids 
GSSG- oxidized GSH 
GTT- glucose tolerance test  
HCC- hepatocellular carcinoma 
HCD- hypercholesterolemic diet 
HDL- high-density lipoprotein 
HFD- high fat diet  
HHCy- hyperhomocysteinemia 
HPLC- high performance liquid chromatography 
HRP- horseradish peroxidase 
HSC- hepatic stellate cells 
IKK- I?B kinase 
IL-6- interleukin 6 
iNOS- nitric oxide synthase 
i.p.- intraperitoneal injection 
IR- insulin receptor 
I/R- ischemia/reperfusion 
IRE1?- inositol-requiring enzyme 1 alpha 
IRS- insulin receptor substrate 
ITT- insulin tolerance test  
i.v.- intravenous injection 
JNK- c-jun N-terminal kinase 
KC- Kupffer cells 
LC3- microtubule-associated protein1 light chain 3 
 
ABBREVIATIONS 
?
LCFA- long-chain fatty acids 
LDL- Low-density lipoprotein 
LDLR- LDL receptor 
LPS- lipopolysaccharide 
LXR- liver X receptor 
M6P- mannose 6 phosphate 
MAM- mitochondria associated membrane 
MAT- methionine adenosyltransferase 
MCD- methionine and choline deficient diet  
MCP-1- monocyte chemoattractant protein 1 
MDC- monodansylcadaverine 
MEOS- microsomal ethanol-oxidizing system 
mGSH- mitochondrial glutathione 
MS- methionine synthase 
MSDH- O-methyl-serine dodecylamide hydrochloride 
mtGPAT- mitochondrial glycerol- 3-phosphate-
acyltransferase 
MTP- microsomal triglyceride transfer protein 
MTT- 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
NAD+- oxidized nicotinamide adenine dinucleotide 
NADH- reduced nicotinamide adenine dinucleotide 
NAFLD- non-alcoholic fatty liver disease 
NASH- non-alcoholic steatohepatitis 
NF-?B- nuclear factor kappa B 
NO- nitric oxide 
NPC- Niemann-Pick type C disease 
NPD- Niemann-Pick disease 
NSMase- neutral sphingomyelinase 
ob/ob- leptin deficient mice 
PAS- phagophore assembly site 
PBS- phosphate buffered saline 
PCNA- proliferating cell nuclear antigen 
PDI- protein disulfide isomerase 
PE- phosphatidylethanolamine 
PERK- protein kinase double-stranded RNA-dependent-like  
ER kinase 
PFA- paraformaldehyde  
PH- partial hepatectomy 
PI3P- phosphatidylinositol 3-phosphate  
PPAR-? or ?- peroxisome proliferator-activating receptor 
alpha or gamma 
RAR- retinoic acid receptor 
RD- regular diet 
RIP- regulated intermembrane proteolysis 
ROS- reactive oxygen species 
 
RT-PCR- real time PCR 
S1P- sphingosine-1-phosphate 
sASMase- secreted ASMase 
SAH- S-adenosylhomocysteine 
SAM- S-adenosylmethionine 
SAMe- S-adenosyl-L-methionine 
SCAP- SREBP-cleavage activating protein 
SCD1- stearoyl-CoA desaturase 1 
SCWAT- subcutaneous white adipose tissue 
SEC- sinusoidal endothelial cells 
SERCA- sarco/endoplasmic reticulum calcium ATPase 
SH- steatohepatitis 
SLs- sphingolipids 
SM- sphingomyelin 
SMase- sphingomyelinase 
SMS- sphingomyelin synthase 
SOD- superoxid dismutase 
SPH- sphingosine 
SPT- serine palmitoyltransferase 
SREBP- strerol-regulatory element binding protein 
SubAB- AB5 subtilase cytotoxin 
T2DM- type 2 diabetes mellitus 
TBST- tris-buffered saline with tween 
TCA- tricarbocylic acid cycle 
TFAM- transcription factor A, mitochondrial 
Tg- thapsigargin  
TG(s)-triglyceride(s) 
TGF-?- transforming growth factor ? 
TLC- thin layer chromatography 
TLR- toll-like receptors 
Tm- tunicamycin 
TNFR- tumor necrosis factor receptor 
TNF-?- tumor necrosis factor alpha 
TRAF2- tumor necrosis factor receptor-associated factor 2 
TRB3- tribbles homolog 3 
TUDCA- tauroursodeoxycholic acid 
TZD- thiazolidinediones 
UCP- uncoupling protein 
UPR- unfolded protein response 
VLDL- very-low-density lipoprotein 
VPS- vacuolar protein sorting 
WHO- World Health Organization 
WT- wild type 
XPB1- X-box binding protein 1 
 1?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION
 2
 
INTRODUCTION 
? 3?
1. THE LIVER. 
The liver is the largest organ in the body, contributing about 2% of the total body 
weight, equivalent to 1.5 kg in the average adult human. The liver appears wedge shaped, 
with its base to the right and its apex projecting to the left as it extends between the right 
and left upper quadrants. At its upper pole, the liver makes direct contact with the 
diaphragm and at its lower pole, the liver lies on the stomach and intestine (Figure I-1. 
A). 
 
 
 
Figure I-1. A. Anterior view of liver in abdominal cavity.   
B. Liver lobes and ligaments (Talley, Lindor et al. 2010). 
 
The liver is divided into two principal lobes a large right lobe and a smaller left lobe by 
the falciform ligament, a fold of the mesentery (Figure I-1. B). Although the right lobe is 
considered by many anatomists to include an inferior quadrate lobe and a posterior 
caudate lobe, based on internal morphology (primarily the distribution of blood vessels), 
the quadrate and caudate lobes more appropriately belong to the left lobe. 
 
1.1. Microscopic organization of the liver: 
Structurally, the liver is composed of the following: 
• Parenchyma: consists of organized plates of hepatocytes or hepatic laminae, 
normally 1-2 cells thick (Figure I-2). These are specialized epithelial cells that 
make up about 80% of the volume of the liver and carry out most of the liver 
A
B
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functions. The hepatic laminae are bordered on either side by the endothelial-
lined vascular spaces called hepatic sinusoids. 
 
 
 
Figure I-2. Details of the histological components of the liver (J. Tortora and H. Derrickson 2009). 
 
• Connective tissue stroma: 
 Contains blood vessels, nerves, lymphatic vessels, and bile canaliculi. 
o Bile canaliculi are small ducts between hepatocytes that collect bile 
produced by the hepatocytes (Figure I-2). From bile canaliculi, bile will 
pass into different ducts until it enters the small intestine to participate in 
digestion. 
o The fibrous capsule of Glisson is a collagenous capsule that covers the 
external surface of the liver. 
 
• Sinusoidal capillaries or hepatic sinusoids: these are highly permeable blood 
capillaries characterized by the absence of tight junctions located between the 
hepatic laminae. The hepatic sinusoids receive oxygenated blood from branches of 
the hepatic artery and nutrient-rich deoxygenated blood from branches of the 
hepatic portal vein, which brings venous blood from the gastrointestinal organs 
and spleen into the liver. Hepatic sinusoids converge and deliver blood into a 
central vein (Figure I-3). From central veins the blood flows into the hepatic 
veins, which drain into the inferior vena cava. Also present in the hepatic 
sinusoids we can find the macrophages known as Kupffer cells.  
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Figure I-3.  Three-dimensional structure of a liver lobule (Adams and Eksteen 2006). 
 
 
• Perisinusoidal spaces or spaces of Disse: located between the sinusoidal 
endothelium and hepatocytes (Figure I-3). The Disse space is the site of exchange 
of materials between blood and liver cells. It lies between the basal surfaces of 
hepatocytes and the basal surfaces of endothelial cells and Kupffer cells that line 
the sinusoids. Proteins and lipoproteins synthesized by hepatocytes are 
transferred to the blood in the perisinusoidal space; this pathway is for liver 
secretions other than bile. In the Disse space we can find the hepatic stellate cells. 
 
The basic functional unit of the liver is the liver lobule, which is shaped like a hexagon. 
The liver lobule is constructed around a central vein that empties into the hepatic veins 
and then into the vena cava. The lobule itself is composed principally of many hepatic 
laminae that radiate from the central vein surrounded by hepatic sinusoids. In the middle 
of hepatic laminae, between the adjacent cells, lie small bile canaliculi that empty into 
bile ducts.  Located at three corners of the hexagon we can find a portal triad containing 
a bile duct, a portal vein branch and a hepatic arterial branch (Figure I-3). 
 
1.2. Liver cell types 
The liver is organized in different cell types: parenchymal cells or hepatocytes, and 
nonparenchymal cells, comprising sinusoidal endothelial cells (SEC), Kupffer cells (KC), 
and hepatic stellate cells (HSC). While hepatocytes occupy almost 80% of the total liver 
volume and perform the majority of numerous liver functions, nonparenchymal liver cells 
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are localized in the hepatic sinusoids and space of Disse and contribute only 6.5% to the 
liver volume, but 40% to the total number of liver cells. It has been increasingly 
recognized that both under normal and pathological conditions, substances released from 
neighboring nonparenchymal cells regulate many hepatocyte functions (Kmieć 2001). 
 
• Hepatocytes are the major functional cells of the liver and perform a wide array 
of metabolic, secretory, and endocrine functions. These large, polygonal and 
specialized epithelial cells represent most of the volume of the liver (Figure I-4). 
Their nuclei are large, spherical, and located in the center of the cell. In the adult 
liver, many cells are binucleate (this is particular so in mice hepatocytes). 
Cytoplasm is generally acidophilic. Hepatocytes are exceptionally active in 
synthesis of protein and lipids for export and as a consequence, ultrastructural 
examination of hepatocytes reveals large quantities of both rough and smooth 
endoplasmic reticulum. Hepatocytes typically contain many stacks of Golgi 
membranes. Golgi vesicles are particularly numerous nearby the bile canaliculi, 
reflecting transport of bile constituents into those channels. Numerous 
mitochondria can be observed (typically 1000/hepatocyte) and depending on the 
metabolic state of the cell large accumulations of glycogen and lipid droplets can 
be found as well (Kmieć 2001). 
• Sinusoidal endothelial cells (SEC) constitute the wall of the hepatic sinusoid  
(Figure I-4). Their key functional role relates to filtration due to the presence of 
small fenestrations that allow free diffusion of many substances and particles of 
sizes smaller than chylomicrons, between the blood and the hepatocyte surface. 
SEC exhibit a large endocytic capacity for many ligands including glycoproteins, 
components of the extracellular matrix, immune complexes, transferrin and 
ceruloplasmin. SEC may function as antigen-presenting cells. They are also active 
in the secretion of cytokines, eicosanoids, endothelin-1, nitric oxide, and some 
extracellular matrix components (Kmieć 2001).  
• Kupffer cells (KC) are tissue resident macrophages located in the hepatic 
sinusoids, especially in the periportal areas (Figure I-4). They have a pronounced 
endocytic and phagocytic capacity. KC are in constant contact with gut-derived 
particulate materials and soluble bacterial products. KC secrete potent mediators 
of the inflammatory response, and thus control the early phase of liver 
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inflammation, playing an important part in innate immune defense. High 
exposure of KC to bacterial products, especially endotoxin (lipopolysaccharide, 
LPS), can lead to the intensive production of inflammatory mediators, and 
ultimately to liver injury. KC also play an important role in the clearance of 
senescent and damaged erythrocytes. Moreover, during liver injury and 
inflammation, KC secrete enzymes and cytokines that may damage hepatocytes, 
and are active in the remodeling of extracellular matrix (Kmieć 2001). 
• Hepatic stellate cells (HSC) formerly known as fat-storing cells, Ito cells, 
lipocytes, perisinusoidal cells, or vitamin A-rich cells are located in the space of 
Disse (Figure I-4). They are characterized by abundance of intracytoplasmic fat 
droplets. In a normal liver HSC store vitamin A, control turnover of extracellular 
matrix, and regulate the contractility of sinusoids. Acute damage to hepatocytes 
promotes the transformation of quiescent stellate cells into myofibroblast-like 
cells with pro-fibrogenic functions that play a key role in the development of 
inflammatory fibrotic response (Kmieć 2001). 
 
 
Figure I-4.  Hepatic major cell types: hepatocytes, HSC in the Space of Disse, SEC forming the 
lining of the sinusoids and the hepatic macrophages, the KC situated in the sinusoids (Friedman 
2000). 
 
1.3. Liver functions 
The liver performs a vast number of functions, some of them essential for life, meaning 
that their impairment can lead to death in a few days. Following there is a summary of 
the most important liver functions: 
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• Carbohydrate metabolism: The liver is especially important for maintaining 
normal blood glucose levels.  
o Glycogen storage: Glycogenesis and storage of glycogen allows the liver 
to remove excess glucose from the blood and store it as glycogen. 
However, if glucose blood levels fall low hepatic stored glycogen is 
degraded (Glycogenolysis) and poured into blood. This is called the 
glucose buffer function of the liver. In a person with poor liver function, 
blood glucose concentration after a meal rich in carbohydrates may rise 
two to three times above physiological levels (C. Guyton and E. Hall 
2000). 
o Conversion of galactose and fructose into glucose. 
o Gluconeogenesis: is also important in maintaining normal blood glucose 
concentration when blood glucose concentration falls below normal 
levels. When this happens, large amounts of amino acids and glycerol 
from triglycerides (TGs) are converted into glucose, thereby helping to 
maintain a relatively normal blood glucose concentration (C. Guyton and 
E. Hall 2000). 
• Fat metabolism:  
o Fatty acid (FA) oxidation: this function allows supplying energy for other 
body functions. To derive energy from neutral fats, fat is first split into 
glycerol and FAs; FAs are metabolized via ?-oxidation primarily in 
mitochondria and its product can enter then the tricarboxylic acid (TCA) 
cycle producing a great amount of energy. ?-oxidation can take place in 
all cells of the body, especially in the hepatic cells. If the liver cannot use 
all the acetyl-coA generated from the ?-oxidation, it generates acetoacetic 
acid from the condensation of two acetyl-CoA molecules, which circulates 
in the blood to other tissues and serves as substrate for energy supply (C. 
Guyton and E. Hall 2000).  
o Synthesis of cholesterol, phospholipids and lipoproteins: 80% of the 
cholesterol synthesized in the liver is converted into bile salts, which are 
secreted into the bile; the rest is transported elsewhere in the form of 
lipoproteins. Phospholipids are likewise synthesized in the liver and 
transported principally in the lipoproteins. Both cholesterol and 
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phospholipids are key components of membrane bilayers and intracellular 
structures, and intermediates of important metabolic pathways (C. 
Guyton and E. Hall 2000). 
o de novo lipogenesis:  it the synthesis of fat from proteins and 
carbohydrates. Almost all the fat synthesis in the body from carbohydrates 
and proteins occurs in the liver. After fat is synthesized in the liver, it is 
transported in the very-low-density-lipoproteins (VLDL) to the adipose 
tissue to be stored (C. Guyton and E. Hall 2000). 
• Protein metabolism: 
o Deamination of amino acids: Deamination of amino acids is required 
before they can be used for energy or converted into carbohydrates or fats. 
o Formation of urea: this is an essential function to remove ammonia from 
the blood. The deamination process forms large amounts of ammonia, 
and additional amounts are continually formed in the gut by bacteria and 
then absorbed into the blood. Therefore, if the liver fails to generate urea, 
the plasma ammonia concentration rises rapidly resulting in 
encephalopathy and death (C. Guyton and E. Hall 2000).  
o Synthesis of plasma proteins: 90% of all the plasma proteins are formed 
in the liver. The remaining gamma globulins are the antibodies formed 
mainly by plasma cells in the lymph tissue of the body. The liver can form 
plasma proteins at a maximum rate of 15 to 50 g/day. Plasma protein 
depletion causes rapid mitosis of the hepatic cells and growth of the liver 
to a larger size (hepatomegaly); these effects are coupled with rapid 
output of plasma proteins until the plasma concentration returns to 
normal. With chronic liver disease, plasma proteins, such as albumin, may 
fall to very low levels (C. Guyton and E. Hall 2000). 
• Synthesis and secretion of bile: The liver synthesizes and secretes bile at a rate of 
600 and 1000 ml/day. Bile serves two important functions: 1) fat digestion and 
absorption because it helps to emulsify large fat particles into many minute 
particles so lipase enzymes can attack their surface and 2) bile serves as a means 
for excretion of several important waste products from the blood including 
bilirubin, and also cholesterol excess (C. Guyton and E. Hall 2000).  
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• Synthesis of coagulation factors: the liver synthesizes coagulation factors 
including fibrinogen, prothrombin, accelerator globulin, Factor VII among others. 
Vitamin K is required for liver metabolism and formation of coagulation factors.  
In the absence of vitamin K, the concentrations of these factors decrease 
markedly, and this can impair blood coagulation (C. Guyton and E. Hall 2000). 
• Vitamins reservoir: The vitamin stored in greatest quantity in the liver is vitamin 
A, but large quantities of vitamin D and vitamin B12 are normally stored as well. 
It also stores vitamin E and K. All these vitamins are released from the liver when 
needed elsewhere in the body (C. Guyton and E. Hall 2000). 
• Iron reservoir: Except for hemoglobin of the blood, the greatest proportion of 
iron in the body is stored in the liver in the form of ferritin. Hepatic cells contain 
large amounts of apoferritin, which binds to iron reversibly. Therefore, when iron 
is available in body fluids in extra quantities, it combines with apoferritin to form 
ferritin and is stored in this form in hepatocytes until needed elsewhere. When 
iron in the circulating body fluids reaches a low level, ferritin releases the iron (C. 
Guyton and E. Hall 2000).  
• Blood reservoir: the liver is an expandable venous organ and large quantities of 
blood can be stored in its blood vessels. Its normal blood volume is about 450 ml, 
almost 10% of the body’s total blood volume. The liver acts as a blood reservoir 
when blood volume is high and it is capable of supplying extra blood in times of 
diminished blood volume (C. Guyton and E. Hall 2000). 
• Blood cleansing: As blood flows through the intestinal capillaries it becomes 
enriched in bacteria derived from the gut. KC efficiently cleanse blood as it passes 
through the sinusoids. It has been estimated that less than 1% of the bacteria 
entering the portal blood from the gut succeed in passing through the liver into 
the systemic circulation (C. Guyton and E. Hall 2000). 
• Detoxification: the liver is able to detoxify and excrete many drugs and 
metabolites (i.e. alcohol, antibodies, etc) into the bile. In a similar manner, 
several of the hormones secreted by the endocrine glands are either chemically 
altered or excreted by the liver, including all the steroid hormones. Bilirrubin 
derived from the heme group of aged red blood cells is absorbed by the liver, 
secreted into the bile, metabolized in the small intestine and eliminated in the 
feces (C. Guyton and E. Hall 2000). 
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• Regulation of liver mass: Unlike other organs, the liver has the ability to 
regenerate itself and restore its original mass after significant hepatic tissue loss 
from either partial hepatectomy or acute liver injury. Partial hepatectomy, in 
which up to 70% of the liver is removed, causes the remaining lobes to enlarge 
and restore the liver to its original size. This regeneration is remarkably rapid and 
requires only 5 to 7 days in rats. During liver regeneration, hepatocytes are 
estimated to replicate once or twice, and after the original size and volume of the 
liver are achieved, the hepatocytes revert to their usual quiescent state (C. 
Guyton and E. Hall 2000). 
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2. FROM OBESITY TO NON-ALCOHOLIC FATTY LIVER DISEASE. 
2.1. Obesity: 
Obesity is characterized by excessive fat accumulation in adipose tissue and other organs. 
Obesity reflects the imbalance between energy intake and energy expenditure. Due to the 
global epidemic of overweight and obesity, which is currently a major public health 
problem in many parts of the world, the World Health Organization (WHO) renamed it 
"globesity". 
 
The body mass index or BMI is a measurement of body fat used in clinical and 
epidemiologic studies to assess obesity in human adults. BMI is calculated as weight (kg) 
divided by height squared (m2). The WHO defines overweight as a BMI equal to or 
greater than 25 kg/m2 and obese as a BMI equal to or greater than 30 kg/m2 (Ahima 
2011). 
 
The WHO estimated that in 2008, 1.5 billion adults were overweight and over 200 
million men and 300 million women, approximately 10% of adults were obese (Ahima 
2011) (Figure I-5). There are three major causes that account for the increasing 
prevalence of obesity: 
1. Calorie intake: there has been a drastic increase in total calorie intake over the 
past two decades. In most developed countries, the total calorie intake levels are 
above the recommended 2000 Kcal/day and getting close to the 3000 Kcal/day. 
2. Calorie quality: there has been a switch from diets rich in vegetables, fruit and fish 
to more fatty (specially saturated fats) and high sugar diets. Chronic intake of 
fatty diets and fructose and frequent consumption of processed food increases the 
risk of obesity.  
3. Lack of exercise: sedentary lifestyle is also a major contributor to weight gain. 
Low levels of physical activity are closely related to body weight gain.  
 
Unfortunately, obesity is no longer a problem of high-income developed countries alone 
as it affects third world countries as well. Indeed, the largest increases in obesity since 
1980 have occurred in low and middle-income countries, particularly in urban settings in 
Oceania, Latin America, and North Africa (Ahima 2011) (Figure I-5).  
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Figure I-5.  Worldwide change in prevalence of obesity in men (A) and women (B) between 1980 and 2008 
(Ahima 2011). 
 
Obesity is a risk factor for other pathological conditions such as insulin resistance and 
type 2 diabetes mellitus (T2DM) (Kahn, Hull et al. 2006) as well as non-alcoholic fatty 
liver disease (NAFLD) (Fabbrini, Sullivan et al. 2010; Cusi 2012), cardiovascular disease 
(CVD) (Van Gaal, Mertens et al. 2006) and cancer (Sun and Karin 2012). 
 
Diet, exercise, and other lifestyle modifications are the first line of protection against 
obesity. However, compliance with these measures is difficult to maintain for long 
periods of time. Anti-obesity drugs are largely ineffective, and even bariatric surgery 
provides and efficient and rapid reduction in weight followed by weight regain over time. 
Thus, there is a need for understanding the regulation of energy homeostasis and the 
mechanisms whereby obesity causes diabetes and other complications like fatty liver 
disease. 
 
2.2. Adipose tissue during obesity: 
Adipose tissue can respond rapidly and dynamically to alterations in nutrient availability, 
contributing to the maintenance of body energy homeostasis. Adipose tissue remodeling 
is an active process that is pathologically accelerated in the obese state (Sun, Kusminski 
et al. 2011). 
2.2.1. Adipose tissue plasticity: 
 The first adaptation in adults to avoid systemic lipotoxicity from chronic 
 overfeeding is enlargement of adipocytes (hypertrophy), followed by a longer-term 
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compensatory mechanism involving fat cell replication (hyperplasia) (Cusi 2012). 
Adipocyte hypertrophy prevails in obesity. Healthy adipose tissue expansion 
consists in effective recruitment of adipogenic precursor cells to the adipogenic 
program, along with an adequate angiogenic response and appropriate remodeling 
of the extracellular matrix. In contrast, pathological adipose tissue expansion 
consists of massive enlargement of existing adipocytes, limited angiogenesis, and 
ensuing hypoxia (Sun, Kusminski et al. 2011) (Figure I-6). 
 
 
Figure I-6. (A) Healthy adipose tissue expansion (B) Pathological adipose tissue expansion (Sun, 
Kusminski et al. 2011). 
 
 
2.2.2. Adipose tissue dysfunction: 
Protection from chronic energy supply and excess TG accumulation in tissues 
such as liver, muscle, and pancreatic beta cells requires an extraordinary 
adaptation by adipocytes that involves activation of several inflammatory 
pathways and inflammatory cells but at the cost of adipose tissue function (Cusi 
2012). 
 
2.2.2.1. Inflammation: 
Obesity is associated with a chronic low-grade systemic inflammation, 
particularly in white adipose tissue, which is believed to contribute to 
metabolic disorders, and progression from hepatic steatosis to non-alcoholic 
steatohepatitis (NASH), fibrosis, cirrhosis and eventually hepatocellular 
carcinoma (HCC) (Cusi 2012). Hypertrophic adipocytes actively produce 
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and secrete cytokines that contribute to the local and systemic inflammation. 
Among others, Tumor Necrosis Factor ? (TNF-?), Interleukin 6 (IL-6) and 
Monocyte chemoattractant protein 1 (MCP-1) are hallmarks of obese 
adipose tissue (Wellen and Hotamisligil 2005) (Figure I-7). 
 
 
Figure I-7. Adipose tissue evolution from lean to obese: inflammation, vascular function and 
metabolic control (Ouchi, Parker et al. 2011). 
 
Inflammatory pathways can be initiated by extracellular mediators such as 
cytokines and lipids or by intracellular stresses induced by obesity like 
Endoplasmatic Reticulum stress (ER stress) (Ozcan, Cao et al. 2004) or 
Reactive Oxygen Species (ROS) production by mitochondria due to an 
increased glucose metabolism. Signals from all of these mediators converge on 
inflammatory signaling pathways, including the kinases c-jun N-terminal 
kinase (JNK) and I?B Kinase (IKK), inducer of Nuclear Factor Kappa B 
(NF-?B) pathway. These pathways not only induce the production of 
additional inflammatory mediators at the transcriptional level, but also 
directly inhibit insulin signaling pathway, thus establishing a feed forward 
cycle between inflammation and insulin resistance (Wellen and Hotamisligil 
2005) (Figure I-8). 
 
2.2.2.2. Macrophage infiltration: 
As discussed before, adipose tissue expansion can lead to hypoxia, adipocyte 
cell death, enhanced chemokine secretion, and deregulation of FA fluxes. 
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This requires macrophages to create a permissive environment for the 
remodeling process. The adipose tissue has a pool of adipose tissue resident 
macrophages (ATM) that during obesity are activated by various stimuli: 
• Adipocyte cell death: Macrophages aggregate, forming crown-like 
structures (CLSs) surrounding necrotic adipocytes in advanced 
obesity (Figure I-7). 
• Chemotactic regulation. There is an increased expression of 
chemokines by the adipose tissue during obesity that promotes 
macrophage mobilization from bone marrow into tissues.  
• Hypoxia.  
• FA flux.  
 
2.2.2.3.  Insulin resistance: 
As previously stated, adipocyte adaptation has its costs. The activation of 
inflammatory pathways described above is known to block the insulin-
signaling pathway leading to insulin resistance in the adipose tissue (Figure I-
8). At this point, the adipose tissue becomes blind to insulin signals driving 
adipose tissue to a catabolic state. The adipose tissue behaves as if the body 
were in a fasting state where enhanced lipolysis increases free FA (FFA) 
release to the circulation and energy storing capacity is inhibited. 
 
 
 
 
Figure I-8. Model of overlapping metabolic and inflammatory signaling in adipocytes (Wellen 
and Hotamisligil 2005). 
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2.3. Systemic implications of adipose tissue dysfunction: 
The increased secretion of cytokines and FFAs to the circulation derived from adipose 
tissue linked to its inability to properly store nutrients coming from the diet increases 
systemic inflammation and promotes ectopic lipid accumulation (Figure I-9). 
 
 
Figure I-9. Systemic effects of adipose tissue dysfunction during obesity (Cusi 2012). 
 
Tissues like liver or muscle take over the physiological function of adipose tissue of 
storing fat. However, since these organs are not prepared for such function, they undergo 
cellular stress and tissue inflammation, leading eventually to tissue dysfunction and 
insulin resistance.  The stress caused by the ectopic fat accumulation, specially saturated 
FFAs, is known as lipotoxicity. Some of the mechanisms of action underlying FA-induced 
lipotoxicity will be discussed in Section 2.5. 
 
2.4. Non-Alcoholic Fatty Liver Disease: 
The rapid increase in obesity worldwide is associated with an increase in prevalence of 
non-alcoholic fatty liver disease. NAFLD is the most common form of chronic liver 
disease in the Western countries and it is considered the hepatic manifestation of 
metabolic syndrome (Bechmann, Hannivoort et al. 2012). 
 
2.4.1. Natural history of NAFLD: 
Historically, NAFLD refers to TG accumulation in the liver in the absence of 
excessive alcohol consumption. NAFLD encompasses a spectrum of liver disorders 
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ranging from simple steatosis progressing through NASH and fibrosis to cirrhosis 
and end-stage liver failure. Simple steatosis is defined histologically as >5% 
hepatic steatosis in the absence of inflammation or hepatocellular damage, 
whereas NASH is characterized by inflammation and hepatocellular damage with 
variable degrees of fibrosis. Simple steatosis rarely progresses to advanced liver 
disease, whereas NASH has the potential to progress to cirrhosis, end-stage liver 
failure and HCC (Cusi 2012) (Figure I-10). 
 
 
Figure I-10. Schematic representation of the pathophysiology of NASH (Cusi 2012). 
 
The pathogenesis of NAFLD has classically been thought of as a “two hit” 
process; the first resulting in hepatic TG accumulation and the second being 
responsible for hepatocyte death and scar formation. As the understanding of the 
pathogenesis of NAFLD evolves, alternative hypotheses are gaining favor, 
switching from a two hit hypothesis to a “multi parallel hits” hypothesis. Some of 
these multi parallel hits will be further discussed in section 2.5. 
 
2.4.2. Epidemiology of NAFLD: 
 NAFLD is the most common cause of liver test abnormalities; NAFLD accounts 
for 70% of all cases of asymptomatic elevated transaminase enzyme levels in US 
adults. Population based studies of Western countries such as the US, Italy and 
Israel have demonstrated a prevalence of NAFLD between 20-30%, whereas the 
prevalence in Eastern countries such as China has been documented to be 13-
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17%. Among the US population, there are significant differences in NAFLD 
prevalence according to ethnicity, affecting 45% of Hispanics, 33% of Caucasians 
and 24% of blacks (Smith and Adams 2011). 
 
The presence of NAFLD is closely associated with metabolic syndrome. The 
prevalence of NAFLD is increased in the presence of obesity, impaired glucose 
tolerance or T2DM, dyslipidemia with hypertriglyceridema and low high-density 
lipoprotein (HDL) cholesterol levels and hypertension (Figure I-11). 85% of 
patients with NAFLD have at least one metabolic risk factor with one-third of 
individuals having the metabolic syndrome itself. The prevalence of obesity in 
patients with NAFLD is reported to range between 61% and 100% and the 
prevalence of dyslipidemia between 27% and 67%. Among morbidly obese 
patients who undergo bariatric surgery, 90% have NAFLD (Smith and Adams 
2011). 
 
Figure I-11. Risk factors that coexist in patients with NAFLD (Cusi 2012). 
 
Subjects with NAFLD are at increased risk of death compared to the general 
population, NAFLD subjects have a 34% increase in hazard ratio for overall 
mortality. In large cohorts, death related to liver disease is the third most 
common cause of death, suggesting it is partly responsible for the increase in 
overall mortality. Risk factors for mortality in subjects with simple steatosis 
include the presence of cirrhosis, impaired fasting glycemia or diabetes. In 
contrast, NASH is more frequently progressive and may lead to cirrhosis with 
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complications of HCC, liver failure and liver related death or requirement for 
liver transplantation. In addition to liver related morbidity and mortality, subjects 
with NASH are at increased risk of cardiac morbidity and mortality (Smith and 
Adams 2011). 
 
2.4.3. Hepatic lipid metabolism in NAFLD: 
There is a close relationship between adipose tissue and liver because adipocytes 
supply more than two-thirds of FAs used for hepatic TG synthesis (Barrows and 
Parks 2006). A lesser but important fraction of hepatic FAs are synthesized de 
novo by the transcriptional up-regulation of enzymes involved in FA synthesis. 
Hepatic lipid accumulation results from an imbalance between lipid availability 
(from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via FFA 
oxidation or TG-rich lipoprotein secretion). Each of these steps is altered in 
NAFLD. Regulation of these pathways is complex and involves nuclear receptors, 
membrane transport proteins and cellular enzymes (Musso, Gambino et al. 
2009). 
 
The sources of FA contributing to fatty liver include: 
• Plasma FFA pool from the adipose tissue: Insulin resistance is associated 
with dysregulation of adipose-derived FFA flux in a fed state, and strong 
evidence exists demonstrating that in NAFLD patients, insulin fails to 
suppress adipose tissue lipolysis. The plasma FFA pool contributes the 
majority of FFAs flowing to the liver in the fasted state and thus provides 
the bulk of the FFAs secreted by the liver in VLDL particles.  
• de novo lipogenesis (DNL): FAs newly made in the liver through DNL. 
During obesity, DNL regulation is lost and constitutively active due to 
activation of transcription factors that regulate key enzymes of DNL. 
• Dietary FAs: which can enter the liver through spillover into the plasma 
FFA pool and through the uptake of intestinally derived chylomicron 
remnants.  
 
 Contribution of FA sources to hepatic TG content in obese subjects: 
• 59% of hepatic TG arose from circulating FFA pool  
• 26% of hepatic TG arose from DNL 
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• 15% of hepatic TG arose from the diet  
 
These metabolic data indicate that both elevated peripheral FFA flux and DNL 
are major contributors to hepatic steatosis in NAFLD. 
 
2.4.3.1. FA uptake: 
Circulating FFAs deriving from adipose tissue lipolysis provide most of the 
hepatic lipid content in NAFLD, thus mechanisms of hepatic FA uptake are 
important to understand the disease. FFAs are highly insoluble in aqueous 
media and are kept in circulation by binding to albumin. It was previously 
thought that FFAs entered the cell by passive diffusion through the bilayer 
lipid membrane. However, many studies proved that uptake of FAs is far 
more complex and involves several steps: dissociation from albumin, 
transport across the membrane, binding to intracellular proteins and 
esterification to acyl-CoA.  
 
The main plasma membrane protein transporters involved in FA 
transmembrane translocation are: caveolins, FA transport proteins (FATPs), 
FA translocase (FAT/CD36) and FA binding proteins (FABPs) (Figure I-12). 
 
Caveolins can be found in the lipid rafts of the plasma membrane (Figure I-
12). These structures are important for cell signaling and protein trafficking 
processes and are essential for lipid droplet formation. Caveolin-1 deficient 
mice exhibit defective lipid droplet formation and are unable to regenerate 
the liver (Pol, Martin et al. 2004). 
 
FATPs are a family of six members. FATP2 and FATP5 are mainly expressed 
in liver. Their expression is regulated by insulin, inflammatory mediators and 
by activators of peroxisome proliferator activated receptor PPAR-? and 
PPAR-?. FATP5 deficiency decreases by 50% FA uptake in primary mouse 
hepatocytes and whole body deficiency protects mice from diet-induced 
obesity, insulin resistance and hepatosteatosis (Doege, Baillie et al. 2006; 
Musso, Gambino et al. 2009). 
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Figure I-12.  Hepatic lipid metabolism and hepatic steatosis. Increased hepatic TG comes from 
FAs that are formed by up-regulated de novo lipogenesis (DNL) and from plasma long chain 
fatty acids (LCFA) that are taken up by the liver; reduced mitochondrial FA oxidation also favors 
TG accumulation (Musso, Gambino et al. 2009). 
 
CD36 is a multifunctional protein since it enhances FA uptake and it is a 
receptor for different ligands including VLDLs and oxidized low-density 
lipoproteins (LDLs) (Figure I-12).  Its expression can be induced by PPAR-? 
and PPAR-? and liver X receptor (LXR). It is expressed in many cell types 
and tissues but its presence is low in hepatocytes. Although, it has been 
reported that its expression is increased in patients with NAFLD. In mouse 
models of diet-induced obesity, increased levels of hepatic TG correlated 
with increased levels of CD36 expression and specific induction of CD36 in 
liver leads to hepatomegaly and fatty liver (Musso, Gambino et al. 2009). 
 
FABPs are small, highly expressed proteins that reversibly bind FAs, 
eicosanoids, and other lipids. These lipid chaperones facilitate the transport 
of FAs and other lipid mediators across cellular membranes.  FABPs are also 
located in the cytosol, where they mediate intracellular transport of FAs 
throughout the cytosol to their nuclear receptors, including PPARs, retinoic 
acid receptor (RAR), LXR? and NF-kB, thus controlling the availability of 
ligands to regulate transcription of genes involved in important metabolic and 
inflammatory processes (Figure I-12). FABPs are a family of 9 members. 
FABP-1 is abundant in liver cytoplasm. The role of FABP- deficiency in diet-
induced hepatic steatosis is controversial. In this regard, one study 
demonstrated that its deficiency protected mice from high saturated fat diet-
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induced liver steatosis and weight gain but it didn't have any impact on 
insulin resistance (Furuhashi and Hotamisligil 2008). 
 
2.4.3.2. de novo hepatic lipogenesis: 
Physiologically DNL occurs postprandially in healthy subjects. In NAFLD, 
however, there is a paradoxical sustained elevation of DNL in fasting 
conditions that lacks further postprandial elevation. The regulation of 
hepatic lipogenesis involves a complex network of nuclear receptors, 
coordinately regulating enzymes involved in different steps of hepatic lipid 
metabolism, from DNL to FA oxidation and uptake onto TG secretion 
(Musso, Gambino et al. 2009). 
 
Hepatic lipogenesis includes de novo synthesis of FAs from acetyl-CoA or 
malonyl-CoA and further processing to TGs. In mammals, FA synthesis is 
catalyzed by acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), an 
enzyme that exhibits a complex regulation by nuclear receptors (PPAR?, 
PPAR? and the bile acid receptor/farnesoid X receptor [FXR]). DNL is 
extremely sensitive to insulin since it activates the expression of FAS, thus 
hyperinsulinemia states such as obesity may activate DNL. At the 
transcriptional level, sterol-regulatory element binding protein 1c (SREBP1c) 
and carbohydrate-responsive element binding protein (ChREBP), a glucose 
dependent transcription factor, synergistically induce expression of FAS and 
ACC.  
 
As FAs and their metabolites are the major cause for lipotoxicity and promote 
ROS formation, FAs are stored for future use as TGs, which are relatively 
inert and consist of three FAs esterified to a glycerol backbone. TGs are then 
either stored in lipid droplets within hepatocytes or processed to VLDL. TG 
synthesis is catalyzed by the enzymes mitochondrial glycerol- 3-phosphate-
acyltransferase (mtGPAT) and diacylglycerolacyltransferase (DGAT). TGs 
are then packaged into VLDL particles by conjugation to apoB-100 in a 5:1 
TG/cholesterol ratio. These processes are controlled by SREBP1c, the LXR, 
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FXR and ChREBP, which link glucose and lipid metabolism (Bechmann, 
Hannivoort et al. 2012). 
 
2.4.3.3. FA oxidation: 
Oxidation of FAs facilitates degradation of activated FAs to acetyl-CoA. It is 
a rapid and effective way of energy allocation since, the oxidation of one 
molecule of palmitate produces up to 129 ATP equivalents.  
 
FAs are activated by acyl-CoA-synthetase to acyl-CoA in the cytosol. This 
process is indispensable for enabling FAs to cross membranes and enter 
organelles. While short and medium-chain FAs pass the mitochondrial 
membrane without activation, activated LCFAs are shuttled across the 
membrane via carnitine palmitoyltransferase-1 (CPT1). Malonyl-CoA, an 
early intermediate of DNL that accumulates upon insulin receptor activation, 
is an allosteric inhibitor of CPT1. Thus, in the fed state, FA oxidation is 
inhibited promoting DNL, which results in fat storage and distribution of 
lipids.  
 
Different hepatic FA oxidative pathways are involved in the pathogenesis of 
NAFLD. Most FAs are metabolized through ?-oxidation, which occurs 
mainly in mitochondria, and to a lesser extent in peroxisomes. A third FA 
metabolizing pathway is ?-oxidation by members of the cytochrome P450 in 
the ER (Figure I-13). The extramitochondrial FA oxidative pathways become 
more important in conditions of increased FA availability in the liver like 
NAFLD. Key enzymes of FA oxidation are regulated by PPAR? (Musso, 
Gambino et al. 2009). 
 
In general, short-, medium- and LCFAs are oxidized within mitochondria, 
while toxic, LCFAs are oxidized within peroxisomes. During the process of ?-
oxidation, electrons are indirectly donated to the electron transport chain to 
drive ATP synthesis. Acetyl-CoA can be further processed via the TCA cycle 
or, in the case of FA abundance, be converted into ketone bodies. As the 
oxidative capacity of the mitochondria becomes impaired, like in cases of 
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diabetes or FA overload, cytosolic FAs accumulate. Alternative pathways in 
the peroxisomes (?-oxidation) and in microsomes (?-oxidation) are 
activated, resulting in the formation of additional ROS (Figure I-13). 
Microsomal ?-oxidation of FAs is catalyzed primarily by cytochrome P450 
enzymes 2E1, 4A10, and 4A14, generating ROS. Additionally, dicarboxylic 
acids, another product of microsomal FA ?-oxidation, impair mitochondrial 
function by uncoupling oxidative phosphorylation. Protonated dicarboxylic 
acids shuttling from the inner to the outer mitochondrial membrane dissipate 
the mitochondrial proton gradient without concomitant ATP production 
(Musso, Gambino et al. 2009) (Figure I-13). 
 
 
Figure I-13. Fatty acid oxidation under physiologic conditions and NASH (Bechmann, 
Hannivoort et al. 2012). 
 
Increased availability of intracellular FAs, as well as PPAR? activation, 
induce microsomal CYP2E1 and CYP4A1 activity, leading to generation of 
ROS and dicarboxylic acids. CYP2E1 is overexpressed in both experimental 
and human NAFLD and in vivo measured CYP2E1 activation correlates with 
the severity of liver necroinflammation, suggesting that this mechanism may 
contribute substantially to ROS-induced hepatic injury (Musso, Gambino et 
al. 2009). The cumulative effect of extramitochondrial FA oxidation is a 
further increase in oxidative stress and mitochondrial impairment. 
 
2.5. Hepatic lipotoxicity: 
By definition, lipotoxicity reflects the toxic effects due to the accumulation of lipids. In 
the context of NAFLD, there is a wide array of lipids known to accumulate including 
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diacylglycerol, ceramide, FC, cholesterol esters and FFAs. Among them, FFAs are 
considered of relevance, particularly saturated FFAs, which impair insulin signaling, 
activate stress pathways and induce cell death, thereby resulting in lipoapoptosis.  
Hepatic lipotoxicity due to FFAs accumulation occurs when the hepatic capacity to 
oxidize, store and export FFAs as TG is overwhelmed by FFA flux from the periphery or 
hepatic de novo lipogenesis (Trauner, Arrese et al. 2010) (Figure I-14). 
 
In contrast to saturated FFAs, unsaturated FFAs are nontoxic and are stored as TG. The 
mechanisms that discriminate toxic versus nontoxic effects of saturated and unsaturated 
FFAs are poorly understood. Thus, experimental studies suggest that lipid 
compartmentalization in hepatocytes and in particular the type or “quality” as opposed 
to the “quantity” of lipids accumulating may play a central role in the risk for progressive 
disease (Alkhouri, Dixon et al. 2009). Key examples of this emerging concept in NAFLD 
include the dissociation between hepatic steatosis and insulin resistance in mice 
overexpressing DGAT2, and the role of FC in the sensitization of fatty liver to 
inflammatory cytokines (Marí, Caballero et al. 2006; Monetti, Levin et al. 2007) 
 
 
 
Figure I-14. Causes and mechanisms of hepatic lipotoxicity in NAFLD (Neuschwander-Tetri 2010). 
 
TG accumulation in the liver in response to lipid overloading has been historically 
considered the “first hit” in NAFLD development and it was associated with features of 
insulin resistance. However, hepatocellular TG storage per se does not appear to be 
directly hepatotoxic but rather may be a marker of hepatocyte exposure to potentially 
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toxic FAs. Therefore, the ability to synthesize TG may, in fact, be protective against 
lipotoxicity of FAs in liver (Trauner, Arrese et al. 2010). 
 
2.5.1. FFAs:  
FFAs are highly noxious to biological systems. There is a great amount of evidence 
linking FFAs to hepatic lipotoxicity. Some of the mechanisms described are listed 
below (Figure I-15): 
 
• Nature of FFAs: Saturated FFAs are more hepatotoxic than unsaturated 
FFAs. The toxic effects of saturated FFAs are believed to be due to their 
inability, relative to unsaturated FFAs, to be esterified and incorporated into 
TG. Saturated FFAs need additional esterification by Stearoyl-CoA 
desaturase-1 (SCD-1) enzyme in order to be incorporated into TG (Ibrahim, 
Kohli et al. 2011). 
 
• Ligands of Toll-like receptors (TLRs): TLRs are a family of pattern-
recognition receptors that play a critical role in the innate immune system by 
activating proinflammatory-signaling pathways in response to microbial 
pathogens. Saturated FFAs, like palmitate, can serve as activating ligands for 
TLR-4, leading to a cascade of inflammatory events precipitating apoptosis 
(Alkhouri, Dixon et al. 2009) (Figure I-15). 
 
• Transcriptional regulation of death receptors: FFA can also induce up-
regulation of death receptors such as Fas and TRAIL receptor 5 (DR5) 
sensitizing liver cells to apoptotic cell death. Both Fas and DR5 expression is 
increased in liver of patients with NASH (Alkhouri, Dixon et al. 2009) 
(Figure I-15). 
 
• Lysosomal pathway: FFAs are capable of directly destabilizing lysosomal 
membranes, leading to inappropriate release of cathepsin B and causing 
activation of apoptotic pathways (Li, Berk et al. 2008; Neuschwander-Tetri 
2010). FFA-induced lysosome permeabilization and release of cathepsin B to 
the cytosol is an early event that occurs prior to mitochondrial depolarization 
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and cytochrome c redistribution to the cytosol. More importantly, cathepsin 
B silencing by siRNA, or chemical inhibition significantly prevented FFA-
induced mitochondrial dysfunction, highlighting the relevance of cathepsin B 
in FFA-induced mitochondrial dysfunction (Alkhouri, Dixon et al. 2009). In 
human liver specimens, release of cathepsin B into the cytoplasm is observed 
in NAFLD patients and it correlates with disease severity (Ibrahim, Kohli et 
al. 2011) (Figure I-15). 
 
• Mitochondrial pathway: Mitochondria are involved in many processes 
essential for liver cell survival, including energy production, redox control, 
calcium homeostasis, and certain metabolic and biosynthetic pathways. In 
addition, mitochondria often play an essential role in cell death mechanisms 
(Tait and Green 2010). Mitochondrial function is impaired in NAFLD and 
this is believed to play an important role in the progression of the disease. 
Patients with NASH display ultrastructural mitochondrial abnormalities, 
decreased mitochondrial DNA and protein expression. However, recent 
findings in mouse genetic models of mitochondrial dysfunction due to 
ablation of Apoptosis inducing factor (AIF) or the mitochondrial 
transcription factor (TFAM) in liver or adipose tissue, dispute this 
association, as these mice are protected against diet-induced obesity and 
insulin resistance (Pospisilik, Knauf et al. 2007; Vernochet, Mourier et al. 
2012). Nevertheless, FFAs can affect mitochondrial function at different 
levels, some of which are listed below: 
o Mitochondrial membrane permeabilization: FFAs are capable of 
inducing mitochondrial membrane permeabilization and increase 
ROS production. This oxidative stress can damage DNA, proteins 
and lipids. Specifically, lipid peroxidation has been linked to 
mitochondrial dysfunction. They are capable of altering 
mitochondrial DNA and proteins decreasing respiratory chain protein 
expression and activity (Musso, Gambino et al. 2009). 
o Proton leak:  FFAs can directly act on the mitochondrial respiratory 
chain and induce an increase in the proton leak. In addition, 
saturated FFAs, through PPAR? activation, can induce the expression 
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of uncoupling protein family members (UCPs). UCPs are proteins 
associated to the mitochondrial inner membrane, where they mediate 
proton leak to uncouple substrate oxidation from ATP synthesis. 
This leads to increasing ROS that may cause cell damage at different 
levels (Musso, Gambino et al. 2009; Gambino, Musso et al. 2011). 
 
• Intrinsic apoptotic pathways: saturated FFAs induce JNK-dependent 
hepatocyte lipoapoptosis by activating the pro-apoptotic proteins Bim and 
Bax (Alkhouri, Dixon et al. 2009). Furthermore, saturated FFAs induce rapid 
degradation of antiapoptotic proteins of Bcl-2 family in hepatocytes 
(Ibrahim, Kohli et al. 2011). These saturated FFA-induced effects can trigger 
intrinsic mitochondrial apoptotic pathways. 
 
• ER stress: excessive saturated FFAs may induce ER stress and subsequent 
activation of the unfolded protein response (UPR). In principle, UPR is a 
compensatory and protective mechanism aimed to establish ER homeostasis. 
However if stress persists, UPR activates apoptotic pathways to eliminate 
damaged cells.   ER stress is a mechanism that links saturated FFAs to 
lipotoxicity in NAFLD (Gentile, Frye et al. 2011) (Figure I-15). This 
mechanism will be further discussed in section 4. 
 
 
 
 
Figure I-15. Mechanisms of FA-induced lipoapoptosis (Alkhouri, Dixon et al. 2009). 
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2.5.2. Ceramide: 
Ceramide is the prototype sphingolipid that has been intensively studied in the 
last two decades due to its emerging role in regulation of cell functions. Indeed, 
although sphingolipids have been considered mere structural components of 
biological membranes, it has been established that ceramide has a dynamic role in 
cell signaling, cell stress and death ligand-induced death (Marí and Fernández-
Checa 2007; Morales, Lee et al. 2007). It has also been recognized as an 
important mediator of insulin resistance and obesity (Holland, Brozinick et al. 
2007). The role of ceramide role in NAFLD and metabolic syndrome will be 
discussed in section 6. 
 
Cells generate ceramide by two different pathways. Its de novo synthesis occurs in 
the ER with the condensation of serine and a saturated acyl-CoA, usually 
palmitoyl CoA, the rate-limiting step catalyzed by serine palmitoyl transferase 
(SPT), and the acylation of sphingosine with FFA catalyzed by ceramide synthases 
(CerS). Ceramide synthesis rate is dependent, among other factors, on the 
availability of palmitic acid and its activation to pamitoyl-CoA; therefore, obesity 
can be associated with excess ceramide production. In addition, ceramide can also 
be generated from sphingomyelin (SM) hydrolysis by sphingomyelinases. The 
generation of ceramide through this pathway is quick and transient and it has 
been involved in apoptosis induced by death ligands such as TNF-? and Fas that 
are also induced in obesity (Alkhouri, Dixon et al. 2009). While the impact of 
ceramide in obesity and NAFLD has not been well described, genetic evidence in 
mice deficient in dihydroceramide synthase, which exhibit 60-80% decreased 
ceramide content, established a role for ceramide in insulin resistance (Holland, 
Brozinick et al. 2007). 
 
In vitro evidence indicated the correlation between staurated FFAs and increased 
ceramide accumulation. Animal studies established that feeding rats high fat diet 
enriched in saturated FFAs resulted in accumulation of hepatic ceramide and SM 
levels. In addition, obese mice with hepatic steatosis also have increased hepatic 
ceramide content (Pagadala, Kasumov et al. 2012). Interestingly, the type of FFAs 
also affects ceramide synthesis since saturated FA but not unsaturated oil infusion 
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results in a 60% increase in hepatic ceramide content in rats, compared to 
controls (Holland, Brozinick et al. 2007). 
 
In contrast to experimental models, human data linking ceramides to the 
pathogenesis of NAFLD are sparse. Nevertheless, data in obese subjects showed 
increased hepatic ceramide and SM levels compared to subcutaneous and intra-
abdominal adipose tissue (Kotronen, Seppänen-Laakso et al. 2010). Moreover, 
hepatic steatosis in human correlates with increased adipose tissue ceramide 
content (Pagadala, Kasumov et al. 2012). It has also been reported that weight 
loss resulted in decreased hepatic ceramide-related gene expression in obese 
patients with NAFLD that correlated with decreased serum ceramide levels. In 
addition, obese patients with T2DM, compared to lean healthy controls, had 
increased plasma ceramides and this observation correlated with degree of insulin 
resistance and plasma TNF-? (Haus, Kashyap et al. 2008). Moreover, liver 
samples of patients with NASH exhibit increased gene expression of key enzymes 
that regulate ceramide production (Moles, Tarrats et al. 2010; Promrat, Longato 
et al. 2011). 
 
Ceramide has been strongly linked to induction of mitochondrial damage and 
apoptosis (Chavez and Summers 2010). Specific mechanisms for ceramide-
induced mitochondrial damage and apoptosis are:  
• Recruitment of pro-apoptotic protein Bax to mitochondrial membranes 
(Birbes, El Bawab et al. 2001; Birbes, Luberto et al. 2005). 
• Generation of ROS through the inhibition of the electron transport chain 
or regulation of NADPH oxidase (García-Ruiz, Colell et al. 1997; 
Cacicedo, Benjachareowong et al. 2005). Interestingly, ROS in turn 
promote further ceramide synthesis (Summers 2006). 
• Mediation of clustering of death receptors at the plasma membrane by the 
action of acid sphingomyelinase (ASMase) thereby triggering the extrinsic 
apoptotic pathway (Grassmé, Riethmüller et al. 2007). 
• Direct increase of mitochondrial membrane permeability and subsequent 
cytochrome c release activating intrinsic apoptosis pathways (Colombini 
2010). 
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• Activation of JNK and NF?B inflammatory pathways that are also known 
to inhibit insulin signaling (Summers 2006). 
Thus, ceramide emerges as a key player in NASH, linking the FFA overload to 
inflammation and insulin resistance, which are the hallmarks of obesity and 
associated comorbidities (Figure I-15). 
 
2.5.3. Free Cholesterol: 
Due to its low abundance in free form, the role of cholesterol in liver diseases, 
and NASH in particular, has been neglected. However, recent data in both 
experimental models and patients have sparked the interest on the role of free 
cholesterol (FC) in liver pathology and NASH. Pioneering work from our 
laboratory showed that nutritional and genetic models of hypercholesterolemia 
promoted the transition from steatosis to NASH due to the specific trafficking of 
FC to mitochondria. The accumulation of FC in mitochondrial membranes 
impaired the transport of glutathione (GSH) from the cytosol to the 
mitochondrial matrix, thereby sensitizing hepatocytes to oxidative stress and 
TNF-? (Figure I-16). Repletion of mitochondrial GSH (mGSH) rescued FC-
loaded livers from TNF-?-induced NASH (Marí, Caballero et al. 2006). 
 
 
Figure 1-16. Mitochondrial FC reduces mGSH and sensitizes cells to other insults (Montero, Mari et 
al. 2010). 
 
In addition, liver samples from patients with NASH exhibit increased FC 
compared to subjects with simple steatosis (Caballero, Fernández et al. 2009; 
Puri, Wiest et al. 2009). Interestingly, increased hepatic FC correlated with 
SREBP2 induction in the liver human samples (Caballero, Fernández et al. 2009; 
Min, Kapoor et al. 2012). Moreover, mitochondrial cholesterol transporter StAR 
overexpression in NASH suggested that mitochondrial FC might be a player in 
NASH (Caballero, Fernández et al. 2009). 
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2.6. NAFLD management: 
2.6.1. Lifestyle intervention: 
The most effective treatment of NAFLD is the weight loss through dietary change 
coupled with exercise. Dietary intervention (with or without exercise) improves 
hepatic steatosis and metabolic profile of patients with NAFLD. In short-term 
studies, a >5% weight loss appears to be the minimal threshold to decrease TG 
accumulation, whereas a 7% to 10% weight loss appears to be needed to reduce 
necroinflammation (Cusi 2012). 
 
2.6.2. Insulin sensitizers:  
Metformin is an insulin-sensitizing agent that is associated with reduced 
cardiovascular mortality in patients with T2DM.  Improvement of insulin 
resistance occurs primarily in the liver. However, in patients with NAFLD, a 
number of small-randomized clinical trials of relatively short duration (6–12 
months) have failed to demonstrate an improvement in liver steatosis, 
inflammation or fibrosis with metformin (Cusi 2012). 
 
2.6.3. Antioxidants: 
As discussed earlier, oxidative stress and lipid peroxidation within the liver appear 
to contribute to progressive liver damage in patients with NAFLD. Therefore, 
several trials investigated the use of antioxidant compounds, including vitamins E 
and C and betaine, for the treatment of NASH. Vitamin E is believed to 
ameliorate intracellular oxidative stress, which makes it an attractive therapeutic 
approach since it targets intracellular targets different from insulin sensitizers and 
offers an opportunity for combined therapy in NASH (Smith and Adams 2011). 
 
Trials of antioxidants did not find any benefit on liver histology. However, a 
combination of pioglitazone and vitamin E were significantly better than placebo 
at improving hepatic steatosis and inflammation but not fibrosis in patients with 
NASH. Unfortunately, safety issues have been raised regarding long-term use of 
vitamin E, as it associates with an increased risk of cardiovascular disease and 
hemorrhagic stroke (Smith and Adams 2011). 
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Recent work from our lab in mouse models of NAFLD underscored a critical role 
for mGSH in the therapeutic potential of superoxide scavenging in NAFDL. 
These findings have potential clinical implications as they may help explain the 
failure of antioxidant treatment in human diseases so far. This study indicates that 
a better approach for NAFLD treatment is the combination of superoxide 
dismutase (SOD) mimetics together with mGSH restoration rather than 
improving SOD action only, illustrating the importance of a delicate equilibrium 
between these two antioxidants to ensure protection and therapeutic benefit (von 
Montfort, Matias et al. 2012). 
 
2.6.4. PPAR agonists:  
Thiazolidinediones (TZDs: pioglitazone and rosiglitazone) are PPAR? agonists 
that redistribute fat from the muscle and liver to peripheral adipose tissue and, 
thereby, improve insulin resistance and inflammation but stimulate weight gain. 
Different clinical trials of 6–24 months duration have demonstrated the efficacy of 
TZDs in patients with NASH. However, concerns have been raised regarding 
long-term safety of TZDs and heart failure, cardiovascular disease, bone loss and 
bladder cancer. For those reasons, pioglitazone has been discontinued in France 
and Germany (Smith and Adams 2011). 
 
Taken together, there is an urgent need for new therapies to effectively treat NAFLD. An 
essential step towards this aim will be to better understand the mechanisms underlying 
NAFLD in order to define new targets and therapeutic strategies. The present thesis aims 
to elucidate the role of ceramide, and in particular, ASMase-mediated ceramide 
generation, on key aspects of NAFLD including, hepatic steatosis, liver injury and insulin 
resistance.  
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3. FROM ALCOHOLISM TO ALCOHOLIC LIVER DISEASE. 
Alcohol has been used in society over centuries all over the world for its mood lifting 
properties and taste. Fortunately, only a small proportion of consumers develop clinically 
significant liver disease. It is probably, the commonest drug of abuse worldwide and 
unfortunately causes considerable morbidity, mortality and social disruption.  
 
The relationship between alcohol and mankind is well documented from the earliest 
times. Winemaking equipment was found in the remains of an early Neolithic village in 
Northern Iran dated about 5.000 BC.  Beer was first produced in Ancient Mesopotamia, 
Egypt and Greece. The Ancient Greeks worshipped the God of wine, Dionysus, and seem 
to have been the first to develop large-scale wine fermentation and production, with 
export to other countries (Figure I-17). The Romans in turn worshipped Bacchus, their 
God of wine, and were significant wine producers, planting vineyards across Europe.  
 
 
Figure I-17. Dionysus. The Greek God of wine represents the intoxicating 
power of wine, its social and beneficial influences. Also known as the Liberator, 
freeing one from one's normal self, by madness, ecstasy, or wine. 
 
Alcohol has long been accepted as part of human daily life, and its consumption gradually 
increased through centuries both in man and women. Sentiment toward moderation in 
drinking was documented in China in the 12th century BC. The association of alcohol 
with liver disease appeared to have been noticed by the ancient Egyptians, who linked the 
use of beer with ascites, and the ancient Greeks, who described the association with 
icterus and gastrointestinal bleeding. At the start of the twentieth century, concern for 
the effects of alcohol misuse in England induced the creation of licensing laws in Britain 
limiting the hours during which alcohol could be served, and these are currently still in 
place (Gordon 2001).  
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Alcohol abuse may result in a broad spectrum of medical, psychiatric and social problems, 
which constitutes an expensive burden to public health services and society in general. 
However, because alcohol is widely available and enjoyable there is a strong interest in 
identifying the threshold of alcohol levels associated with tissue damage and the 
molecular mechanisms of alcohol-induced liver injury. 
 
3.1. Alcohol absorption, distribution and metabolism: 
Blood alcohol peak occurs approximately 20 minutes after ingestion. The rate of rise and 
height of peak is a function of alcohol absorption and tissue distribution. It has been 
suggested that the peak value may also be influenced by first-pass metabolism of alcohol 
by alcohol dehydrogenase (ADH) activity within the gastric mucosa (Stewart and Day 
2011). 
 
3.1.1. Alcohol absorption: 
Alcohol is absorbed from the gastrointestinal tract by simple diffusion. Because of 
slow absorption of ethanol in the stomach, 50% to 80% of absorption occurs in 
the duodenum and upper jejunum. The rate of absorption is delayed following a 
meal and increases in proportion to the alcohol concentration of the drink 
consumed. Because absorption is more rapid from the intestine than the stomach, 
any pathologic condition, drug, or surgical intervention that delays or increases 
gastric emptying will also affect alcohol absorption accordingly (Stewart and Day 
2011). 
 
First-pass metabolism of alcohol: the presence of ADH in gastric mucosa 
contributes to a first alcohol oxidation that determines both alcohol 
bioavailability and its toxic effects. Any given condition that influences gastric 
ADH activity will affect alcohol bioavailability. 
 
3.1.2. Alcohol tissue distribution: 
Following absorption, the tissue distribution of alcohol is determined principally 
by blood flow and water content. Thus, in organs with rich vasculature, such as 
brain, lungs, and liver, alcohol levels rapidly equilibrate with the blood. Alcohol is 
poorly soluble in lipids, which take up only 4% of the amount of ethanol that can 
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be dissolved in a corresponding volume of water. As a result, tissues with a high 
fat/water ratio attain much lower alcohol levels than organs such as the kidneys, 
where the high water content results in urinary alcohol levels 1.3 times higher 
than those in blood. The low lipid solubility of alcohol also explains why, 
following ingestion of the same amount of alcohol per unit weight, obese subjects 
attain higher levels of blood alcohol than lean subjects (Stewart and Day 2011). 
 
3.1.3. Hepatic ethanol metabolism: 
More than 90% of circulating alcohol is oxidatively metabolized, primarily in the 
liver, and excreted as carbon dioxide and water. The remaining is eliminated 
unchanged the urine (<1%) and breath (1% to 5%). 
 
Alcohol oxidation in the liver takes place via three steps. First, alcohol is oxidized 
principally within the cytosol to acetaldehyde. Then acetaldehyde is further 
oxidized to acetate, primarily within the mitochondria, and finally, acetate is 
released into the blood and oxidized to carbon dioxide and water in peripheral 
tissues (Figure I-18). 
  
 
 
Figure I-18. The three pathways of alcohol oxidation: alcohol dehydrogenase (ADH), microsomal 
ethanol-oxidizing system (MEOS), and catalase (Stewart and Day 2011). 
INTRODUCTION 
?38
At least three enzyme systems with the capacity to oxidize alcohol to 
acetaldehyde have been described in the liver (Stewart and Day 2011): 
 
• The Alcohol Dehydrogenase (ADH) pathway: ADH catalyzes the 
oxidation of a variety of alcohols to aldehydes and ketones. This includes 
catalyzing the oxidation of ethanol to acetaldehyde with the transfer of 
hydrogen to the cofactor nicotinamide adenine dinucleotide (NAD+), 
which is converted to its reduced form, NADH (Figure I-18). The 
resulting increase in the ratio of NADH/NAD+, which is further increased 
by acetaldehyde oxidation, is partly responsible for the metabolic 
imbalances that occur following alcohol ingestion and has been considered 
to play a major role in the initial pathogenesis of alcohol-induced fatty 
liver. The principal regulatory mechanism for the ADH pathway is the 
capacity of the mitochondria to reoxidize NADH back to NAD+.  
• The Microsomal Ethanol-Oxidizing System (MEOS) pathway:  MEOS is 
an accessory pathway to metabolize ethanol that principally involves a 
specific alcohol-inducible form of cytochrome P450 designated CYP2E1. 
The enzyme is located on the ER and requires oxygen and NADPH 
(Figure I-18). CYP2E1 appears to play an important role at high blood 
alcohol levels or following chronic alcohol abuse, due to its up-regulation. 
Moreover, alcohol induction of CYP2E1, and microsomal enzyme systems 
in general, has also been implicated in the tolerance to various drugs 
commonly observed in alcoholics, and may explain their increased 
susceptibility to hepatotoxicity by other drugs and xenobiotics that are 
converted to toxic metabolites by microsomal enzyme systems.  
• The Catalase pathway: This enzyme is located in the peroxisomes of most 
tissues and requires the presence of H2O2 (Figure I-18). The reaction is 
limited by the availability of H2O2, which in normal circumstances is low 
and suggests that the catalase pathway accounts for less than 2% of overall 
in vivo alcohol oxidation.  
 
After alcohol oxidation, more than 90% of the acetaldehyde generated is further 
oxidized in the liver to acetate by aldehyde dehydrogenases (ALDH). ALDH, like 
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ADH, uses NAD+ as a co-factor and further increases the NADH/NAD+ ratio 
(Figure I-18). ALDH inhibitors such as disulfuram (Antabuse) have been used in 
the treatment of alcoholism to sensitize alcoholics to the unpleasant effects of 
alcohol intake secondary to high levels of acetaldehyde. This same principle has 
been described in people with mutations in ALDH, particularly prevalent among 
Japanese population (Stewart and Day 2011). 
 
3.2. Natural history of Alcoholic Liver Disease: 
Alcoholic liver disease (ALD) presents as a broad spectrum of disorders, ranging from 
simple fatty liver to more severe forms of liver injury, including alcoholic steatohepatitis 
(ASH), cirrhosis, and HCC. Up to 90% of patients with heavy alcohol intake have some 
degree of steatosis, which is usually asymptomatic and rapidly reversible with abstinence. 
Continued heavy alcohol consumption, however, leads to inflammation of the liver 
characterized by the infiltration of polymorphonuclear leukocytes and hepatocellular 
damage, both of which define ASH. Eventually, patients develop liver fibrosis deposition 
(30%) and cirrhosis (8–20%), which confers a high risk of complications (such as ascites, 
variceal bleeding, hepatic encephalopathy, renal failure and bacterial infections). Severe 
forms of ASH have a very high short-term mortality (Gao and Bataller 2011) (Figure I-
19). 
 
 
 
Figure I-19.  Spectrum of ALD, risk factors and comorbidity (Gao and Bataller 2011).  
 
The fact that only about 30% of heavy drinkers develop advanced ALD indicates that 
other factors are involved. Several risk factors for ALD have been identified. These 
include sex, obesity, drinking patterns, dietary factors, non–sex-linked genetic factors, 
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and cigarette smoking. In addition, long-term alcohol drinking has synergistic effects with 
hepatitis virus B or C and/or human immunodeficiency virus infection, nonalcoholic fatty 
liver disease, and disorders such as hemochromatosis to accelerate progression of liver 
diseases (Gao and Bataller 2011). 
 
As alcohol abuse can lead to severe damage in the nervous system, heart, kidney and 
pancreas, patients with ALD may also develop a variety of symptoms unrelated to the 
liver, such as psychiatric manifestations, heart failure, renal failure and abdominal pain. 
 
3.3. Epidemiology of ALD: 
Alcohol abuse is a major cause of preventable morbidity and mortality worldwide. 
According to the WHO, morbidity from alcohol misuse in developed countries accounts 
for 10.3% of disability-adjusted life-years (DALYs—a measure of overall disease burden 
that reflects the years of healthy life lost owing to both premature mortality and 
prolonged poor health), a figure that comes second only to the morbidity associated with 
tobacco use in developed countries (11.7% of DALYs). Alcohol misuse also affects 
individuals in developing countries, where it is responsible for almost 9% of DALYs. 
Worldwide, ALD is responsible for about 4% of DALYs (Altamirano and Bataller 2011). 
 
ALD is probably the main cause of death among people with severe alcohol abuse and is 
responsible for about 3.8% of global mortality. Remarkably, data from the European 
Liver Transplant Registry show that ALD was recorded as the indication for liver 
transplantation in almost half (41.6%) of procedures performed between 1996 and 2005. 
ALD is, therefore, the second most common indication for liver transplantation in 
Europe and North America (Altamirano and Bataller 2011). 
 
3.4. Pathogenesis of ALD: 
Mechanisms through which ethanol metabolism causes steatosis, oxidative stress and 
hepatotoxic effects are discussed below: 
 
3.4.1. Steatosis: 
The accumulation of TG, FFAs and cholesterol within the liver is an early and 
reversible effect of alcohol consumption in humans and animal models of ALD. It 
INTRODUCTION 
? 41?
is the consequence of increased substrate supply (glycerol and FFAs), increased 
esterification, and decreased export of TG from the liver. 
 
3.4.1.1. Increased adipose tissue lipolysis: 
Alcohol intake increases lipolysis in adipose tissue increasing FFAs in 
circulation that are up taken by the liver providing the substrate for TG 
synthesis (Stewart and Day 2011). 
 
3.4.1.2. Altered redox state: 
The ethanol-oxidizing pathways ADH and MEOS are coupled to the 
reduction of NAD+ to NADH.  The increased NADH/NAD+ ratio has 
profound effects on the metabolism of carbohydrates and lipids. 
Gluconeogenesis is impaired and substrate flow through the TCA cycle is 
diminished, with acetyl CoA diverted toward ketogenesis and FA synthesis. In 
addition to increased FA synthesis, the altered redox state also directly 
inhibits FA ?-oxidation in the mitochondria. Through these two 
mechanisms, the altered redox state can contribute toward increased 
substrate supply and FFA accumulation (Stewart and Day 2011). 
 
3.4.1.3. PPAR?  inhibition: 
Ethanol can also inhibit FA oxidation through inhibition of the transcription 
factor PPAR?, a known regulator of FA oxidation in the liver. Ethanol 
feeding decreases transcription and DNA binding activity of PPAR?, leading 
to the accumulation of FFAs in the liver after ethanol feeding, thus promoting 
TG synthesis and potentially necroinflammation and fibrosis (Stewart and 
Day 2011). 
 
3.4.1.4. TG export inhibition: 
Another contributor to alcohol-induced hepatic steatosis is the decrease in 
the export of TG from the liver. Usually fat is exported into the circulation in 
the form of VLDL. Chronic ethanol ingestion generates a defect in VLDL 
exporting mechanisms. Acetaldehyde can bind to ?-tubulin and disrupt 
microtubule dynamics. In addition, ethanol intake down-regulates 
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microsomal triglyceride transfer protein (MTP), principal enzyme responsible 
for packing TG and apolipoprotein B (ApoB) into VLDL particles (Stewart 
and Day 2011). In addition, ethanol-mediated decrease in 
phosphatidylcholine contributes to the impairment in VLDL secretion (Ji, 
Shinohara et al. 2008). 
 
3.4.2. Ethanol hepatotoxicity: 
3.4.2.1. Inhibition of the methionine cycle: 
Ethanol is capable of inhibiting transmethylation reactions in the liver and 
this is the major mechanism leading to abnormal methionine metabolism 
associated with ethanol consumption. Methionine adenosyltransferase 
(MAT) catalyzes the synthesis of S-adenosyl-L-methionine (SAMe) from 
methionine and ATP. After donation of a methyl group, SAMe becomes S-
adenosylhomocysteine (SAH), which, through homocysteine, acts as a 
precursor for GSH. Methionine synthase (MS) regenerates methionine from 
homocysteine in a reaction that requires normal levels of folate and vitamin 
B12, and betaine-homocysteine methyltransferase (BHMT) regenerates 
methionine from homocysteine in a reaction that requires betaine (Figure I-
20). The principal enzyme inhibited by ethanol is MS, causing as a result 
hyperhomocysteinemia (HHcy) (Stewart and Day 2011). 
 
 
Figure I-20. Methionine metabolism (Anstee and Day 2012). 
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HHcy has been implicated in the pathogenesis of atherosclerosis, Alzheimer 
disease and ALD through activation of ER stress, which can explain many 
processes of homocysteine-promoted cell injury such as apoptosis, fat 
accumulation, and inflammation (Ji and Kaplowitz 2004). As for the fat 
accumulation, ER stress triggered by homocysteine increases the gene 
expression of SREBP1c, transcription factor that promotes FA synthesis via 
up-regulation of lipogenic enzymes. Studies have shown that ethanol induces 
SREBP1c in rat hepatoma cell lines and mouse liver with a concomitant 
increase in the expression of lipogenic genes, and that this induction may be 
related to inhibition of AMP-activated protein kinase (AMPK) (You, Fischer 
et al. 2002). However, SREBP1c deletion prevents alcohol-induced hepatic 
steatosis but it is associated with liver injury and up-regulation of SREBP2 
and cholesterol synthesis (Ji, Chan et al. 2006). 
 
Ethanol induces HHcy, triggers ER stress, and promotes the features of ALD 
including steatosis. Furthermore, feeding mice betaine, a methyl donor 
converting homocysteine to methionine via BHMT, significantly inhibits the 
development of steatosis, implying that it is the inhibition of methylation and 
resulting HHcy that is responsible for alcohol-induced steatosis (Ji and 
Kaplowitz 2003). It has been shown that the effect of ethanol on 
development of HHcy is independent of TNF-?, and that these two 
mechanisms induce steatosis independently and in parallel (Stewart and Day 
2011). 
 
3.4.2.2. ER stress: 
The contribution of ER stress to ALD has been identified in animal models. 
First, in intragastric model of alcohol-fed mice, severe steatosis, scattered 
apoptosis and necroinflammation were observed. Microarray gene expression 
profiling of liver samples from the intragastric alcohol-fed versus pair-fed mice 
revealed altered expression of genes related to ER stress response. Moderate 
up-regulation of SREBP1c and SREBP2 expression and their responsive 
genes was detected by RT-PCR and immunoblotting (Ji 2008). 
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In addition to HHcy, alcohol intake induces ER stress by other mechanisms 
including acetaldehyde-protein adduct formation, and oxidative stress. 
Oxidative stress resulting mainly from alcohol-induced CYP2E1 and 
increased ratio of NADH/NAD+ causes many nonspecific effects, including 
the ER stress response. Acetaldehyde is able to induce ER stress in cultured 
Hep G2 cells and activation of SREBP1c in rat hepatoma cells (Lluis, Colell 
et al. 2003). Homocysteine-induced ER stress in ALD has been also observed 
in vivo (Kaplowitz and Ji 2006; Ji 2008). 
 
ER stress turns on key mechanisms which contribute not only to ALD but 
also to NAFLD, including:  
 
1. Induction of steatosis through activation of SREBPs, transcription 
factors that will up-regulate both cholesterol and TG synthesis. 
2. Induction of inflammation and death pathways if ER homeostasis 
cannot be re-established. 
 
ER stress response will be further discussed in Section 4. 
 
3.4.2.3. Acetaldehyde: 
It is widely considered that acetaldehyde, the first metabolite of ethanol, has 
a central role in the pathogenesis of ALD. Several mechanisms of 
acetaldehyde toxicity have been established: 
 
• Protein and DNA adducts: acetaldehyde can bind covalently to 
albumin, tubulin, hemoglobin, plasma proteins, collagen, and 
microsomal enzymes and results in both stable and unstable adduct 
formation. This binding may affect protein function, which has been 
implicated in the pathogenesis of ALD (Figure I-21). Defects in 
assembly of microtubules, protein excretion, and enzymatic activity 
have all been attributed to acetaldehyde; however, no clear-cut 
evidence exists for the contribution of these mechanisms to disease 
progression (Stewart and Day 2011). Along the potential disruption 
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of protein function, the formation of protein-acetaldehyde adducts 
results in the production of immunodominant antigenic determinants 
that activate the adaptive immune system and contribute to ALD 
progression. 
• ER stress: related to generation of protein adducts due to its 
reactivity, acetaldehyde induces ER stress by a poorly understood 
mechanism (Lluis, Colell et al. 2003). However, it is tempting to 
speculate that perturbation of protein secretion and perpetuation of 
protein-acetaldehyde adducts in the ER may promote ER stress, 
which in turn may lead to disturbed protein and lipid homeostasis, 
such as cholesterol regulation and trafficking to mitochondria. 
• Reduced mGSH pool: acetaldehyde induces a selective reduction of 
mGSH and increases hepatocyte sensitivity to TNF-?. The 
mechanism of acetaldehyde-induced mGSH depletion involves 
inhibition of GSH transport from cytosol into the mitochondria 
secondary to accumulation of cholesterol within the mitochondrial 
inner membrane, resulting in increased viscosity (Lluis, Colell et al. 
2003). 
 
3.4.2.4. Oxidative stress: 
It has been established a role for oxidative stress and lipid peroxidation in the 
pathogenesis of ethanol-induced liver injury. These are some of the evidences:  
  
• Products of lipid peroxidation can be detected in the peripheral 
blood of heavy drinkers and in the livers of patients with ALD, and 
the magnitude of lipid peroxidation correlates with the degree of liver 
injury (Figure I-21). 
• In patients and animal models of ALD, lipid peroxidation is most 
prominent in the perivenular region where liver injury is typically 
most severe. 
• A variety of sources of oxidative stress have been identified in patients 
with ALD and in animal models of disease. 
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• Ethanol consumption results in the depletion of endogenous 
antioxidant capabilities and patients with ALD have evidence of 
antioxidant deficiencies. 
• In animal models of ALD, dietary and genetic manipulations that 
increase oxidative stress increase the severity of liver injury and 
reducing oxidative stress ameliorates hepatic injury (Stewart and Day 
2011). 
 
 
Figure I-21. Mechanisms of ethanol hepatotoxicity in ALD(Stewart and Day 2011).  
 
In addition to oxidative stress, ethanol consumption results in a depletion of 
endogenous antioxidant defenses. Consumption of GSH during oxidative 
stress and inhibition of the synthesis of its precursor SAMe through 
inhibition of MS and MAT1A contribute to the decreased levels of hepatic 
SAMe and GSH observed in patients with ALD.  
 
Moreover, depletion of mGSH precedes and promotes the progression of 
alcoholic liver injury in animal models increasing sensitivity of hepatocytes to 
TNF-? induced cytotoxicity (Lluis, Colell et al. 2003; Marí, Morales et al. 
2012). 
 
3.4.2.5. Mitochondrial cholesterol: 
Mitochondria are cholesterol-poor organelles with estimates ranging from 
0.5-3% of the content found in other cellular membranes. This cholesterol in 
mitochondria plays important physiological roles in specific processes 
including steroidogenesis and synthesis of steroid hormones in specialized 
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tissues, as well as bile acids in hepatocytes. As discussed in the NAFLD 
section 2.5.3., the over enrichment of cholesterol in mitochondria can result 
in mitochondrial dysfunction and impairment of specific carriers, including 
the mitochondrial transporters of GSH, through alterations in mitochondrial 
membrane order.  
 
Alcohol feeding causes mGSH depletion due to alcohol-stimulated 
cholesterol de novo synthesis. Alcohol causes cholesterol-mediated loss of 
mitochondrial membranes dynamics, which then impairs mitochondrial 
transport of GSH from the cytosol resulting in its depletion (Lluis, Colell et 
al. 2003).  
 
The mechanisms involved in the trafficking of cholesterol to this 
compartment involve a role of StART family of proteins in the mitochondrial 
delivery of cholesterol. StARD1, founding member of the growing family of 
proteins, plays a major role in the intramitochondrial movement of 
cholesterol from the mitochondrial outer membrane to the mitochondrial 
inner membrane. Moreover, StARD1 mRNA and protein have been detected 
in primary human hepatocytes and Hep G2 cells, and its overexpression in 
rat hepatocytes increased bile acid production (Garcia-Ruiz, Marí et al. 
2011).  
 
Another emerging player of cholesterol trafficking to the mitochondria is 
caveolin-1 since it has cholesterol-binding properties, which makes it a 
potential intracellular transporter of lipids. Work in our lab described that 
caveolin-1 knockout mice exhibit increased mitochondrial cholesterol 
causing mitochondrial dysfunction and disease susceptibility including NASH 
(Bosch, Marí et al. 2011). 
 
3.4.2.6. Endotoxin activation of innate immunity: 
Endotoxin, which refers collectively to the LPS components of the cell wall 
of all gram-negative bacteria, appears to play an important role in the 
development of ALD. Alcohol consumption not only causes enteric dysbiosis 
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and bacterial overgrowth but also increases gut permeability and 
translocation of bacteria-derived LPS from the gut to the liver. These 
changes ultimately contribute to increased levels of LPS observed in patients 
with ALD. In Kupffer cells, LPS interacts with TLR4 leading to production 
of oxidative stress and proinflammatory cytokines, including TNF-?, which 
causes hepatocellular damage. Alcohol consumption also activates 
complement C3 and C5, which subsequently activate Kupffer cells (Gao and 
Bataller 2011). Thus, LPS acting as a second hit in an alcohol-induced fatty 
liver contributes to ALD progression (Figure I-21). 
 
3.4.2.7. TNF-ASMase-Ceramide axis in ALD: 
TNF is of great relevance to liver pathology, as its expression and levels 
increase in many forms of liver diseases such as ALD. TNF is a 
proinflammatory cytokine produced mainly by activated macrophages and in 
smaller levels by other cell types. TNF exerts a variety of effects that are 
mediated by TNF receptor 1 and 2 (TNFR1 and TNFR2), with TNFR1 
being mainly responsible for the apoptotic effects of TNF. In vivo data, have 
demonstrated the implication of TNF in alcohol-induced hepatocyte death. 
Mice lacking TNFR1 are protected against alcohol-induced liver damage. 
Moreover, treatment with antibodies anti-TNF attenuates hepatic necrosis 
and inflammation caused by chronic exposure to ethanol. Furthermore, 
patients with ALD exhibit increased expression of TNF and TNFR1 in 
plasma and liver (Fernandez-Checa, Colell et al. 2005). 
 
Normally, hepatocytes are resistant to TNF-? as it generates both survival 
and death pathways. Interestingly, hepatocytes isolated from alcohol-fed rats 
develop an unusual sensitivity to TNF-? exposure in the absence of any other 
sensitizing factor (Colell, García-Ruiz et al. 1998). Acetaldehyde induces ER 
stress activating cholesterol synthesis, which results in FC accumulation in 
mitochondrial membranes. This FC impairs mGSH transport depleting GSH 
reserves, thus sensitizing hepatocytes to TNF-? (Lluis, Colell et al. 2003) 
(Figure I-22). Other models that decrease mGSH levels such as 
acetaminophen also sensitize hepatocytes to TNF-induced apoptosis. These 
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observations indicate that changes in antioxidant status resulting in altered 
redox environment may be key in the final outcome of hepatocytes in 
response to TNF-? (Fernandez-Checa, Colell et al. 2005). 
 
 
 
Figure I-22. Role of cholesterol and ceramide in ALD (Fernández, Colell et al. 2008).  
 
An interesting intermediate of TNF-induced hepatocellular death is the 
sphingolipid ceramide, which has been implicated as effector of TNF-
mediated apoptosis (Hannun and Luberto 2000). Ceramide can be generated 
through several mechanisms, including de novo synthesis in the ER and by the 
hydrolysis of membrane SM by the action of SMases. This pathway promotes 
specific macrodomain formation in the plasma membrane allowing 
oligomerization of cell surface proteins such as TNF receptors. In particular, 
ASMase has been shown to contribute to FAS and irradiation-mediated 
apoptosis through targeting glycosphingolipids to the mitochondria (García-
Ruiz, Colell et al. 2003) and through the down-regulation of MAT1A with 
the subsequent SAMe depletion (Marí, Colell et al. 2004). These studies 
established a hierarchical ordering of intermediates in TNF-? signaling where 
ASMase was required for optimal caspase-8 activation. Thus, TNF-? induces 
apoptosis through ASMase activation and subsequent increased ceramide 
levels, which activate caspase-8 to start cell death programs (Fernandez-
Checa, Colell et al. 2005). 
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In addition, chronic alcohol feeding to mice activates hepatic ASMase, and 
increases hepatic ceramide levels. This activation contributes to hepatic 
steatosis (Deaciuc, Nikolova-Karakashian et al. 2000; Setshedi, Longato et 
al. 2011; Liangpunsakul, Rahmini et al. 2012). Moreover, imipramine 
ASMase inhibition in alcohol-fed mice improves hepatic steatosis, decreases 
ceramide levels and stress kinases activation like JNK (Liangpunsakul, 
Rahmini et al. 2012). Although more mechanistic studies will be needed to 
completely understand the participation of ASMase in ALD, these findings 
point ASMase as potential new target for ALD treatment 
 
3.5. Management of ALD: 
Despite the profound economic and health impact of ALD, little progress has been made 
in the management of patients with this severe clinical condition and no new drugs for 
ALD have been successfully developed since the early 1970s, at which time the use of 
corticosteroids was proposed for the treatment of severe alcoholic hepatitis. The current 
therapeutic options for ALD include: 
 
3.5.1. Abstinence: 
Just like in NAFLD, the most successful treatment is a life style change 
eliminating ethanol intake. Continued alcohol ingestion is the single most 
important risk factor for progression of the disease. Abstinence is also critical for 
patients with advanced disease who could eventually require liver transplantation, 
because patients who actively engage in alcohol consumption are not eligible for 
transplantation programs. Referral to rehabilitation programs, in combination 
with family support, is usually necessary. Some patients require pharmacological 
treatment to help fighting ethanol cravings but special care must be taken because 
of the potential hepatotoxicity of these drugs (Gao and Bataller 2011). 
 
3.5.2. Corticosteroids: 
Of all the treatments available for patients with severe ALD, corticosteroids are 
the most intensively studied, and probably the most effective. Steroids are aimed 
at suppressing the hepatic inflammatory response seen in liver biopsies from 
patients with severe ALD. Despite many clinical trials, the debate over the use of 
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steroids in ALD continues. It appears that they are probably beneficial in patients 
with severe disease; however, mortality on treatment remains high. On the other 
hand, is relatively contraindicated in the large number of patients with 
concomitant infection and gastrointestinal bleeding. In addition, there are also 
significant numbers of patients that fail to respond to corticosteroids. It is because 
of these limitations that alternative therapeutic strategies have been sought (Gao 
and Bataller 2011; Stewart and Day 2011). 
 
3.5.3. TNF-?  blockage: 
As TNF-? is an important mediator of ALD treatments targeting TNF-? action 
have been developed. Pentoxifylline is a phosphodiesterase inhibitor that blocks 
transcription of TNF-? and decreases serum levels of the gene product. 
Pentoxifylline has been used in patients with severe ASH who cannot be given 
corticosteroids. Unfortunately, pentoxifylline is not effective as a rescue therapy 
for patients who do not respond to corticosteroids (Gao and Bataller 2011). 
Another TNF-? blocking strategy was the use of monoclonal antibodies against 
TNF-?. Early-stage studies showed positive results in terms of survival and safety, 
but later-stage clinical trials showed that these drugs actually increased mortality 
and risk of infection among patients with ASH. These reagents are therefore not 
recommended for the treatment of ASH (Gao and Bataller 2011). 
 
3.5.4. SAMe: 
SAMe is a methyl donor that has been shown to protect against alcoholic liver 
injury via multiple mechanisms, including antioxidant functions, maintenance of 
mitochondrial function, and down-regulation of TNF-?. An early-stage trial 
showed that SAMe as a supplemental agent significantly decreased mortality and 
need for liver transplantation among patients with ALD and it had a favorable 
safety profile. However, long-term, high-quality, randomized trials are required to 
establish its therapeutic effects (Gao and Bataller 2011).  
 
3.5.5. Antioxidants: 
Because ALD is associated with increased levels of oxidative stress, a number of 
studies have investigated the benefits of antioxidants (e.g. vitamin E). 
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Unfortunately, in early-stage studies, survival times of patients with ASH did not 
increase. However, a combined therapy study with N-acetylcysteine with 
corticosteroids showed an increase number of patients survived a short-therm 
follow-up period (Gao and Bataller 2011).  
 
3.5.6. Liver transplantation 
Liver transplantation has been used to treat patients with decompensated ALD. 
Outcomes are equal to or better than those obtained when it is used to treat end-
stage liver disease from other causes. Several liver transplantation centers have 
therefore proposed that this be a rescue option for patients with severe ASH who 
do not respond to medical therapy and are unlikely to survive the mandatory, 6-
month abstinence period but who fulfill all other standard criteria for 
transplantation, including a thorough psychosocial evaluation (Gao and Bataller 
2011).  
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4. ENDOPLASMATIC RETICULUM STRESS IN LIVER DISEASE. 
The ER is the intracellular organelle responsible for synthesis, folding, trafficking, and 
maturation of proteins. In addition, the ER has other important functions such as TG, 
sphingolipids and cholesterol synthesis, drug metabolism, as well as storage and release of 
Ca2+. The ER membrane is composed of very low concentrations of cholesterol and 
complex sphingolipids, which likely provides an adequate environment for insertion and 
transport of newly synthesized lipids and proteins. The requirement for such a specialized 
lipid environment may be relevant to diseases characterized by abnormal lipid 
accumulation (Zhang and Kaufman 2008). 
 
Under normal conditions, a homeostatic equilibrium exists between influx of unfolded 
peptides and folding capacity of the ER. As the physiologic rate of protein synthesis 
changes, a signal transduction pathway between the ER and other organelles has evolved 
to mediate adaptation to the new folding demands to regain homeostasis and promote 
survival. These physiological adaptive responses are called the unfolded protein response 
or UPR. The UPR is of particular importance in cells rich in ER content and responsible 
for protein synthesis, such as hepatocytes. The insufficiency of the ER stress response to 
meet the increased folding needs of the cell, activates a pathologic response resulting in 
lipogenesis, inflammation, and activation of apoptotic pathways.  
 
Hepatocytes, like other secretory cells, are rich in ER. Because of their high protein 
synthesizing capacity, it is easy to postulate that ER stress plays an important role either 
in preventing or mediating pathological changes in various liver diseases (Zhang and 
Kaufman 2008). 
 
When protein load in the ER increases, three main branches of the UPR are activated. 
These homeostatic responses aim to bring the organelle and the cell into a state of 
equilibrium through several strategies: 
• Increase chaperone capacity: producing more chaperones to increase folding 
capacity of the ER. Prototype: glucose-regulated protein 78 (GRP78) 
• Enhancing folding capacity: through transcriptional up-regulation of enzymes 
participating in protein folding processes. Prototype: Protein disulfide isomerase 
(PDI). 
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• Inhibition of protein synthesis: decreasing protein entry through affecting the 
translation and synthesis of new polypeptides. Prototype: inhibitory 
phosphorylation of eukaryotic translation factor-2? (p-eIF2?), initiator of 
protein translation. 
• Enhancing ER-associated protein degradation (ERAD) and autophagy. 
Prototype: ER degradation enhancer, mannosidase alpha-like 1 (EDEM). 
 
The three branches of the UPR are: 
1. Activating transcription factor-6 (ATF6) 
2. Inositol-requiring enzyme-1? (IRE1?) 
3. Protein kinase double-stranded RNA-dependent–like ER kinase (PERK).  
 
All of them are transmembrane sensors embedded in the ER, which are kept inactive by 
binding to the intraluminal chaperone, GRP78. When the ER is stressed either by 
glucose deprivation, the depletion of calcium stores, oxidative stress or the accumulation 
of misfolded proteins, GRP78 is displaced from the stress sensors to aid in protein folding 
(Figure I-23). This event initiates an intricate cascade that ultimately determines the fate 
of the cell. These sensors are activated by self-association and autophosphorylation 
(IRE1? and PERK) or translocation to the Golgi (ATF6) for proteolytic release of the 
active transcription factor (referred to as regulated intramembrane proteolysis [RIP]) 
(Dara, Ji et al. 2011) (Figure I-23). 
 
 
Figure I-23. The unfolded protein response (Malhi and Kaufman 2011). 
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PERK acts by global inhibition of protein synthesis through phosphorylation of eIF2?. 
PERK also regulates the transcription of ribosomal RNA via phosphorylated eIF2? and 
preferentially increases the translation of activating transcription factor 4 (ATF4), which 
in turn activates the transcription of C/EBP (CCAAT/enhancer binding protein) 
homologous protein (CHOP), involved in cell death pathways. IRE1? is an 
endoribonuclease that activates X-box binding protein 1 (XBP1) by unconventional 
splicing of XBP1 messenger RNA, resulting in transcription of UPR elements and ER 
stress response element genes that control ERAD and chaperones. IRE1? also degrades 
the messenger RNA of many secretory and transmembrane proteins and thus also helps in 
decreasing the protein load that enters the ER. Active ATF6 after RIP translocates to the 
nucleus, which together with ATF4 and sXBP1, activate ER stress response and UPR 
elements. The products of the genes regulated by these elements facilitate the folding and 
elimination of accumulated proteins via EDEM, a component of ERAD, as well as up-
regulation of chaperones that aid in protein folding (Dara, Ji et al. 2011) (Figure I-23). 
 
All arms of the UPR are signal transduction mechanisms that lead to the production or 
release of transcription factors, which regulate the UPR (sXBP, ATF4, ATF6). This 
mechanism is primarily a cytoprotective survival response that seeks to regulate protein 
folding and restore homeostatic balance. When the activation of the UPR fails to 
promote cell survival, a proapoptotic ER stress pathway is activated, which can 
ultimately lead to apoptotic cell death, inflammation, and/or fat accumulation (Zhang 
and Kaufman 2008). 
 
4.1. ER stress, inflammation and cell death: 
The pathologic ER stress response can be activated in a variety of ways. Some of them are 
summarized bellow:  
• Increased CHOP expression leading to activation of the proapoptotic pathways 
by:  
o Promotion of oxidative stress and inflammation which down-regulates 
anti-apoptotic Bcl2 proteins and up-regulates transcription of pro-
apoptotic protein Bim.  
o CHOP induces growth arrest and DNA damage-inducible protein 34 
(GADD34), which associates with protein phosphatase- 1 and promotes 
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dephosphorylation of p-eIF2? resuming protein synthesis, which could be 
harmful if protein overload were to continue (Figure I-24). 
o CHOP and ATF4 together induce tribbles homolog 3 (TRB3), which 
inhibits the cytoprotective, insulin-sensitizing Akt kinase. 
• PERK-mediated global protein translation shutdown results in decreased I?B, 
which leads to inflammation through NF-?B activation (Figure I-24). 
• IRE1?-mediated recruitment of proapoptotic signals such as tumor necrosis 
factor receptor–associated factor 2 (TRAF2) and JNK which can lead to 
autophagy, insulin resistance, and apoptosis. TRAF2 can recruit IKK and 
promote NF-?B-mediated inflammation (Figure I-24). 
• Proapoptotic Bcl2 proteins regulate apoptotic cell death via altering Ca2+ 
homeostasis have been linked to the ER stress response and in particular to the 
IRE1? branch. When activated, Bcl2 proteins can lead to Ca2+ release, calpain 
activation causing mitochondrial depolarization, and increased ROS, as well as 
the activation of caspase 4, which along with JNK modulates apoptosis. Ca2+ 
release is a critical factor in affecting mitochondrial function, particularly in areas 
in which the ER is in close association with the mitochondria; so-called 
mitochondria associated membrane (MAM) (Dara, Ji et al. 2011) (Figure I-24). 
As mitochondria dysfunction is associated with ER stress via Ca2+ release from the 
ER, understanding of the mechanism of mitochondrial Ca2+ uptake, and 
subsequent onset of mitochondrial permeability transition may be of interest to 
modulate ER stress mediated cell death. 
  
 
Figure I-24.  Cell signaling pathways in prolonged ER stress (Dara, Ji et al. 2011). 
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4.2. ER stress and lipogenesis: 
Prolonged ER stress response leads to steatosis: SREBPs are a family of ER resident 
proteins which function as transcription factors in the control of FA, TG, and cholesterol 
synthesis. They are synthesized as inactive precursors bound to the ER in a complex with 
SREBP-cleavage activating protein (SCAP).  In the presence of cholesterol and 
oxysterols, SCAP undergoes conformational changes causing it to bind to its protein 
inhibitor Insig. Insig prevents translocation of the SREBP/SCAP complex to the Golgi. 
Protein attenuation after ER stress induction decreases Insig protein synthesis and as a 
result SCAP is free to escort SREBPs to the Golgi where they undergo RIP activation, 
translocate to the nucleus and promote lipogenesis (Basseri and Austin 2012) (Figure I-
25). 
 
 
Figure I-25.  ER stress-induced lipogenesis (Flamment, Hajduch et al. 2012).  
 
In addition, ER stress activation of JNK pathway can lead to insulin resistance (Ozcan, 
Cao et al. 2004) and insulin resistance leads to steatosis. Moreover, PERK-induced 
protein synthesis attenuation decreases ApoB, a very important lipoprotein vital for 
VLDL assembly and secretion. Impaired VLDL secretion via decreased ApoB contributes 
to ER stress-induced hepatic steatosis. Furthermore, GRP78 may directly interact with 
SREBPs inhibiting its translocation, so displacement of GRP78 induced by increased 
unfolded proteins in the ER may also allow SREBPs to translocate to the Golgi and 
undergo RIP contributing this way to hepatic steatosis (Dara, Ji et al. 2011) (Figure I-
25). 
 
4.3. ER stress and fatty liver disease: 
The relationship between ER stress and fatty liver is reciprocal. Steatosis has been shown 
to promote ER stress and viceversa; ER stress response leads to steatosis.  Induction of 
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ER stress response by treatment with tunicamycin leads to alteration of SREBP 
expression and hepatic steatosis in Hep G2 cells (Dara, Ji et al. 2011). 
 
On the other hand, genetically obese ob/ob mice displaying hepatic steatosis show 
increased markers of ER stress in liver and white adipose tissue. This observation is 
paired with JNK activation and linked insulin resistance through JNK-mediated 
inhibitory phosphorylation of insulin signaling pathway. Likewise, mice exposure to high 
fat diet for four months also increases ER stress markers compared to mice fed a regular 
diet (Ozcan, Cao et al. 2004). Moreover, treatment with chemical chaperones, which 
may increase ER folding capacity, has been shown to decrease ER stress, insulin 
resistance and resolve fatty liver in ob/ob mice (Ozcan, Yilmaz et al. 2006). In addition, 
selective liver deletion of XBP1 in mice results in marked hypocholesterolemia and 
hypotriglyceridemia. Furthermore, hepatic overexpression of protein chaperone GRP78 
in ob/ob mice reduces ER stress markers and inhibits SREBPs expression and activation, 
resulting in decreased hepatic TG and cholesterol content and improved insulin 
sensitivity (Kammoun, Chabanon et al. 2009). Furthermore, it has been demonstrated 
that alterations in ER lipid composition in obesity disrupts Ca2+ homeostasis through 
inhibition of sarco/endoplasmic reticulum calcium ATPase (SERCA) activity causing liver 
ER stress. Correction of obesity-induced alteration of ER phospholipid composition 
improves ER stress and glucose homeostasis (Fu, Yang et al. 2011). These data 
demonstrates that ER stress response can promote lipogenesis and fatty liver and that its 
inhibition can help improve hepatic manifestations of NAFLD like steatosis, insulin 
resistance and inflammation.  
 
The human relevance of these findings in mouse models was established in a study that 
used human liver and white adipose tissue samples from obese patients who underwent 
gastric bypass. Samples before the procedure showed increased ER stress markers that 
were markedly lowered after the surgery-induced weight loss (Gregor, Yang et al. 2009). 
In another study, liver samples from patients with NAFLD and NASH demonstrated 
increased eIF2? phosphorylation and GRP78 expression (Puri, Mirshahi et al. 2008).  
 
Regarding ALD, hepatic ethanol-induced steatosis and apoptosis has been linked to ER 
stress. Mice fed alcohol intragastrically exhibit severe steatosis, apoptosis, and 
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necroinflammation as well as up-regulation of UPR genes and ER stress response (Ji 
2008). In addition, increased expression and activation of SREBPs has been detected in 
alcohol-fed mice, further supporting the relation between alcohol, steatosis, and ER 
stress (Dara, Ji et al. 2011). Moreover, CHOP knockout mice fed ethanol show no 
change in ER stress markers or steatosis but they display marked inhibition of apoptosis 
(Ji, Mehrian-Shai et al. 2005). Furthermore, in micropigs fed alcohol, liver steatosis is 
accompanied by increased transcription of GRP78, SREBP, and activated caspase 12 
(Dara, Ji et al. 2011). Also, cirrhotic rat livers exhibit markers of ER stress response after 
challenge with lipopolysaccharide, which has been implicated in alcohol-induced liver 
injury (Tazi, Bièche et al. 2007). 
 
The mechanism proposed for ethanol-induced ER stress is HHcy, hallmark of alcohol 
intake, which is believed to interfere with protein folding, thus causing ER stress. Alcohol 
feeding decreases MS activity, Hcy cannot be recycled to methionine resulting in HHcy. 
HHCy interference with protein folding causes ER stress that activates SREBPs leading 
to TG and cholesterol accumulation. The later one will affect mitochondrial membrane 
physic properties resulting in impairment of mGSH transport. mGSH depletion 
sensitizes the cells to other insults (Lluis, Colell et al. 2003). On the other hand, ER 
stress will also activate apoptotic pathways like CHOP and lead the cell to death (Figure 
I-26). 
 
 
Figure I-26. Ethanol-induced ER stress model (Kaplowitz and Ji 2006). 
 
Knowing that HHcy causes alcohol-induced ER stress, several studies aimed to decrease 
its levels by supplementing the alcoholic diets with betaine that will activate BHMT Hcy 
conversion to methionine or by directly overexpressing BHMT itself. These strategies 
have proven to decrease ER stress response, steatosis and inflammation both in cells and 
mouse models (Dara, Ji et al. 2011). These results indicate that lowering Hcy exposure 
to the liver is key in preventing alcohol-induced liver injury.  
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5. AUTOPHAGY IN LIVER DISEASE. 
The word autophagy is derived from the Greek roots “auto” (self) and “phagy” (eating) 
and refers to cellular catabolic processes in which cellular components are transported to 
lysosomes for degradation.  
 
Autophagy is a gatekeeper of cellular functions. Degradation of damaged and excess 
organelles as well as elimination of invading pathogens is essential to maintain cell 
homeostasis. Autophagy is the principal catabolic pathway allowing cells to survive the 
stress of intrinsic and extrinsic insults. Because of its ability to rapidly eliminate unwanted 
structures, this conserved eukaryotic pathway plays a central role in a multitude of 
physiological processes including cell death, development, cellular remodeling, 
differentiation and energy homeostasis (Czaja 2010). In addition, it plays a protective 
role against aging, tumorigenesis, neurodegeneration and infections. As a consequence of 
its crucial role in cell and organism physiology, impaired autophagy correlates with 
various severe pathologies including cardiovascular and autoimmune diseases, neuro- and 
myo-degenerative disorders, and liver diseases (Ravikumar, Sarkar et al. 2010; Komatsu 
2012). 
 
Three major types of autophagy have been described in eukaryotes: chaperone-mediated 
autophagy (CMA), microautophagy and macroautophagy. CMA involves a direct 
translocation of cytosolic proteins containing a pentapeptide motif across the lysosomal 
membrane.  Microautophagy is the process by which cytoplasmic material is sequestered 
through a direct invagination of the lysosomes. Macroautophagy, from now on 
autophagy, which is highly conserved from yeast to humans, is a bulk degradation process 
involved in the clearance of long-lived proteins and organelles.  
 
The autophagic process can be separated in five different stages (Figure I-27):  
• Induction: in liver, several stimuli can induce autophagy. For example, 
intracellular pathogens, hypoxia, ROS, ER stress, starvation or amino acid 
deprivation, radiation, proteasome inhibition and protein aggregation. The initial 
event upon induction is the formation of a membranous cistern called the 
phagophore, or isolation membrane. This compartment appears to be generated 
from what has been defined in yeast as the phagophore assembly site (PAS) or 
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pre-autophagosomal structure, a putative early autophagosome precursor that is 
formed by the sequential association of at least a subset of Autophagy-related 
genes (Atg) proteins, which are known to be specifically involved in autophagy. 
• Expansion: the phagophore expands through acquisition of additional lipids 
allowing the kidnapping of intracellular material targeted for degradation.  
• Vesicle completion: the double-membrane vesicle is completed when the inner 
and outer bilayers fuse to form two distinct membranes, one inside the other. At 
this point of the process the vesicle is called autophagosome. 
• Fusion: completed autophagosomes first fuse with endosomal structures to form 
amphisomes, and then with lysosomes forming the autolysosomes.   
• Cargo degradation: autophagosome fusion with the lysosome allows the 
degradation of the inner vesicle and its cargo by acid hydrolases residing in these 
lytic compartments. 
 
 
 
Figure I-27. Autophagic process (Mari, Tooze et al. 2011). 
 
Lastly, the basic metabolites generated from this catabolic processing of biological 
macromolecules are transported into the cytoplasm, where they are reused as either a 
source of energy or as building blocks for new proteins and lipids (Mari, Tooze et al. 
2011) (Figure I-27). 
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5.1. Autophagic machinery: 
So far, more than 30 different Atgs have been identified in yeast and most of them have 
mammalian homologs that participate in autophagy or in autophagy-related processes. 
Several multi molecular complexes have been found to contribute to autophagosome 
formation (Mehrpour, Esclatine et al. 2010; Ding, Manley et al. 2011) (Figure I-28): 
 
1. ULK1 protein-kinase complex: regulates autophagy initiation. This complex 
works downstream of mammalian target of rapamycin (mTOR) and serves as the 
cellular sensor for nutrient status to initiate autophagy by recruiting downstream 
autophagy proteins to the autophagosomes (Figure I-28). 
2. VPS34-Beclin1 class III PI3-kinase complex: regulates autophagy initiation. 
VPS34 is a class III PI-3-kinase that acts as an essential regulator of autophagy by 
producing phosphatidylinositol-3-phosphate (PI3P). The Beclin1 complex 
regulates VPS34 activity. Bcl-2 and Bcl-xL interact with Beclin1 to keep 
autophagy in check by dissociating the interaction of Beclin 1 and VPS34 (Figure 
I-28). 
3. Atg9-Atg2-Atg18 complex: regulates expansion of PAS by carrying lipids. Atg9 is a 
transmembrane protein located on the PAS. Atg9 is thought to cycle between the 
trans-Golgi network, late endosomes and the PAS to bring the additional 
membrane sources necessary for the growth of the autophagosomal membranes 
(Figure I-28). 
4. Atg5-Atg12-Atg16 complex: it is an ubiquitin-like conjugation system that 
provides the necessary platform for autophagy activation (Figure I-28). 
5. LC3 (microtubule-associated protein 1 light chain 3) conjugation systems: is the 
second ubiquitin-like conjugation system that regulates elongation of 
autophagosome membranes. LC3 is cleaved by Atg4 to form LC3-I. Then LC3-I 
is conjugated to phosphatidylethanolamine (PE) via Atg7 and Atg3. The 
unconjugated form LC3-I is in the cytosol, whereas the PE-conjugated form 
(LC3-II) targets the autophagosomal membrane following the Atg12-Atg5-Atg16 
complex. This association of LC3-PE to autophagosomes is considered important 
for membrane extension of the autophagosome and the eventual closure of the 
membrane to form a complete vesicle. LC3-I/II is thus widely used as a marker 
for monitoring the autophagic process (Figure I-28). 
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Figure I-28. Autophagic machinery (Ding, Manley et al. 2011). 
 
Newly formed autophagosomes are randomly distributed in the cytoplasm. During their 
maturation, autophagosomes move along microtubules toward the microtubule-
organizing center, where the lysosomes are enriched. Autophagosomes then fuse with 
lysosomes to form autolysosomes possibly through the small GTPase Rab7 and/or two 
lysosomal membrane proteins, LAMP1/2. Chemicals that disrupt microtubule structures 
such as vinblastine can inhibit autophagy. In addition to disruption of the fusion 
machinery, chemicals that increase lysosomal pH such as chloroquine and bafilomycin A 
1 or lysosomal protease inhibitors such as leupeptin and pepstatin A are all potent 
autophagy inhibitors. 
 
5.2. Autophagy regulation: 
Several signaling pathways appear to be involved in the regulation of autophagy in 
mammalian cells. The most relevant are summarized below: 
• Class I PI3K-Akt-mTOR: mTOR is a serine/threonine kinase involved in many 
aspects of cellular physiology, including transcription, translation, cell size and 
cytoskeletal organization. mTOR inhibition is a key signaling step in autophagy 
activation. The use of the mTOR inhibitor rapamycin significantly activates 
autophagy in rat hepatocytes (Ding, Manley et al. 2011). The activity of mTOR 
is regulated by the integration of various signals, including growth factors, insulin, 
nutrients, energy availability and cellular stressors such as hypoxia, osmotic stress, 
reactive ROS and viral infection. In response to growth factors, PI3K increases 
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PI3P that activate Akt, which in turn activates mTOR, thus inhibiting autophagy  
(Figure I-29). 
• AMP-activated protein kinase: AMPK is another upstream regulator of mTOR. 
AMPK monitors cell energy status through sensing adenosine monophosphate 
(AMP)/ATP ratio. Low-energy status, reflected by high AMP/ATP ratio, 
activates AMPK. AMPK activation down-regulates mTOR activity resulting in 
decreased protein translation and activation of autophagy (Figure I-29). 
• Bcl-2 family proteins: antiapoptotic Bcl-2 family proteins such as Bcl-2 can 
suppress autophagy by directly binding and inhibiting Beclin 1 complex. In 
contrast, proapoptotic BH3-only Bcl-2 family proteins can induce autophagy 
through their binding to antiapoptotic Bcl-2 proteins and subsequent 
displacement of the inhibitory Bcl-2 from Beclin 1 complex (Figure I-29). 
• ER stress: misfolded proteins in the ER normally undergo degradation through 
ERAD mediated by ubiquitin proteasome system. It was found that inhibition of 
proteasome activity triggers ER stress and autophagy through activation of IRE1? 
and JNK. JNK may further phosphorylate Bcl-2 and dissociate its binding from 
Beclin 1 and in turn activate autophagy (Figure I-29). 
• ROS: Inhibition of mitochondrial complexes as well as the use of mitochondrial 
uncouplers generate ROS and induce autophagy. Moreover, this induction can be 
suppressed by antioxidant treatment. One possible mechanism of ROS-mediated 
autophagy induction is the inhibition of Atg4-induced delipidation of LC3-II 
from the autophagosome for its recycling, thus activating autophagy (Figure I-29). 
 
 
Figure I-29. Autophagy regulation (Ding, Manley et al. 2011). 
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5.3. Macrolipophagy and NAFLD: 
It was recently established a new role of autophagy in the regulation of hepatic lipid 
metabolism (Singh, Kaushik et al. 2009). Besides the classical cytosolic lipases, autophagy 
regulates intracellular lipid stores through a process called macrolipophagy. Lipid 
droplets become trapped inside the double-membrane-bound autophagosome vesicles 
and are transported to lysosomes, where they are degraded to FAs (Figure I-30). The 
ability of autophagy to respond to changes in nutrient supply allows the cell to alter lipid 
droplet metabolism to meet energy demands. This alternative lysosomal lipid degradative 
pathway in hepatocytes explains their ability to rapidly mobilize large amounts of lipids 
despite their low levels of cytosolic lipases in comparison with adipocytes. In a 
physiological state, insulin inhibits both lipolysis and macrolipophagy (Rautou, Mansouri 
et al. 2010). 
 
 
Figure I-30. Macrolipophagy. A. Normal state, the minority of 
autophagosomes contain lipid and usually in combination with other cytosolic 
components. B. Nutrient deprivation, more autophagosomes contain lipids, 
often in the absence of other cargo (Dong and Czaja 2011). 
 
Pathophysiological changes in autophagy function can alter cellular lipid metabolism and 
promote disease states. For instance, autophagy inhibition can promote liver steatosis. 
Hepatocyte-specific Atg7-knockout mice have markedly increased hepatic lipid 
deposition (Singh, Kaushik et al. 2009). In both genetic (ob/ob mice) and dietary mouse 
models of chronic obesity and insulin resistance, a sustained increase in lipid availability 
results in markedly decreased hepatic autophagy (Liu, Han et al. 2009; Singh, Kaushik et 
al. 2009; Yang, Li et al. 2010). This decreased autophagy level impacts on other cellular 
functions and particularly on ER stress. Indeed, in liver tissue of lean mice, deficiency of 
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autophagy, induced by suppression of Atg7, results in ER stress (Yang, Li et al. 2010). 
This could be explained by the known role of autophagy in the degradation of unfolded 
proteins and in the removal of superfluous ER membranes: defect in autophagy may lead 
to the accumulation of unfolded proteins and thus to ER stress. In obesity, ER function 
is compromised due to nutrient and energy surplus in an inflammatory setting. 
Concomitantly, autophagy level is decreased, suggesting that failure to achieve autophagy 
may further impair ER function in the face of continuous energy and nutrient stress, 
contributing to organelle dysfunction and insulin resistance, a known consequence of ER 
stress. Interestingly, restoration of Atg7 expression results in significant reduction of 
obesity-induced ER stress in the liver of ob/ob mice. It rescues the defects in insulin 
receptor signaling, reduces serum insulin level, improves glucose tolerance and whole 
body insulin sensitivity through the suppression of hepatic glucose production and 
enhancement of insulin-stimulated glucose disposal in the periphery. It also decreases 
hepatic FA infiltration and liver TG accumulation (Singh, Kaushik et al. 2009; Yang, Li 
et al. 2010). Autophagy therefore represents a cellular target for abnormalities in lipid 
metabolism and accumulation.  
 
Interestingly, it has been described an opposite role of autophagy in adipocytes: 
inhibition of autophagy in adipocytes, rather than its stimulation, confers them a brown-
fat-cell-like phenotype that favors FA oxidation and increases insulin sensitivity (Singh, 
Xiang et al. 2009). In addition, adipose tissue autophagy seems to be essential for 
adipogenesis and its deficiency causes lipodistrophy (Zhang, Goldman et al. 2009). 
 
5.4. Autophagy and lysosomal storage disorders: 
Lysosomes are essential to fully complete autophagy; therefore, disorders that impair 
lysosomal fusion with autophagosomes or degradation capability will negatively impact 
autophagy. 
 
Among all lysosomal storage diseases, the sphingolipidose disease Niemann-Pick type C 
disease (NPC) is of special interest. NPC is a genetic disease caused by mutations in 
NPC1 or NPC2 genes whose protein products are thought to act cooperatively in the 
efflux of cholesterol from the late endosomes and lysosomes. As a result of NPC1 or 
NCP2 deficiency, FC derived from receptor-mediated endocytosis of LDL-cholesterol 
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accumulates in endolysosomal compartments in neurons and hepatocytes causing 
progressive neurological impairment that often begins in childhood. NPC is ultimately 
fatal and is currently untreatable (Schuchman 2010). Moreover, many patients exhibit 
severe liver function deterioration leading to premature death even before neurological 
symptoms arise (Schuchman 2010). A broad array of sphingolipids like SM and 
glycosphingolipids accumulate as well. NPC deficient mice show increased accumulation 
of autophagosomes in the brain. This is due, in part, to the induction of autophagy 
through increased Beclin 1, important player of initiation of autophagosome formation 
and maturation (Pacheco and Lieberman 2007). In addition, treatment of wild type 
fibroblast with U18666A, a small molecule that induces NPC-like lipid trafficking 
defects, increases Beclin 1 and LC3-II levels, suggesting that FC accumulation or 
sphingolipids may act as a proximal trigger (Ishibashi, Yamazaki et al. 2009; Lieberman, 
Puertollano et al. 2012). This induction was accompanied by the accumulation of the 
autophagic substrate p62/Sequestosome 1 (SQSTM1) (Pacheco and Lieberman 2007). 
These findings suggest that NPC1 deficiency leads to both induction of the early phases 
of autophagy, and impairment of autophagic flux. In addition, lysosomal cholesterol 
accumulation associated with NPC1 deficiency protects against lysosomal 
permeabilization and subsequent cell death induced by lysomotropic agents (Appelqvist, 
Nilsson et al. 2011). Thus, given that FFA induce lysosomal permeabilization (Li, Berk et 
al. 2008), lysosomal cholesterol accumulation may be a protective mechanism against cell 
injury of potential relevance in steatohepatitis and metabolism liver disease.  
 
NPC is a severe form of Niemann-Pick disease, while Niemann-Pick types A and B 
exhibit with milder symptoms. NPD type A and B are inherited disorders caused by loss 
of function mutations in the gene encoding ASMase. Reduced function or deficiency in 
ASMase leads to accumulation of sphingolipids and cholesterol as well in the cellular 
membranes. Till date, no experimental evidences on autophagy in these diseases or mouse 
models of these diseases have been published.  
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6. CERAMIDE & ACID SPHINGOMYELINASE IN METABOLIC DISEASES. 
The concept of "bioactive lipids", defined as changes in lipid levels that result in 
functional consequences, has been developed over the years. In the past 2 decades, many 
studies focused on this concept providing evidence on the role of bioactive lipids in cell 
biology and regulation of many cell functions. Thus seminal findings expanded the view 
that lipids are more than structural components of membrane bilayers, regulating a wide 
array of processes, including differentiation, proliferation, senescence and cell death 
among others. 
 
6.1. Sphingolipids: 
A big group of bioactive lipids that centered attention in the past two decades are the 
sphingolipids (SLs). SLs are a major class of lipids that are ubiquitous constituents of 
membranes in eukaryotes. As most of the lipids, when first discovered SLs were 
considered to play only structural roles in membrane formation. The backbone of SLs is 
sphingosine (SPH). J. L. W. Thudichum named the backbone of SLs in 1884 for its 
enigmatic ‘‘Sphinx-like’’ nature. Over the past 20 years, much progress has been achieved 
on SLs knowledge and new tools have been developed to uncover their function in 
physiology and disease.  
 
All SLs are defined by their 18-carbon amino-alcohol backbone or SPH, which is 
synthesized in the ER from an aminoacid and a FFA. Acylation of SPH by ceramide 
synthases (CerS) yields ceramide, the prototype SLs. Different acyl-CoAs can be used to 
form ceramide giving as a result a heterogeneous family of species whose function depends 
on the chain length of the FFA added (Hannun and Obeid 2011).  
 
Importantly, ceramide serves as a hub in SL metabolism, acting as a precursor of many 
other SLs. Complex SLs may be formed by addition of head groups to ceramide: 
• Sphingomyelins: SMs have a phosphocholine or phosphoethanolamine molecule 
with an ester linkage to the 1-hydroxy group of a ceramide. 
• Glycosphingolipids (GSLs): are ceramides with one or more sugar residues 
attached in a ?-glycosidic linkage at the 1-hydroxyl position. 
o Cerebrosides have a single glucose or galactose at the 1-hydroxy position. 
? Sulfatides are sulfated cerebrosides. 
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o Gangliosides have at least three sugars, one of which must be sialic acid. 
 
Ceramide is key in SL metabolism, serving as a precursor to ceramide-1-phosphate 
(C1P), SM and the entire family of GSLs. Moreover, in the degradative pathway, 
ceramide is the precursor of SPH, which in turn can be phosphorylated to sphingosine-1-
phosphate (S1P). Thus, ceramide not only stands as a key player in SL metabolism, but 
its functions depend on its biotransformation into other derivatives (Gault, Obeid et al. 
2010).  
 
6.2. Ceramide metabolism: 
Cumulative evidence over the last few decades revealed that most stress stimuli (e.g. 
inflammatory mediators, heat, UV radiation, hypoxia, chemotherapeutics, and oxidative 
stress) increase ceramide production as part of an evolutionarily conserved cellular 
response. Three major pathways account for the production of ceramide within the cell: 
 
• De novo ceramide synthesis: this pathway is compartmentalized in the ER and its 
rate-limiting step is the availability of substrates for the first reaction. De novo 
synthesis begins with the transfer of a serine residue onto an acyl-CoA, preferably 
a saturated one like palmitoyl-CoA, via serine SPT to form 3-keto-sphinganine 
(3KSn). Three subsequent enzymatic reactions, catalyzed by 3KSn reductase, 
CerS, and dihydroceramide desaturases, convert this transient intermediate into 
ceramide (Figure I-31). Originally, it was thought that this pathway was a slow 
and constant source of ceramide generation important for cellular membrane 
structure. However, recent studies showed how de novo synthesis enzymes are 
regulated under pathological scenarios where inflammation and ROS regulate 
their gene expression. In addition, inhibition of this pathway, correlating with 
decreased levels of ceramide content, improved pathological conditions such as 
obesity, insulin resistance, diabetes and atherosclerosis. These studies suggest that 
disruption of de novo ceramide synthesis may have a beneficial impact on 
metabolism (Bikman and Summers 2011). 
• Sphingomyelin hydrolysis pathway: is a second ceramide-generating pathway that 
involves the hydrolysis of the phosphocholine head group from SM by a small 
family of sphingomyelinase (SMase) enzymes distinguished by their pH optima 
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and/or subcellular distribution (Figure I-31). Compared with the de novo 
synthesis, the generation of ceramide through SMase activation is quick and 
transient, and has been involved in the apoptosis induced by apoptotic stimuli, 
such as death ligands, chemotherapeutic agents or ionizing radiation (Morales, 
Lee et al. 2007). Several SMases have been characterized of which two classes are 
of relevance in signaling: 
o The membrane-bound neutral SMases (NSMases) exhibit an optimum 
pH of 7.4. Three mammalian NSMases have been cloned. NSMase2 
exhibits a requirement for Mg2+ and a pH optimum of 7.4 and it is 
membrane bound. However, its expression is specific to the brain. 
NSMase3 exhibits Mg2+ dependency and pH optimum of 7.4 but unlike 
NSMase2 is ubiquitously expressed. NSMase3 is distributed mainly in the 
ER and Golgi and becomes activated very quickly upon stimulation with 
TNF-?. NSMase1 function still needs to be characterized.  
o Acidic SMases (ASMases) exhibit a pH optimum around 5. Three 
different pools or ASMase isoforms have been described. An acidic 
lysosomal/endosomal ASMase consistent with its strict acidic pH 
requirement, a secretory ASMase associated with inflammation and stress 
responses, and a receptor-activated ASMase, which undergoes a 
translocation to the outer cell membrane in specific microdomains, where 
it creates signaling platforms by the cell surface for receptors such as Fas. 
In addition, ceramide pool released upon ASMase activation has been 
shown to contribute to TNF-mediated death by downstream mechanisms 
that ultimately target and recruit mitochondria (Morales, Lee et al. 
2007). 
• Salvage pathway: ceramide can also be produced by the catabolism of other 
complex SLs. Through a series of events referred to as SL recycling or the salvage 
pathway, complex SLs (SM and GSLs) are degraded within acidic cellular 
compartments by resident enzymes to form ceramide, which is itself degraded 
into SPH and FFAs that are able to enter the cytosol. Once in the cytosol, SPH 
is converted back to ceramide via CerS. Though less well known, the salvage 
pathway may account for over half of the SL pool within the cell (Bikman and 
Summers 2011).  
INTRODUCTION 
? 71?
 
 
Figure I- 31. Sphingolipid metabolism (Ogretmen and Hannun 2004). 
 
SL metabolism is very dynamic and once ceramide is formed it can either mediate its 
actions as a secondary messenger or it can be metabolized into other SL. Ceramide is 
primarily used for the synthesis of SM by transferring a phosphocholine headgroup from 
phosphatidylcholine through the action of SM synthases, thereby also generating 
diacylglycerol (Figure I-30). Ceramide can also be phosphorylated by ceramide kinase 
(CK) to form C1P, which in turn can be recycled by a C1P phosphatase or glycosylated 
by glucosyl or galactosyl ceramide synthases (GCS) (Figure I-30). Ceramide is also 
metabolized by ceramidases (CDases), which remove the amide-linked FA to form SPH 
(Figure I-30). Three types of CDases have been classified by their pH optimum and 
subcellular localization: acid CDase, neutral/alkaline CDase, and alkaline CDase. SPH is 
then available for recycling into SL pathways or for phosphorylation by one of two SPH 
kinases, SK1 and SK2, to form S1P (Figure I-30). In turn, S1P phosphatases 
dephosphorylate S1P regenerating SPH. Finally, S1P lyase can metabolize S1P to release 
ethanolamine phosphate and hexadecenal (Bartke and Hannun 2009) (Figure I-31). 
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In addition to ceramide, S1P has attracted a great deal of attention due to its role 
regulating cell functions. Ceramide mediates many cell-stress responses, including the 
regulation cell growth, differentiation, senescence necrosis and apoptosis. However, S1P 
has crucial roles in cell survival, cell migration and proliferation, inflammation, 
angiogenesis and resistance to apoptotic cell death. Thus, in most contexts, S1P shows 
antagonizing effects to those of ceramide.  S1P binds to G-coupled receptors (S1P 
receptors) on the cell surface regulating various intracellular signaling pathways. The 
control of cell fate by these two lipids (ceramide/S1P) has been called the SL rheostat or 
SL biostat (Bartke and Hannun 2009; Brocklyn and Williams 2012). Other members of 
the family of bioactive SLs include C1P, which has roles in inflammation and vesicular 
trafficking, and glucosylceramide, which is involved in post-Golgi trafficking and in drug 
resistance (Bartke and Hannun 2009).  
 
It is worth mentioning that SM has been established as a membrane partner of 
cholesterol. SM regulates the capacity of membranes to absorb cholesterol and thereby 
controls sterol flux between the plasma membrane and regulatory pathways in the ER. 
This relationship exemplifies the importance of cholesterol/sphingolipid-rich domains in 
cholesterol homeostasis, as well as other aspects of cell signaling and transport (Ridgway 
2000). 
 
6.3. Ceramides and disease: 
Ceramide has been linked to many complex diseases like alcoholism, obesity, 
atherosclerosis, pulmonary disease, neurodegenerative diseases and cancer. 
 
Obesity and alcohol intake set the stage for increased ceramide generation.  On one 
hand, increased circulation FFAs coming from the adipose tissue may induce ceramide de 
novo synthesis. On the other hand, both obesity and alcohol intake are characterized by 
inflammation and increased circulating levels of inflammatory cytokines, especially TNF-
?, which in turn activates ASMase generating ceramide from SM hydrolysis.  
 
Several groups have demonstrated that small changes in tissue ceramide are enough to 
antagonize insulin action, providing a link between abnormalities in SL metabolism and 
the mechanism of insulin resistance (Summers 2006). For instance, genetic ablation or 
INTRODUCTION 
? 73?
pharmacological inhibition of de novo ceramide synthesis in obese mouse models 
improves body weight, whole body insulin sensitivity and hepatic steatosis (Holland, 
Brozinick et al. 2007; Yang, Badeanlou et al. 2009). Furthermore, hepatic ceramide levels 
are increased in NAFLD (Deevska, Rozenova et al. 2009; Pagadala, Kasumov et al. 
2012). In addition, chronic alcohol feeding in mice activates ceramide generation, 
contributing to hepatic steatosis (Deaciuc, Nikolova-Karakashian et al. 2000; Setshedi, 
Longato et al. 2011; Liangpunsakul, Rahmini et al. 2012). 
 
Human data showed that the presence of hepatic steatosis compared to control subjects 
correlates with increased adipose tissue ceramide concentrations.  In addition, weight loss 
decreases hepatic ceramide expression in obese patients with NAFLD and it correlates 
with lower serum ceramides. Furthermore, bariatric surgery decreases plasma ceramide 
levels and this decrease correlates with improved insulin sensitivity (Pagadala, Kasumov 
et al. 2012). Moreover, plasma ceramides are elevated in obese subjects with type 2 
diabetes and correlate with the severity of insulin resistance (Haus, Kashyap et al. 2008).  
 
All these data suggest that targeting ceramide production in metabolic diseases could 
improve the symptoms of several metabolic pathologies. Specifically, targeting the TNF-
inducible SM hydrolysis into ceramide by ASMase might be of great importance since 
inflammation is a hallmark of almost all these diseases. Therefore, preventing ASMase 
activation might ameliorate or stop the progression of many pathologies.  
 
6.4. Acid sphingomyelinase: 
Acid sphingomyelinase (ASMase; EC 3.2.1.14) is a key SL metabolism enzyme that 
catalyzes the cleavage of the phosphocholine head group of SM to generate ceramide. 
The enzyme has an optimal pH of 5.0 and an optimal temperature of 37ºC. Importantly, 
ASMase retains 50% of its activity at a neutral pH of 7.0, which explains ASMase ability 
to work in other locations with higher pH (Zeidan and Hannun 2010). 
 
Human ASMase is coded by SMPD1 gene located on the short arm of chromosome 11. 
There are no homologous or pseudogene sequences to SMPD1. It is a highly conserved 
gene among mammals and its human amino acid sequence shares 82% of homology with 
the mouse ASMase. ASMase undergoes extensive posttranslational modifications. 
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Glycosylation is an important determinant of glycoprotein sorting and folding. ASMase 
has six potential glycosylation sites that are required for its proper trafficking as well as to 
protect it from the proteolytic activity in the lysosomes (Zeidan and Hannun 2010).  
 
The precursor of ASMase is a 75 KDa protein that is cleaved within the Golgi to a major 
72 KDa form and a minor 57 KDa form. Within the Golgi, mannose 6 phosphate (M6P) 
residues are added to the enzyme for recognition by the M6P receptors in the trans-Golgi 
enabling ASMase to be transported via the endosomal system to the lysosomes. Within 
the lysosome, ASMase is further processed to a mature 70 KDa form (Figure I-32). The 
minor 57KDa form is targeted to the secretory pathway without alternative carbohydrate 
processing (Figure I-32). This is the secretory form of ASMase or sASMase (Zeidan and 
Hannun 2010). Another trafficking pathway involving the transmembrane Golgi protein 
sortilin has been also suggested as an alternative trafficking pathway for ASMase targeting 
the lysosomes (Zeidan and Hannun 2010) (Figure I-32). 
 
 
 
Figure I-32 . Cellular trafficking of ASMase (Zeidan and Hannun 2010). 
 
To the date, three different ASMase pools have been described (Morales, Lee et al. 
2007): 
1. The acidic lysosomal/endosomal ASMase consistent with its strict acidic pH 
requirement. 
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2. The secretory ASMase, which has a key role in atherosclerosis, cell surface 
signaling and host inﬂammation. 
3. The receptor-activated ASMase, which undergoes a translocation to the outer 
cell membrane in specific microdomains, where it converts SM into ceramide 
allowing receptor dimerization. Thus, it creates signaling platforms by the cell 
surface.  
 
ASMase is activated by numerous receptors and non-receptor mediated cellular stimuli. 
Some of them are summarized below: 
 
1. Death receptors (TNF-?, CD95 and TRAIL). 
2. Radiation (UV-C and ionizing radiation). 
3. Chemotherapeutic agents. 
4. Viral, bacterial and parasitic infections. 
5. Cytokines (IL-1?). 
6. Oxidative stress (Induced by ischemia/Reperfusion or H2O2). 
 
6.5. ASMase in hepatic injury and metabolic disorders: 
To date, ASM inhibition using siRNA, pharmacologic inhibitors, or KO mice has been 
shown to render cells and animals resistant to the apoptotic effects of diverse stimuli, 
including but not limited to Fas, hepatic ischemia/reperfusion (Llacuna, Marí et al. 
2006), radiation, chemotherapy, and TNF-? (García-Ruiz, Colell et al. 2003; 
Schuchman 2010). At a mechanistic level, previous work in our laboratory, showed that 
ASMase contributes to TNF/FAS or irradiation-induced apoptosis by targeting 
glycosphingolipids to the mitochondria and down-regulating of MAT1A, which leads to 
SAMe depletion, which sensitizes cells to other insults (García-Ruiz, Colell et al. 2003; 
Marí, Colell et al. 2004).  
  
ASMase has been shown to promote several forms of liver injury. Some of them are 
described below:  
• Hepatic Ischemia/Reperfusion (I/R): pharmacological inhibition of ASMase or 
ASMase knockdown by siRNA decreased ceramide generation during hepatic I/R, 
and attenuated serum ALT levels, hepatocellular necrosis, cytochrome c release, 
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and caspase 3 activation. The administration of TNF-? neutralizing agent, 
pentoxifylline blocked ASMase activation suggesting that TNF-? production is 
upstream of ASMase during I/R liver damage (Llacuna, Marí et al. 2006).  
• Hepatic fibrosis: recent studies in our lab illustrated a role of ASMase in 
promoting hepatic stellate cell activation and liver fibrogenesis by regulating its 
downstream effectors cathepsin B/D (Moles, Tarrats et al. 2010). Interestingly, in 
a model of complete ASMase ablation, the lack of ASMase promotes liver fibrosis 
through a compensatory mechanism involving cathepsin B overexpression 
suggesting that the overexpression of cathepsin B may underlie the phenotype of 
Niemann Pick Disease (Moles, Tarrats et al. 2012). 
• Liver cholestasis: ASMase has also been linked to bile-salt-induced liver injury. 
Primary rat hepatocytes treated with deoxycholic acid triggers ASMase activation 
and ceramide production that leads to JNK activation (Gupta, Natarajan et al. 
2004). Bile salts activate ASMase by dropping the pH of ASMase-carrying 
lysosomes (Becker, Reinehr et al. 2007). Thus, ASMase is a key player in liver 
injury in cholestatic diseases as well. 
• Wilson disease: Wilson disease is an autosomal recessive disorder resulting from a 
mutation in the copper transporter ATP7B. This condition leads to toxic 
accumulation of copper leading to chronic hepatitis, progressive liver failure and 
anemia. ASMase/ceramide pathway mediates liver cirrhosis and anemia in Wilson 
disease. Addition of copper to hepatocytes triggers ASMase activation and 
consequent apoptosis. Furthermore, blood samples of these patients show higher 
ASMase activity and ceramide levels (Lang, Schenck et al. 2007). Therefore, 
targeting ASMase might be useful for treatment of the clinical complications of 
Wilson disease.  
 
Given the role of ASMase as an intermediate in stress responses and cell death regulation, 
ASMase is also involved in metabolic disorders: 
 
• Obesity and insulin resistance: Early work on 3T3L1 adipocytes and rat 
hepatoma FAO cells showed that TNF-? inhibits insulin signaling via stimulation 
of TNFR1 and ASMase activation that results in negative phosphorylation of 
insulin receptor substrate (IRS) 1 and 2 which significantly reduces its ability to 
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interact with the insulin receptor (IR) (Kanety, Hemi et al. 1996; Peraldi, 
Hotamisligil et al. 1996). Later on, a group identified the death domain of 
TNFR1 responsible for the inhibitory effects of TNF-? on tyrosine 
phosphorylation of IRS-1, implicating ceramide generated by ASMase as a 
downstream mediator of the inhibition of IR signaling (Csehi, Mathieu et al. 
2005). In addition, TNF-? via ASMase activation and ceramide production 
decreases mRNA levels of glucose transporter Glut4 in 3L3L1 adipocytes (Long 
and Pekala 1996). In a human setting, non-obese patients with type 2 diabetes 
have elevated Zn2+-dependent ASMase activity in serum (Górska, Barańczuk et 
al. 2003). Moreover, adipose tissue from genetically obese ob/ob mice has 
increased expression of ASMase among other important enzymes of SL 
metabolism (Samad, Hester et al. 2006). Moreover, a recent study using ASMase 
deficiency in a genetic background of LDL receptor ablation (ALDLRDKO) 
showed that in a diet-induced obesity model ASMase deficiency increases insulin 
sensitivity, improves glucose tolerance and adiposity and protects from liver TG 
accumulation (Deevska, Rozenova et al. 2009). However, these animals 
demonstrate a paradoxical increase in hepatic ceramide content due to de novo 
ceramide synthesis induced by SPT activation. This study, suggested a mechanism 
by which ASMase regulates the partitioning of the major FA in the modified diet, 
palmitate, into two competitive and inversely related pools, TG and SLs, 
apparently via modulation of SPT (Deevska, Rozenova et al. 2009). Intriguingly, 
another study overexpressing ASMase in leptin receptor deficient db/db mice, 
reported glucose tolerance improvement with glycogen and lipid accumulation in 
the liver. In addition, this study showed that ASMase-/- mice were glucose 
intolerant due to Akt and AMPK regulation (Osawa, Seki et al. 2010). Thus, the 
role of ASMase in insulin resistance is still quite controversial. 
• Fatty liver: A known dietary model of NASH is the methionine and choline 
deficient diet or MCD, which causes steatosis, mitochondrial dysfunction, 
hepatocellular injury, oxidative stress, inflammation, and fibrosis. Previous work 
in our lab examined the individual contributions of methionine and choline 
deficiency to MCD-induced liver injury and fibrosis showing that ASMase but 
not NSMase activity was induced upon two days of exposure to MCD or 
methionine deficient diet correlating with increased ceramide levels in the liver 
INTRODUCTION 
?78
(Caballero, Fernández et al. 2010). Importantly, increased ASMase gene 
expression has been reported in patients with NAFLD, which correlated with 
disease progression (Moles, Tarrats et al. 2010). Regarding alcoholic liver disease, 
recent studies focused on the role of ASMase in signs of liver injury. Ethanol 
treatment of hepatoma cells as well as feeding ethanol-containing Lieber-DeCarli 
diet to mice inhibited AMPK through increased hepatic ASMase activity and 
ceramide content. These effects were abrogated by imipramine, an ASMase 
inhibitor. This study suggested that the generation of ceramide via ASMase is 
stimulated by ethanol (Liangpunsakul, Sozio et al. 2010). Recent work from this 
group showed how imipramine reduces alcohol-induced hepatic steatosis by 
decreasing ASMase activity, hepatic ceramide content and recovering the alcohol-
induced AMPK inhibition. Moreover, imipramine improved ethanol-impaired 
glucose tolerance and attenuated inflammatory pathways such as JNK and p38 
(Liangpunsakul, Rahmini et al. 2012). Moreover, elevation of secretory ASMase 
activity has been reported in peripheral blood of active drinkers (Reichel, Beck et 
al. 2011).  
 
Taken together, these findings support the idea that ASMase plays an important role in 
metabolic diseases, however the mechanisms underlying its activation and its downstream 
effectors command the actions that will make progress the disease remains unclear.
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ALD and NAFLD are two of the most prevalent metabolic liver diseases. Especially, 
NAFLD is of particular concern due to its association with obesity, insulin resistance and 
T2DM. Although etiology of both ALD and NAFLD are obviously different, they share 
common cellular and molecular mechanisms, which elicit similar histological and 
biochemical manifestations. Key events involved in either disease include hepatic 
steatosis, oxidative and ER stress, hepatocellular damage and a state of low grade chronic 
inflammation characterized by elevated circulating levels of TNF-? and FFAs. The latter 
two are of special interest since TNF-? and FFAs are key regulators of ceramide synthesis. 
Ceramide is a SL that mediates many cell responses including regulation of cell growth, 
differentiation, apoptosis and insulin signaling and it has been linked to many complex 
diseases including alcoholic liver disease, obesity and insulin resistance. Condensation of 
palmitic acid with serine is the rate-limiting step of de novo ceramide synthesis and hence 
increased palmitic acid availability increases ceramide synthesis. Moreover, TNF-? is a 
known activator of a second important pathway of ceramide generation, the hydrolysis of 
SM into ceramide by the action of ASMase. ASMase ceramide generation is quick and 
transient and generates ceramide in specific cellular localizations linked to the activation 
of apoptotic pathways. It has been demonstrated that ASMase gene expression and 
activity are increased both during ALD and NAFLD and ASMase ablation protects mice 
from different models of hepatic injury. Unfortunately despite intense investigation, 
molecular pathways underlying ALD and NAFLD are still poorly understood, limiting the 
efficacy of the current therapeutic armamentarium available for ALD and NAFLD. To 
contribute to fill this gap of knowledge the aims of this thesis were: 
 
AIM 1: 
? To study the role of ASMase in non-alcoholic steatohepatitis as potential 
regulator of systemic glucose homeostasis, hepatic steatosis and hepatic injury in a 
mouse model of high fat diet-induced obesity. 
 
AIM 2: 
? To determine the role of ASMase in alcoholic steatohepatitis as a potential 
regulator of hepatic steatosis and hepatic injury in a Lieber-DeCarli alcoholic 
mouse model and confirm the relevance of our findings in human samples of 
ASH. 
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1. MOUSE MODELS: 
All studies were performed in male mice to avoid hormonal fluctuations of female estrous 
cycle. Animals had free access to water and food with the exception of the Lieber-DeCarli 
liquid diet model where mice were pair-fed. All mice were raised under speciﬁc pathogen-
free conditions with controlled temperature and humidity on a 12 h light–dark cycle in 
the animal care facility of the Medical School of Universitat de Barcelona.  
 
1.1. ASMase knockout mice: 
ASMase knockout mouse was created in 1995 in Dr. Schuchman's lab as a model of 
types A and B Niemann-Pick disease, as these types of NPD result from deficient ASMase 
activity (Horinouchi, Erlich et al. 1995). A PGK-neomycin expression cassette was 
inserted into the exon 2 of the ASMase murine genomic sequence, disrupting its coding 
sequence. As a result knockout mice have no detectable ASMase activity in their tissues. 
These mice are in a C57BL/6 genetic background. ASMase deficient mice follow a severe, 
neurodegenerative course that ends with a premature death between six and eight months 
of age. At the time of death, knockout mice weigh less than half of their wild type 
littermates.  Cholesterol and SM levels are elevated in blood, liver and brain.  These mice 
also show atrophy of the cerebellum and marked deficiency of Purkinje cells. Moreover, 
most tissues display presence of foam cells. Affected males can breed until 20 weeks of age 
and affected females until 10 weeks. 
 
1.1.1. ASMase breeding: 
ASMase knockout mice (C57BL/6 strain) were propagated using heterozygous 
breeding pairs (kindly provided by Dr. Gulbins and Dr. Kolesnick). ASMase-/- 
phenotype is inherited as an autosomal recessive trait so heterozygous breeding pairs 
yield 25% wild type (WT) mice and 25% ASMase-/- mice and 50% of heterozygous 
mice.  
 
1.1.2.  ASMase DNA extraction: 
Mice deficient in ASMase were genotyped by PCR using ear-clipped DNA. Genomic 
DNA was extracted from ear clipped tissue at weaning time (21 days) with 
QuickExtract DNA kit (Epicentre, QE09050): 
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• Add 50μl of QuickExtract solution to each tube containing the tissue. 
• Vortex the mix for 30 sec. 
• Incubate 6 min at 65ºC. 
• Vortex the mix for 30 sec. 
• Incubate 2 min at 98ºC. 
• Vortex the mix for 30 sec and place the tube on ice. 
• Centrifuge the tube at 14.000 rpms for 2 min. 
• Use 1μl of the extracted DNA (200ng of DNA approximately) for each PCR 
reaction. 
• Store DNA at -20ºC. 
 
1.1.3. ASMase genotyping: 
Wild type primers were used to amplify a 269-base pair (bp) product that is specific 
for exon 2 of the wild type ASMase gene. To amplify the mutant gene, the same 
forward primer as wild type was used and a reverse neomycin gene-specific antisense 
primer was used to amplify a 523-bp product that was specific for the mutant gene 
containing part of the neo cassette and exon 2 of the ASMase gene (Table M1). 
 
  Wild Type ASMase-/- 
Forward 5'-AGCCGTGTCCTCTTCCTTAC-3' 
Reverse 5'-CGAGACTGTTGCCAGACATC-3' 5'-GGCTACCCGTGATATTGCTG-3' 
 
Table M1. ASMase knockout genotyping primers. 
 
PCR mix: 
 
 [Stock] [Final] x1 (μl) 
dH2O   till 25 μl 18,875 
dNTP 10mM 0,2mM 0,50 
Taq Buffer (w/o Mg) x10 1x 2,50 
DMSO 100x 1% 0,25 
Primer Fw 50μM 1μM 0,50 
Primer Rev WT 50μM 0,5μM 0,25 
Primer Rev KO 50μM 0,5μM 0,25 
MgCl2 50mM 1,5mM 0,75 
EcoTaq (Ecogen, ETAQ-500) 5U/μl 0,625U 0,125 
DNA 200ng/μl 200ng 1 
 Final volume 25μl 
 
Table M2. ASMase knockout genotyping PCR mix. 
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PCR protocol: Polymerase chain reaction amplification conditions consisted of  
• Step1: 3 min at 93ºC.  
• Step2: 39 cycles of [45 sec at 93°C, 45 sec at 58°C, and 45 sec at 72°C].  
• Step 3: 3 min at 72ºC.  
• Step 4: Forever at 10ºC. 
 
Gel and development:  
• Prepare a loading buffer mix with 1ml of loading buffer (AppliChem, 
A3144) and 1μl of the nucleic acid staining solution RedSafe (Chembio, 
#21141).  
• Add 5μl of this mix to each PCR reaction.  
• Prepare a 1,5% agarose gel with 100ml of 1x Tris Borate EDTA Buffer 
(TBE, Sigma, T4415) and 1,5g of Agarose (Sigma, A9539).  
• Load the samples in the gel and run them in 1x TBE at 80v for 1h.  
• Develop the gel in a Gel Doc™ XR+ System (Bio Rad) exciting the SafeRed 
component with UV light. One single band at 269bp indicates wild type, 
two bands at 269bp and 523bp indicates heterozygous and one single band 
at 523bp indicates ASMase-/-. 
 
 
1.2. TNFR1, TNFR2, TNFR1/R2 knockout mice: 
Tumor Necrosis Factor Receptor 1 (TNFR1) knockout mice, Tumor Necrosis Factor 
Receptor 2 (TNFR2) knockout mice, and Tumor Necrosis Factor Receptor 1 and 2 
(TNFR1/R2) mice (C57BL/6 strain) were a generous gift from Dr. Bluethmann 
(Discovery Technologies, Hoffmann-La Roche Ltd., Basel, Switzerland). These 
knockouts are viable and fertile. Homozygous breeding pairs were kept in the animal 
facility to obtain the three kinds of TNFR knockout.  
 
1.3. Wild type mice: 
All wild type mice (C57BL/6 strain) were purchased from Charles River, USA, with the 
exception of ASMase-/- studies where wild type littermates were used as controls. Prior to 
their use in a study, purchased mice rested for one week in order to get acquainted to the 
new environment.   
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2. IN VIVO EXPERIMENTAL MODELS: 
All experimental protocols used in this thesis met the guidelines of the Animal Care 
Committee of Hospital Clinic-Universitat de Barcelona. 
 
2.1. Diet models of steatohepatitis: 
The diets used in this thesis are the high fat diet (HFD), the methionine and choline 
deficient diet (MCD), the hypercholesterolemic diet (HCD) and the ethanol-containing 
Lieber-DeCarli liquid diet (EtOH).  HFD, MCD and HCD studies had as control diet 
the regular diet (RD) from the animal facility (Harlan, 2014). For alcohol studies, a 
control Lieber-DeCarli liquid diet was used (Ctrl) (Table M3). 
 
 RD/HCD* HFD MCD Ctrl EtOH 
Protein 20% 20% 14.8% 17.3% 17.3% 
Fat 13% 60% 12.4% 35% 35% 
Carbohydrates 67% 20% 72.8% 47.7% 47.7%** 
 
Table M3. Diet percentage of macronutrients.  
* HCD is a RD supplemented with 2% cholesterol and 0.5% sodium cholate.  
** 36% of Kcal derived from ethanol. 
 
2.1.1. Diet-induced obesity model: 
Obesity is strongly associated with hepatic steatosis and insulin resistance in humans. 
When normal, lean C57BL/6 male mice are fed diets with high content in saturated 
or unsaturated fats, mice exhibit an increase in body weight due to a gradual 
accumulation of body fat (Hebbard and George 2011). This is a chronic dietary 
model (3-4 months) that courses with increased inflammation, oxidative and ER 
stress, insulin resistance and hepatic steatosis.  
 
This model of diet-induced obesity (DIO) was used to induce insulin resistance and 
hepatic steatosis in the absence of ASMase. Mice were exposed from 4 weeks of age 
to a HFD (Research Diets, D12492) containing 60% of total Kcal content derived 
from fat. Mice were anesthetized using a lethal dose of sodium pentobarbital 
(0.1g/Kg) and sacrificed at 16 weeks of age (12 weeks on HFD) after a 6h fasting 
period (9h-15h). Blood, tissue lipids, protein and mRNA profiles were analyzed. For 
the amitriptilyne studies, C57BL/6 males were exposed to HFD since week 5 and 
were sacrificed at 21 weeks of age (16 weeks on HFD).  
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2.1.2. MCD diet-induced NASH model: 
Feeding mice a MCD diet is a frequently used nutritional model of NASH that 
induces serum alanine transaminase (ALT) elevation and hepatic histological changes 
characterized by steatosis, focal inflammation, oxidative stress, hepatocyte necrosis, 
and fibrosis (Hebbard and George 2011). MCD diet is high in sucrose and fat 
(72.8% sucrose, 12.4% fat), but lacks methionine and choline, which are essential 
for hepatic ?-oxidation and VLDL production. This results in accumulation of 
intrahepatic lipid and decreased VLDL synthesis. MCD-fed mice exhibit increased 
inflammation with activated macrophage infiltration into the liver. MCD diet 
activates NF-?B and increases levels of IL-6, transforming growth factor ? (TGF-?) 
and TNF-? contributing to the liver injury. Histological changes occur rapidly (in 10 
days, acute model of steatohepatitis) and are morphologically similar to those 
observed in human NASH. In contrast to the DIO, this dietary model does not 
cours with obesity or insulin resistance.  
 
10 week-old male wild type and ASMase-/- mice were exposed to MCD diet 
(TestDiet, 578B) for two weeks. The diet was prepared every two days. 
 
Diet preparation protocol: 
 
• Mix 1,5g of Noble Agar (Sigma, A5431) in 100ml of tap water. 
• Heat in the microwave until it boils and the noble agar melts completely.  
• Allow to cool down. 
• Add 60g of powdered MCD diet per each 100ml. 
• Let it solidify. 
• Cut in pieces to feed the mice. 
 
2.1.3. Hypercholesterolemic diet-induced steatohepatitis model: 
The HCD is a nutritional model of hepatic microvesicular steatosis characterized by 
FC accumulation in membranes.  FC sensitizes hepatocytes to TNF-? -induced 
apoptosis and steatohepatitis development due to FC accumulation in mitochondria,  
which results in mGSH depletion (Marí, Caballero et al. 2006). HCD is a RD 
supplemented with 2% purified cholesterol and 0.5% sodium cholate (Dyets Inc.).  
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In results Aim 1, HCD was fed to 6-10 week-old wild type mice for 2 days in order 
to induce FC accumulation in lysosomal membranes and test whether FC 
accumulation would protect against lysosomal membrane permeabilization-induced 
apoptosis. In results Aim 2, HCD diet was fed to 6-10 week-old wild type mice for 3 
days to induce FC accumulation, which down-regulates SREBP2 activation and its 
targeted genes. This strategy was used to dissociate StAR mRNA regulation from 
SREBP2 and link it to ER stress. 
 
2.1.4. Alcohol-induced ASH model: 
Ethanol feeding as part of a totally liquid diet (Ethanol containing Lieber-DeCarli 
liquid diet, EtOH diet) was developed in 1963 by Lieber CS and DeCarli LM in 
response to the need to develop an animal model in which alcohol consumption was 
clinically relevant while dietary control was maintained.  Previously, ethanol had 
been administered to rats in drinking water, but due to a natural aversion to ethanol, 
the intake resulted in negligible blood ethanol levels. This model was insufficient to 
cause significant liver damage. However, the aversion to ethanol can be overcomed 
with the ethanol-containing liquid diet formula. This diet ensures a high daily 
consumption of 12-18g of ethanol/Kg and elevated blood ethanol levels (100-
150mg/dl). EtOH diet causes significant liver lesions within 4 weeks inducing 
functional changes including impaired energy production, significant induction of 
microsomal ethanol oxidizing system (CYP2EI), generation of free radicals and 
alterations in defense mechanisms against this oxidative stress, which results in GSH 
depletion and lipid peroxidation. Thus, the Lieber-DeCarli liquid diet provides way 
to reproduce early stages of ALD and facilitates the study of the pathogenesis of ALD 
(de la M Hall, Lieber et al. 2001). 
 
In this thesis, male ASMase-/- mice, TNFR1, TNFR2 or double TNFR1/R2 null 
mice and wild type mice (8-10 weeks of age) were pair fed with either Ctrl or EtOH 
diets (Test Diet, LD101 and LD101A, respectively) in which alcohol accounted for 
36% of calories (Colell, García-Ruiz et al. 1998). Ethanol content of the diet was 
gradually increased over an 8-day period until they received 5% ethanol from day 8 
for 4 weeks. 
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Diet preparation: 
 
• Control Lieber-DeCarli liquid diet: to prepare 1 liter of diet mix 770ml of 
tap water and add 230g of control diet. Mix with a blender. 
• Ethanol-containing Lieber-DeCarli liquid diet: to prepare 1 liter of diet mix 
809ml of tap water, 140g of the test diet (LD101A) and 51ml of 96% 
ethanol. Mix with a blender.  
 
Diets were prepared fresh daily and were administered in feeding tubes. Control and 
EtOH diet were pair fed taking in account that each animal eats approximately 20ml 
of liquid diet per day. 
 
Alcohol diet adaptation protocol: 
 
• Day 1: feed control Lieber-DeCarli liquid diet. 
• Day 2-3: feed 2/3 of control diet and 1/3 of ethanol diet. 
• Day 4-5: feed 1/2 of control diet and 1/2 of ethanol diet. 
• Day 6-7: feed 1/3 of control diet and 2/3 of ethanol diet. 
• Day 8-end of the study: feed ethanol containing Lieber-DeCarli liquid diet. 
 
2.2. In vivo Treatment models: 
2.2.1. ASMase inhibition models: 
In order to explore potential therapeutic options to treat ASH and NASH we used a 
model of pharmacological inhibition of ASMase. For that purpose, mice were treated 
with amitriptilyne to functionally inhibit ASMase. Amitriptyline is a tricyclic 
antidepressant that also ease migraines, tension headaches, anxiety attacks and some 
schizophrenic symptoms. It has been reported that amitriptyline detaches ASMase 
from the lysosomal inner membrane inactivating the enzyme and exposing it to 
proteolytic degradation (Kornhuber, Tripal et al. 2010). 
 
Advantages of this model are the good solubility in aqueous solutions so it can be 
administered to mice in drinking water. In addition, as a potential human treatment 
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for ASH and NASH, amitriptyline is a drug already approved to treat other 
affections. 
 
2.2.1.1. Amitriptyline in drinking water: 
To evaluate whether ASMase inhibition modulates NAFLD, 5 week-old wild 
type mice were exposed to RD or HFD for 16 weeks and treated with 1mM 
amitriptyline hydrochloride (Sigma, A8404) dissolved in the drinking water 
with a 1% saccharin sodium salt hydrate (Sigma, S1002) to avoid taste 
rejection. After a drinking test, we approximated a dosage per mouse and day 
of 20-25mg/Kg/day of amitriptyline.  
 
2.2.1.2. Amitriptyline intra-peritoneal injection: 
To evaluate whether ASMase inhibition modulates ALD, 8-10 week-old wild 
type mice were fed alcohol and from week two mice were treated with a daily 
intra-peritoneal (i.p.) injection of 2.5mg/Kg amitriptyline as previously 
described (Lang, Schenck et al. 2007). For the last two weeks of ethanol 
feeding amitriptyline dose was doubled to 5mg/Kg.  
 
2.2.2. Acute liver damage models: 
Accumulation of lipids in the cytoplasm of hepatocytes, mostly in the form of FFA 
and TG, is considered the first step in the development of steatohepatitis. Hepatic 
steatosis sensitizes the liver to secondary insults. In this thesis we used two models of 
acute liver damage:  LPS and concanavalin A (Con A). Both models imply TNF-? 
release from the cells but LPS is believed to act mainly through soluble TNF-? 
binding to TNFR1 and Con A through cell-bound TNF-? that binds to TNFR2. 
 
2.2.2.1. Lipopolysacharide:  
LPS is a major constituent of the cell wall of most gram-negative bacteria. It 
is a highly immunogenic antigen with the ability to enhance immune 
responses. In vivo, it is known to cause hepatitis (Tsukamoto, Machida et al. 
2009). In the HFD model, 8-10 week-old wild type and ASMase-/- mice were 
exposed to HFD for 6 weeks to develop some degree of liver steatosis and 
then were treated with 5mg/Kg LPS (Sigma, L4391) i.p. for 24h at the end 
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of the study. In the ethanol studies, at the end of the study after 4 weeks of 
ethanol feeding mice received an i.p. injection of LPS (5mg/Kg).  
 
2.2.2.2. Concanavalin A: 
Con A is a plant lectin with high affinity towards the hepatic sinus, which 
results in activation of T cells in the liver promoting the secretion of 
cytokines. When given intravenously to mice it leads to immune-mediated 
liver injury. Hepatotoxicity following Con A administration involves the 
systemic release of soluble TNF-? as well as cell-bound TNF-?, which acts 
through TNFR2. (Jaruga, Hong et al. 2004). In the ethanol model, at the 
end of the study after 4 weeks of ethanol feeding mice received an intra-
venous (i.v.) injection of Con A (0.5mg/Kg) 24 hours before sacrifice. 
 
2.2.3. ER stress-induction model: 
In order to prove that ASMase-/- mice were capable to sense and respond to ER 
insults in vivo, wild type mice and ASMase-/- mice were treated with 1mg/Kg 
Tunicamycin (Tm) (Sigma, T7765) for 24 hours. Tm is an inhibitor of N-
acetylglucosamine transferases; preventing formation of N-acetylglucosamine lipid 
intermediates and glycosylation of newly synthesized glycoproteins in the ER. 
Proteins that require glycosylation will remain in the ER and form protein aggregates 
causing ER stress and activating UPR. 
 
2.3. Liver regeneration-Partial hepatectomy model: 
Mice were anesthetized with 2% isoflourane with a 1,5-2L/min-oxygen flow for a 25g 
wild type mouse. Mice were subjected to midventral laparotomy with 70% liver resection 
(median lobe and left lateral lobe). Weight of the excised liver was determined. Sham 
surgery entailed midventral laparotomy. Survival was higher than 80% and all deaths 
were due to post-surgery complications during the first 24h post-PH. Hepatocyte 
proliferation was determined by detecting Proliferating cell nuclear antigen (PCNA) at 
different time points and liver regeneration index was calculated as the ratio of the liver 
remnant to body mass and ×100. 
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3. IN VIVO METABOLIC STUDIES: 
 
3.1. Blood glucose levels: 
Obesity and T2DM curse with hyperglycemia even in fasting periods. To assess glycemia 
in mice, blood glucose levels were measured every 4 weeks after a 6h period of fasting 
(9a.m. to 3p.m.).  Blood glucose concentration was determined using 5μl of blood from 
the tail using Ascensia BREEZE blood glucose meter (Bayer).  
 
3.2. Glucose tolerance test: 
T2DM is characterized by glucose intolerance, which contributes to peripheral (muscle, 
fat, and liver) insulin resistance as well as islet ?-cell dysfunction. The glucose tolerance 
test (GTT) is used in clinical practice and research to identify individuals with normal or 
impaired glucose tolerance. GTT is a tool to identify impaired glucose tolerance. 
 
GTTs were performed with an i.p. glucose injection (2g/Kg) on conscious mice after an 
overnight (15h) fasting at 10 weeks of age. Mice were kept in individual cages during the 
experiment. Blood glucose clearance was measured at times 0, 15, 30, 60, 90 and 120 
min after glucose injection using 5μl of blood from the tail using Ascensia BREEZE blood 
glucose meter. Statistical significance was assessed using the area under the curve of blood 
glucose levels of each animal during the experiment. 
 
3.3. Insulin tolerance test: 
Obesity and T2DM present a decrease in insulin action on insulin-responsive tissues such 
as liver, adipose tissues and muscle. This decrease in insulin function is called insulin 
resistance or intolerance. Insulin tolerance test (ITT) allows systemic assessment of 
insulin sensitivity by determining the fall in plasma glucose after injection of insulin. 
 
ITTs were performed with an i.p. insulin injection (0.75IU/Kg, Actrapid, Novo nordisk) 
after a 6h fasting period (from 9a.m. to 3p.m.) at 14 weeks of age. Mice were kept in 
individual cages during the experiment. Blood glucose clearance was measured at times 0, 
15, 30, 60, 90 and 120 min after insulin injection using 5μl of blood from the tail using 
Ascensia BREEZE blood glucose meter. Statistical significance was assessed using the 
area under the curve of blood glucose levels of each animal during the experiment. 
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3.4. Insulin portal vein infusion: 
This technique is used to assess in vivo insulin sensitivity of tissues, especially liver, 
adipose tissue and muscle. After stimulation, insulin sensitivity can be assessed by 
checking insulin signaling events via WB. 
 
Following 6 hours of food withdrawal, mice were anesthetized with an i.p. injection of 
tribromoethanol (250mg/Kg), and insulin (1IU/Kg, Actrapid-Novo Nordisk) or 
phosphate buffered saline (PBS, Sigma, P3813) in a 200μl final volume was injected 
through the portal vein. 30G bended needles were used to inject the vein. Three minutes 
after infusion, tissues were removed, frozen in liquid nitrogen and stored at -80°C until 
processing. Tissue insulin sensitivity was assessed by monitoring insulin receptor and Akt 
phosphorylation via WB.  
 
 
4. SERUM ANALYSIS: 
At the time of sacrifice, mice were anesthetized with a lethal dose of 100mg/Kg of sodium 
pentobarbital. Blood was harvested from the lower cava vein with heparinized 16G 
needles in order to avoid hemolysis. Blood was centrifuged for 15 min at 10.000 rpms at 
4ºC and serum was collected from the top phase avoiding bottom phase contamination. 
 
4.1. Total cholesterol, HDL and LDL: 
Serum total cholesterol, HDL and LDL levels were measured with a biochemical 
analyzer at the Centre de Diagnòstic Mèdic of  Hospital Clínic i Provençal  de Barcelona.  
 
4.2. Alanine transaminase: 
ALT is found in serum and other tissues but is most commonly associated with liver. 
ALT is measured clinically to determine liver health. Its increased presence in serum 
indicates hepatocellular damage. We used ALT as indicator of liver injury. Serum ALT 
levels were measured with a biochemical analyzer at the Centre de Diagnòstic Mèdic of 
Hospital Clínic i Provençal de Barcelona.  
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5. HISTOLOGY: 
 
5.1. Tissue harvesting and preservation: 
Tissues were quickly harvested after blood collection and were either:  
- Flash frozen in liquid nitrogen for cryostat sections, or if wanted, in a cassette 
with OCT and slowly freeze down on dry ice. OCT is an embedding medium for 
frozen specimens to ensure Optimal Cutting Temperature (Tissue-Tech #4583). 
- Placed in histology cassettes, fixed in formalin (10% paraformaldehide) (Sigma, 
HT501128) for 48h and embedded in paraffin for microtome sections. 
 
Flash frozen tissues were cut with a cryostat (Microm, HM550) at 14μm at an 
approximate temperature of -20ºC. Sections were placed in superfrost slides (MENZEL-
GLÅSER, J18000AMNZ).  
 
Formalin fixed tissues were included in paraffin in an automated paraffin inclusor (Citadel 
1000, Shandon) following this protocol: 
• 1h in H2O two times. 
• 1h in 70% ethanol two times. 
• 1h in 90% ethanol two times. 
• 1h in 100% ethanol two times. 
• 1h in xylol two times. 
• 2h in paraffin two times. 
 
Once tissues were embedded in paraffin, paraffin blocks were made to improve the 
cutting process in the microtome (Leica, RM2155). Sections at 7μm were used for 
hematoxylin and eosin staining and cuts at 5μm were used for immunohistochemistry. 
Sections were placed in histogrip-treated slides. 
 
5.2. Stainings: 
5.2.1. Hematoxylin and Eosin staining (H&E): 
H&E staining is the most widely used stain in histology. It has the ability to 
demonstrate a wide range of normal and abnormal cell and tissue components and it 
is a relatively simple stain to carry out on paraffin or frozen sections. Hematoxylin 
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has a basic pH and it has affinity for acid structures such as the nuclei, which are 
referred as basophilic structures. Eosin acts as an acid dye staining basic structures, 
which are referred as acidophilic structures. This staining was performed in 7μm liver 
and EWAT sections. 
 
Protocol: 
• Melt the paraffin in a stove at 100ºC. 
• Wash out the paraffin 10 min in xylol. 
• Sample hydration: Rehydrate the sample with dilution series of ethanol 
(100%- 90%- 70%- 30%) till distilled water. Hydrated sections will allow 
aqueous reagents to penetrate into the tissue. 
• Hematoxylin staining: 4 min of Hematoxylin Solution, Harris Modified 
(Sigma, HHS32) for liver sections or 10 min for adipose tissue sections. 
Nuclei and acidic structures will appear reddish-purple stained.  
• Wash out the extra hematoxylin with abundant running tap water. 
• Differentiation: removes hematoxylin background staining and improves 
contrast. Rinse in alcoholic-HCl 96% (480ml absolute alcohol + 20ml HCl 
12N) until a reddish stain appears. 
• Rinse in ammoniacal water (distilled water with 3-4 drops of 25% ammoniac 
solution) until the staining turns blue again. 
• Wash with running tap water for 2 min. 
• Rinse with distilled water for 2 min. 
• Eosin staining: rinse the sections in alcoholic eosin (Sigma, HT110132) for 
1,5 min. This step will stain many non-nuclear elements in different shades of 
pink. 
• Sample dehydration: rinse samples through alcohol to remove all traces of 
water (70%- 90%- 100% alcohol). Eosin staining washes out with water so 
the more we maintain the samples in 70% ethanol the less eosin staining will 
remain. Rinse in xylol for 5 min after that. 
• Mount sections: use the DPX mounting media for histology (Fluka, 44581). 
Add a small drop of DPX to the specimen. Carefully place a cover slip onto 
the drop, avoiding air bubbles.  
• Remove any excess of mount with a paper towel. 
MATERIALS & METHODS 
?98
• Samples can be observed with transmitted light microscopy.  
 
5.2.2. Oil-Red staining: 
Oil-Red O is a fat-soluble dye used for staining of neutral lipids like TGs. It has the 
appearance of a red powder with maximum absorption at 518 nm. This staining was 
performed on liver frozen sections to determine liver macrosteatosis. 
 
Solutions: 
- Oil-Red Stock Solution: 0,5g Oil-Red O (Sigma, O0625) in 100ml of 
isopropanol. Stir the solution over night in a capped container to avoid 
isopropanol evaporation. 
- Oil-Red Working Solution: 60ml of stock solution with 40ml of distilled water. 
Stir and let it sit for several days so oil red is completely dissolved. Always paper- 
filter before using it. 
 
Protocol: 
• Rinse in distilled water 5 min, three times. 
• Dip in 60% isopropanol 10 sec. 
• Rinse in Oil-Red working solution 30 min. 
• Remove Oil-Red excess by rinsing in 60% isopropanol 5 min, two times. 
• Wash with distilled water 5 min, 4 times. 
• Counterstain with hematoxylin 5 min. 
• Wash with distilled water 5 min, 3 times. 
• Mount sections: use an aqueous mounting media (Aquatex, Merck, 
#108562) Carefully place a cover slip on the mounting media, avoiding air 
bubbles. 
• Allow samples to dry. 
• Samples can be observed with transmitted light microscopy.  
 
5.2.3. Filipin staining: 
Filipin is an antibiotic isolated by chemists in 1955 from a previously unknown 
actinomycete, Streptomyces filipinensis, which was discovered in a soil sample collected 
in the Philippine Islands, hence the name Filipin. Filipin has been widely used as a 
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probe for sterol location in biological membranes. Interaction with cholesterol alters 
filipin absorption and fluorescence spectra allowing visualization with a fluorescence 
microscope capable of excitation at 340-380 nm and emission at 385-470 nm. It is a 
tool for histochemical identification of unesterified cholesterol both in vivo and in 
vitro. This method of detecting cholesterol in cell membranes is used clinically in the 
study and diagnosis of Type C Niemann-Pick disease. 
 
Protocol: 
• Washes: in a 50ml container, wash the sections with PBS 2 times for 5 min. 
• Fixation: fix sections 1h at room temperature (RT) with formalin 10%. 
• Washes: wash with PBS 3 times for 5 min. 
• Filipin staining: prepare 50ml of PBS containing 0.2mg/ml filipin (Sigma,F-
9765)  and incubate over night at 4ºC protected from the light. (For a 50ml 
solution, weigh 10mg of filipin and dissolve it in 200μl of DMSO. Once 
dissolved, add it to the 50ml of PBS) note: reduce filipin concentration if the 
samples are known to have high levels FC like ASMase-/- liver sections. 
• Washes: wash with PBS, 3 times for 5 min. 
• Mounting: Use abundant fluorescent mounting medium (Dako #S3023) to 
mount the cover slips.  Let dry for a few hours protected from the light. 
• Microscope: use UV light to visualize the staining.  
 
5.2.4. PCNA immuno staining: 
Proliferating cell nuclear antigen, commonly known as PCNA, is a protein that acts 
as a cofactor of DNA polymerase delta and helps increase the processivity of leading 
strand synthesis during DNA replication. PCNA is strongly associated in the nuclear 
regions where DNA synthesis is occurring therefore it is used as a marker of 
proliferation and in this thesis, as a marker of liver regeneration after partial 
hepatectomy. PCNA staining was performed in paraffined liver sections from sham or 
partial hepatectomy operated mice using the Dako kit (K4006). 
 
Reagents: 
Make sure that all reagents are at RT before using them. All incubations will be at 
RT too. 
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- Washing buffer: PBS (20mM NaH2PO4; 150mM NaCl, pH7.0) Keep at 4ºC. 
- Citrate buffer: 2% sodium citrate, pH 6.0. 
- Primary antibody dilution buffer: 0.05M Tris-HCl, pH 7.2-7.6 and 1% BSA 
(Dako antibody diluent, S0809). 
- Negative control: Sham animals will be used as negative control. 
- Substrate-chromogen buffer: 1ml of this solution is enough to perform the 
immunohistochemistry in 10 slides. Calculate how many 1ml aliquots of this 
buffer (bottle 3a) will be needed and add 20μl of bottle 3b. Mix immediately 
and place it on top of the tissue with a Pasteur pipette. This buffer is stable 5 
days at 4ºC. Always mix before using it. 
 
Protocol: 
• Deparaffinize and rehydrate tissue sections:  
o Rinse 6 min in xylol twice. 
o Rinse 4 min in 100% ethanol twice. 
o Rinse 4 min in 96% ethanol twice. 
o Dip 30 sec in distilled water. 
o Rinse 5 min in PBS. 
• Demasking of antigen: this treatment will undo the bounds made by the 
action of formalin during the fixation.  
o Put the slides in a container compatible with the microwave.  
o Cover the slides with citrate buffer. 
o Heat 9 min in the microwave at 800W until it boils and then count 
4 min. 
o Let it cool down for 20 min. 
• Endogenous peroxidase blocking: endogenous peroxidase activity is any 
activity that results in the degradation of H2O2. Such activity is a property of 
catalases in the liver. Since this protocol has a horseradish peroxidase-based 
detection method it is necessary to block the endogenous peroxidase activity 
to reduce background staining.  
o Apply peroxidase-blocking solution on top of the liver sections for 10 
min. 
o Wash 5 min with PBS three times. 
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• Primary antibody incubation: dilute the anti-PCNA antibody (Millipore, 
CBL407) 1/200 in primary antibody dilution buffer.  
o Apply 50μl of antibody to every sample. 
o Incubate 30-50 min at RT in a humidity chamber. 
o Wash 5 min in PBS three times. 
• Peroxidase labeled polymer:  
o Tap off excess PBS and wipe slides.  
o Apply enough Labeled Polymer to cover specimen.  
o Incubate 30 min at RT in a humidity chamber. 
o Wash 5 min in PBS three times. 
• Substrate-chromogen:  
o Wipe slides as before.  
o Apply enough of the prepared Liquid DAB + substrate-chromogen 
solution to cover specimen on a plastic tray (DAB is very toxic, be 
cautious.) 
o Incubate for 2-3 min until it develops. 
o Rinse gently with distilled water from a wash bottle (do not focus 
flow directly on tissue).  
o Collect substrate-chromogen waste in a hazardous materials 
container for proper disposal.  
• Hematoxylin counterstain: 
o Apply a few drops of hematoxylin in excess on top of the samples 
with a plastic Pasteur pipette.  
o Incubate 30 sec to 2 min at RT. 
o Rinse gently in distilled water.  
o Dip slides 10 times into 0.037mol/L.  
o Rinse slides in distilled or deionized water for 2–5 min.  
• Mounting: 
o Mount specimens and coverslip with the aqueous-based mounting 
medium Aquatex. 
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6. MITOCHONDRIAL ANALYSIS: 
Cholesterol and GSH was determined in wild type and ASMase null mice liver isolated 
mitochondria. 
 
6.1. Mitochondria isolation: 
Buffers: 
- Buffer A:  225mM Mannitol; 75mM Sucrose; 0,1mM EGTA; 1mg/ml FFA-BSA and 
10mM Hepes-KOH, pH 7.4. Keep at 4ºC. 
- Buffer B: 395mM Sucrose; 0,1mM EGTA and 10mM Hepes-KOH, pH 7.4. Keep 
at 4ºC. (Use this buffer to prepare percoll gradients.) 
     
Protocol: 
• For each gram of liver add 2ml Buffer A (Always maintain this 1:2 ratio). 
• Cut the liver in pieces and add twice the volume of buffer A (Vfinal= 6ml). 
• Use a pestle homogenizer at 1200 rpms to homogenate the sample (4 times up 
and down). 
• Aliquot a sample of 700-800μl for Homogenate measurements.  
• Centrifuge the rest of homogenate at 700 g, 15 min at 4˚C. 
• Discard the pellet and collect the supernatant.  
• Centrifuge the supernatant at 10.000 g, 15 min at 4˚C. 
• Discard the supernatant and re-suspend the pellet containing the mitochondrias 
in 0,5ml of Buffer B (so the final volume will be approx 1ml). 
• Per each gram of tissue, prepare 2 tubes with two gradients of 26% Percoll 
(Sigma, P1644) (7ml) and 60% Percoll (3ml) in Buffer B.  
• Add the entire sample on top of the 26% Percoll top layer. 
• Equilibrate the tubes to the same weight with Buffer B.  
• Ultra centrifuge samples at 15.500 rpms, 35 min at 4˚C. In this step, 
mitochondria will pass through the 26% Percoll gradient and will stop at the 
beginning of the 60% Percoll. 
• Discard with a plastic Pasteur pipette the layers above the mitochondria’s band. 
• Gently collect the mitochondria’s band with a glass Pasteur pipette and put them 
in a new tube.  
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• Add a big volume of Buffer B to the mitochondria and centrifuge it at 10.000 g, 
15 min at 4˚C to wash them. Repeat this step twice. 
• Discard the supernatant and resuspend the pellet containing the mitochondria 
with 350μl of Buffer A. (Approx. volume so the final volume of mitochondria is 
around 500μl due to the remaining volume of buffer B after discarding the 
supernatant) 
 
6.2. Mitochondrial free cholesterol quantification: 
In alcohol studies mitochondrial FC was measured from isolated mitochondria from wild 
type and ASMase null mice fed either control or ethanol diets.  
 
Cholesterol measurements were performed with high performance liquid chromatography 
(HPLC). This protocol can measure both total and FC. Total cholesterol samples will 
undergo saponification to free all the sterified cholesterol. Thus, the reading of saponified 
samples will represent total cholesterol levels (the sum of free and sterified cholesterol). 
 
Protocol: 
• Cholesterol standards: prepare 1mg/ml cholesterol (Sigma, C8867) stock solution 
in isopropanol. Prepare 7 standard points 0-5-10-20-40-80-100μg. Prepare two 
sets, one for the FC and one for the total cholesterol samples. These standards 
will be carried along with the samples and will undergo the lipid extraction and 
saponification. 
• Use 1mg of mitochondria in a final volume of 200μl (Adjust the volume with 
PBS). Use two tubes per sample for total and FC quantification. 
• Add 200μl of ethanol- 33% KOH (100% ethanol and 1/10 33% KOH). 
• Vortex 1 min. 
• Saponification: 
o Total cholesterol: incubate 30 min at 60ºC (saponification process) 
o FC: incubate 30 min at RT. 
• Let the samples cool down. 
• Lipid extraction: 
o Add 200μl of miliQ H2O. 
o Add 400μl of Hexane HPLC proof.  
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 Always maintain the extraction relation of sample:ethanol-KOH:H2O:Hexane 
(1:1:1:2). 
o Vortex 1 min and wait 1 min three times. 
o Spin down 2 min at 10.000 rpms at RT. 
o Collect 200μl from the hexane top layer containing the cholesterol and 
transfer it into a new tube. (Lipid extraction efficiency: 200μl 
recovered/400μl hexane). 
o Dry the hexane in a speed vac 45 min. 
• Add 200μl of isopropanol. 
• Vortex 3 min. 
• Spin down 2 min at 10.000 rpms at RT. 
• Transfer the extraction into HPLC tubes. 
• HPLC detection: 
o Use a μBondapak C18 10μm 125Å column (WATERS, WAT027324) 
with an absorbance of 200 nm using the WATERS 717 plus Autosapler 
system.  
o Mobile phase composition: 
? Pump A: Acetonitrile. 
? Pump B: Isopropanol:Acetonitrile:miliQ H2O (60:30:10) 
o Flow rate: 1ml/min 
o Reading time: 15 min per sample. Cholesterol peak will appear around 
the 7th min of reading. 
• Quantification of the cholesterol peak is calculated according to a calibration line 
derived from commercial cholesterol with known concentrations. 
 
6.3. Mitochondrial total GSH quantification: 
GSH is a non-essential tripeptide that is synthesized in the body from the amino acids L-
cysteine, L-glutamic acid, and glycine. It is an antioxidant that prevents damage to 
important cellular components caused by oxidative stress. Thus its abundance in the 
mitochondria protects this organelle and the cell from ROS-induced damage.  
 
For total glutathione quantification (GSH and oxidized GSH (GSSG)) we used the 
enzymatic recycling method, using GSH reductase (GR) (Sigma, G3664).  
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Figure M1. Recycling assay mechanism. GSSG, oxidized GSH; GR, GSH reducatase;  
DTNB, Ellman's reagent; TNB, 5-thionitrobenzoic acid; GSTNB, mixed disulfide GSH-TNB. 
 
The sulfhydryl group of GSH reacts with DTNB (5,5'-dithio-bis-2-nitrobenzoic acid, 
Ellman’s reagent. Sigma, D8130.) and produces a detectable yellow-colored TNB (5-
thionitrobenzoic acid). The mixed disulfide, GSTNB (GSH linked to TNB) that is 
concomitantly produced, is reduced by GR to recycle the GSH and produce more TNB 
(Figure M1).  
 
The rate of TNB production is directly proportional to this recycling reaction, which in 
turn is directly proportional to the concentration of GSH in the sample. Measurement of 
the absorbance of TNB at 412 nm provides an accurate estimation of total GSH in the 
sample. 
 
ELLMAN ASSAY 
Buffers: 
- Ellman Buffer: 0,5M KH2PO4 (Fluka, 60220) at pH 8.0. Keep at 4ºC. 
- Ellman Reagent: 10mM DTNB; 11,9mM NaHCO3 (Sigma, S5761); 0,1M 
Na2HPO4·2H2O (Fluka, 71643) at pH 7.4. Store it at  -20ºC in 500μl aliquots. 
 
Protocol: 
• Prepare a 1mM GSH (Sigma, G6529) stock in PBS. 
• Prepare a GSH standard curve in PBS: 0- 10- 20- 30- 40- 50 and 60 μM in a 
final volume of 4ml. 
• Mix in a tube: 2ml of Ellman buffer, 1ml of standard and 30μl of Ellman Reagent. 
Perform the assay in duplicates. 
• Mix thoroughly and wait 3 min before reading it. 
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• Read in a spectrophotometer (Beckman Coulter, DU800) at an absorbance of 
412 nm. 
 
The values obtained will be multiplied by 198 (coefficient of extinction of the 
spectrophotometer) and will represent the real concentration of the GSH standards 
prepared that we will use in the recycling assay as well. We will use these data to 
normalize the absorbance obtained in the recycling assay for the GSH standards. 
 
RECYCLING ASSAY: 
Buffers: 
- 0.5M NaPO4 at pH 7.4: prepare by mixing 95ml of NaH2PO4·H2O 1N, 405ml of 
Na2HPO4·2H2O 1N and adjust with miliQ water up to 1L. Keep at RT. 
- Recycling buffer: 1mM EDTA (Sigma, E5134); 0,1mM DTNB; 0,15mM NADPH 
(Sigma, N1630) and 50mM NaPO4 at pH 7.4. Freshly prepared and protected from 
light. 
 
Protocol: 
• Prepare the recycling buffer, protect it from the light and warm it at 37ºC. 
• Enzyme: prepare the GR at a concentration of 10U/ml in miliQ water. It will be 
stable a few weeks at 4 ºC. 
• Mix in a tube: 2,5ml of recycling buffer at 37ºC, 100μl of sample/standard and 
100μl of GR.  
• Mix by inversion. 
• Reed during 40sec in the spectrophotometer at an absorbance of 412 nm. 
• GSH concentrations will be determined referring the samples to the standard 
curve normalized by the Ellman's assay and by protein concentration. 
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7. HEPATIC LIPID ANALYSIS: 
 
7.1. Hepatic triglycerides, free fatty acid and total cholesterol content: 
Liver TG, FFA and total cholesterol levels were measured at the Centre de Diagnòstic 
Mèdic of Hospital Clínic i Provençal de Barcelona from liver homogenates. Results were 
normalized by homogenate protein concentration. 
 
7.2. Hepatic total ceramide and S1P quantification by HPLC: 
Lipids were obtained and measured using HPLC to detect and quantify both SPH and 
S1P in one sample: 
 
Protocol: 
• First lipid extraction: 
o Use 2-5mg of protein from liver homogenates in a final volume of 250μl. 
o Add to 750μl of methanol:chloroform (1:2, v/v).  
o Vortex thoroughly and centrifuge at 5.000 rpm for 2 min.  
o Collect the chloroform phase extracts into a new tube. (Record the 
recovered volume to adjust the results by the extraction efficiency factor.) 
o Dry in a speed vac. 
• Deacylation: 
o Resuspend samples in 250μl of 1M KOH-methanol. Use heat if 
necessary. 
o Incubate samples1h at 100ºC.  
o Allow samples to cool down. 
• Second lipid extraction: 
o Add 500μl of chloroform and 250μl of PBS. 
o Thorough vortex and centrifuge at 5.000 rpm for 2 min.  
o Collect the chloroform phase containing the free long-chain bases into a 
new tube. (Record the recovered volume to adjust the results by the 
extraction efficiency factor.) 
o Dry in a speed vac. 
• Derivatization:  
o Dissolve samples in 50μl of methanol.  
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o Add 100μl of naphthalene-2,3-dicarboxaldehyde (NDA, Invitrogen, 
N1138) reagent, which is prepared fresh daily by mixing  50μl of 50mM 
boric acid in water (pH adjusted to 9 with KOH), 25μl of 5mM sodium 
cyanide in water and 25μl NDA 5mM in methanol.  
o Incubate 10 min at 50ºC in the dark. 
o Add 300μl of methanol.  
• Centrifuge the samples and transfer them into HPLC tubes. 
• HPLC detection:  
o Use a reverse phase C18 column (Teknokroma, TR-016343) using a 
Gilson fluorimetric detector (GILSON 322) with an excitation 
wavelength of 252 nm and an emission wavelength of 483 nm.  
o Mobile phase composition for the gradient system:  
? Pump A: 5mM potassium phosphate buffer (pH=6.5):methanol 
(85:15, v/v).  
? Pump B: acetonitrile:methanol (75:25, v/v). 
o Flow rate: 1ml/min.  
o Gradient program:  0-1 min 52.94 A, 47.06 B; 1-6 min 52.94-5.88 A, 
47.06-94.11 B; 6-21 min 5.88 A, 94.11 B; 21-25 min 5.88-52.94 A, 
94.11-47.06 B, 25-30 min 52.94 A, 47.06 B.  
o Reading time: 30 min per sample. S1P peak will appear around the 7th 
min for the reading and SPH(ceramide) at the 14th min approximately. 
• Quantification of the ceramide and sphingosine-1-phosphate peaks is calculated 
according to a calibration curve (from 0,01mM to 0,1mM) derived from 
commercial, purified sphingosines (Sigma, S6879). 
 
7.3. Hepatic total sphingomyelin: 
SM is the substrate of ASMase. We analyzed hepatic SM levels in liver homogenates with 
a commercial colorimetric kit (Cayman, #10009928). 
 
Protocol: 
• Use 1-2mg of protein from liver homogenate and adjust to a final volume of 
250μl with homo buffer (see section 10.1). 
• Add 250μl of methanol and vortex. 
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• Add 500μl of chloroform. 
• Vortex for 1 min and wait for 1 min three times. 
• Spin down for 5 min at 5000 rpms at RT.  
• Collect 400μl of chloroform (bottom layer). 
• Dry for 1h at 45ºC in a speed vac. 
• Resuspend in 100μl of detergent solution from the kit. (use 200μl in KO samples 
since they have much higher SM levels. Correct later the values obtained x2) 
• Vortex for 10 min. 
• Heat 10 min at 50ºC. 
• Vortex until dissolved. 
• Spin down. 
• Load 10μl of sample per well using duplicates. 
• Follow Cayman kit instruction for the assay protocol. 
• Read at 585 nm in a plate reader (Bio Rad, xMark microplate 
spectrophotometer). 
Note: Remember that the range of the kit is 5-50mg/dl. ASMase-/- samples tend to have 
high concentrations of SM. Take that in account to not exceed the kit detection range. 
 
7.4. Hepatic lipidomic analysis of ceramide fatty acid chains: 
Lipodomic analysis was carried out in Dr. Jesús Balsinde's Laboratory at the Institute of 
Molecular Biology and Genetics CSIC, Medical School of Universidad de Valladolid, 
CIBERDEM, Valladolid, Spain.  
 
Protocol: 
32nmol of internal standard [Cer(d18:1/17:0)] was added to every sample. Total lipids 
were extracted by chloroform:methanol as described before. Samples were evaporated 
until dryness, redissolved in chloroform/methanol (2:1) and spotted in HPTLC, 
separating ceramides from other lipids with chloroform/formic acid (85:15 v/v) as mobile 
phase. Silica portions containing ceramides were scraped from the plates and lipidic 
fractions were reextracted by chloroform:methanol. Samples were evaporated and 
resuspended in 200μl chloroform/methanol (1:2 v/v) 5mM ammonium acetate.  Extracts 
were stored under N2 at -80ºC until analysis.  
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Analyses were carried out in a Bruker esquire6000 ion-trap mass spectrometer, by direct 
infusion of the sample (400μl·h-1), 2 min acquisition.  
 
Ceramide species were characterized by tandem MS in MRM and positive mode, 
detecting 266/284 for sphingosine (d18:0), 264/282 for sphinganine (d18:1) and 
282/300 for phytosphingosine (t18:0). 
 
8. HEPATIC ASMase ACTIVITY: 
Hepatic ASMase activity was determined in liver homogenate samples using a 
fluorescence-based method. Fluorescent-labeled SM, (7-nitro-2-1,3-benzoxadiazol-4-yl) 
or NBD-SM, is cleaved hydrolytically by ASMase giving the fluorescent product NBD-
ceramide. This product can be separated from the remaining substrate on thin layer 
chromatography (TLC) plates and can be quantified by detecting fluorescence intensity. 
 
Buffers: 
- Homogenization buffer: 1mM Hepes pH 7.4; 0,2% Triton X-100. 
- ASMase buffer: 250mM NaAc (CH3COONa · 3H2O. Sigma, S8625) pH 5.0; 0,1% 
Triton X-100. 
 
Protocol: 
• Use 75μg of protein per reaction. 
• Adjust to a final volume of 250μl with the reaction buffer containing ASMase 
buffer and 10μM NBD-C6-Sphingomyelin (Molecular Probes, N3524). 
• Reaction: incubate 1h at 37ºC in a thermomixer (Eppendorf, Thermomixer 
Confort) at 350 rpm. 
• Stop the reaction by adding 750μl of a 2:1 mix of chloroform:methanol. 
• Vortex 3 times for 1 min the samples. At this point, lipids will pass to the organic 
phase. 
• Spin for 5 min at 5.000 rpm at RT to separate aqueous from organic phase. 
• Extract 400μl of the organic phase avoiding methanol contamination. 
• Dry the samples in a speed vac. (Approx. 1h 30 min). 
• Resuspend the dried lipids in 50μl of a 1:1 mix of chloroform:methanol. 
• Vortex well. 
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• Load 40μl of the sample on each TLC lane (Whatman, 4865-821) adding 20μl at 
a time. Wash the lipid pipettes with methanol between samples. 
• Allow the loaded TLC to dry. 
• Introduce the TLC in a gas chamber with 100ml of a 70:30:5 mix of 
chloroform:methanol:NH4OH. 
• Allow the samples to run through the TLC up to 3/4 of the plate. 
• Dry the TLC. 
• Read the results by exciting with UV light the TLC and capturing an image of the 
fluorescence (Bio-rad, Gel Doc XR). SM will be the lower band with a strong 
signal since we add it in excess in the reaction and the higher band will be the 
ceramide cleaved during the reaction. 
• Results can be quantified with Image J by measuring density of pixels. 
 
 
9. METHIONINE METABOLISM: 
 
9.1. Serum homocystein quantification: 
Serum homocysteine concentrations were measured per protocol in the clinical 
laboratory of the Hospital Clínic of Barcelona. 
 
9.2. Hepatic SAM and SAH quantification: 
Hepatic S-adenosylmethionine and S-adenosylhomocysteine were determined by HPLC 
as previously described (Song, Zhou et al. 2007). 
 
Protocol: 
• Deproteinize samples with 0,5M perchloric acid (v/v 1:1). 
• Vortex and spin down for 10 min at 13.000 g at 4ºC. 
• Collect the supernatant for HPLC quantification. (At this point samples can be 
frozen and kept at -80ºC until HPLC processing.) 
 
HPLC detection: 
• Use a reverse phase 5μm Hypersil C18 column (WATERS) with an absorbance 
of 254 nm using the WATERS 717 plus Autosapler system.   
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• The mobile phase composition for the isocratic flow:  
o Pump A: 40mM Amonium phosphate; 8mM 1-Heptanesulfonic acid 
sodium salt (Sigma, 221554); 6% Acetonitrile (Sigma, 270717) at pH 5.0 
adjusted with 70% acid.  
o Pump B: miliQ water. 
• Flow rate: 1ml/min.  
• Reading time: 30 min per sample.  
• Quantification of SAM and SAH peaks are calculated according to a calibration 
curve. 
 
 
10. PROTEIN EXPRESSION ANALYSIS: 
 
10.1. Homogenization and lysis: 
Buffers: 
- For liver homogenates: Homo buffer (70mM saccharose, 220mM mannitol, 2mM 
Tris-HCl pH 7.4, 0,1mM EDTA, 0,1% free-FA BSA) supplemented with protease 
and phosphatase inhibitors (Roche, #11 836 170 001 and 04906 837 001). This 
buffer was used to homogenize samples for further lipid analysis. 
- For lysates: RIPA buffer (150mM NaCl, 1.0% IGEPAL, 0.5% sodium deoxycholate, 
0.1% SDS, 50mM Tris, pH 8.0) (Sigma, R0278) supplemented with protease and 
phosphatase inhibitors. This buffer was used to obtain protein extracts for western 
blot analysis. 
 
Protocol: 
• Homogenize 100mg of liver with a pestle homogenizer in 1ml of homo buffer. 
• Dilute 4 times liver homogenates with RIPA lysis buffer. (Note: For adipose 
protein extraction, 100mg of tissue were homogenized directly in 0,3ml of RIPA 
lysis buffer with protease and phosphatase inhibitors.) 
• Incubate the samples 15 min at 4ºC vortexing them from time to time. 
• Spin down 5 min at 10.000 rpms at 4ºC. 
• Collect the supernatant avoiding contamination from pellet and upper lipidic 
phase. 
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10.2. Protein quantification: 
Homogenates and lysates were quantified for protein concentration using Bradford 
protein assay. Bradford assay is a protein determination method that involves the binding 
of Coomassie Brilliant Blue G-250 dye to proteins that is detectable at an absorbance of 
595 nm. There are certain chemical-protein or chemical-dye interactions that may 
interfere with the assay. In our case, it is important to always dilute the RIPA buffer at 
least 4 times to dilute the IGEPAL below 0.25%. 
  
Protocol: 
• Prepare bovine serum albumin (BSA) standard points to build a standard curve 
(E.g. 0- 0,1- 0,2- 0,3- 0,4 and 0,5 mg/ml) in PBS. 
• Dilute samples in PBS to fit in the standard curve (Liver homogenates 1/75 
dilution, liver lysates 1/20). 
• Perform the assay in a 96 well plate in triplicates. 
• Add 4μl of the diluted sample per well. 
• Using a multichannel pipette add 200μl of Quick Start Bradford Protein Assay 
(Bio-rad, 500-0201). 
• Incubate at RT for at least 5 min. Samples should not be incubated longer than 
1h at RT. 
• Set the spectrophotometer plate reader to 595 nm. Measure the absorbance of 
the standards, blanks, and unknown samples.  
• Samples will be referred to the BSA standard curve and they will be assigned a 
protein concentration.  
 
10.3. Sample preparation: 
To be able to separate the proteins in a polyacrilamide gel, samples are mixed with a 
loading buffer to ensure protein stability and weight when loading them into the wells. 
Protocol: 
• Bring all samples to the same protein concentration so we can load 20-50μg of 
protein per well in a volume of 15-40μl. Adjust the volumes with RIPA buffer. 
• Add 1/3 of the volume of loading buffer XT Sample Buffer 4x (Bio-Rad, 161-
0791) with a 0,05% of ?-mercaptoethanol. 
• Pipette up and down. 
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• Boil the samples 5 min at 100ºC. 
• Allow samples to cool down. 
• Vortex and spin down. 
As a protein standard marker for protein electrophoresis we used Novex Sharp Pre-
stained Protein Standard (Invitrogen, LC5800). 
 
10.4. Western blotting: 
In this thesis we used SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis to separate proteins from liver, hepatocytes and EWAT extracts.  This 
technique allows separation of proteins according to their electrophoretic mobility, a 
function of the length of the polypeptide chain and its charge. SDS is an anionic 
detergent that linearizes proteins and confers them a negative charge. The binding of SDS 
to the polypeptide chain imparts an even distribution of charge per unit mass, thereby 
resulting in a fractionation by approximate size during electrophoresis. After the SDS-
PAGE, separated proteins in the gel are electrotransfered into a nitrocellulose membrane 
and specifically detected on the surface of the membrane with antibodies. 
 
Buffers: 
- Running buffer: depending on the size of the protein to be detected we used 
- 20x XT MES Running Buffer (Bio-rad, 161-0789), to resolve low 
molecular weight proteins. Dilute in distilled water. 
- 20x XT MOPS Running Buffer (Bio-rad, 161-0788), to resolve high 
molecular weight proteins. Dilute in distilled water. 
- Electrotransfer buffer: prepare the buffer and cool it down to 4ºC. 
- 10x T/G buffer: Tris/Glycine buffer (Bio-rad, 161-0771). For 1L: 100ml 
of T/G buffer, 200ml of methanol and 700ml of distilled water. 
- TBST:  
- Tris Buffered Saline, with Tween 20 (TBST), pH 8.0 (Sigma, T9039). 
Contents of one pouch, when dissolved in one liter of distilled will yield 
0.05M Tris buffered saline (NaCl - 0.138M; KCl - 0.0027M); TWEEN® 
20 - 0.05%, pH 8.0, at 25 °C. We complement it with 5ml of 10% 
TWEEN 20 solution (Bio-rad, 161-0781) per liter to reach the 0.1% 
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tween. This buffer is used to wash, block and incubate the membranes 
with the antibodies. 
 
Protocol: 
• Electrophoresis:  
o Load 20-50μg of protein into the 4-12% SDS–polyacrylamide gel (Bio-
rad, 345-0124). 
o Electrophoresis system: Criterion Cell (Bio-rad, 165-6001) vertical midi 
format electrophoresis cell and PowerPac Basic Power Supply (Bio-Rad, 
165-6019). 
o Start the electrophoresis at 80v for 30 min and then increase the voltage 
up to 110v until the protein of interest is well resolved (check protein 
standard for an approximate molecular weight). 
• Transfer:  
o Pre-wet materials in transfer buffer.  
o Stack in the following order forming a sandwich:  
? Case (black)  
? Sponge 
? Whatman paper (Whatman, 10426693) 
? Gel 
? Hybond ECL nitrocellulose membrane (Amersham, RPN303D) 
? Whatman paper 
? Sponge 
? Case (red). 
o Make sure that no bubbles remain in the sandwich, as they will interfere 
with the transfer. 
o Place the sandwich in the transfer apparatus with black side of the case 
facing black side of the apparatus. 
o Electrotransfer system: Criterion blotter (Bio-Rad, 170-4070) and 
PowerPac Basic Power Supply. 
o Electrotransfer 45 min at 50v on ice. 
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• Blocking: to avoid unspecific binding of antibodies, empty membrane areas were 
blocked for 1h with 5% BSA (Sigma, A4503) TBST at RT in a small container 
on an orbital shaker.  
 
10.5. Immunodetection- Primary and secondary antibodies: 
Membranes were incubated with primary antibodies in a 5% BSA-TBST solution 
overnight at 4ºC and shaking. For specific incubation conditions see table M4. 
 
Antibody Host Dilution Buffer Brand Catalog # 
anti-Akt1/2/3  Rb 1:1000 5% BSA TBST SCBT sc-8312 
anti-ATG7 Rb 1:500 TBST Abgent AP1813b 
anti-?Tubulin-HRP Mo 1:5000 TBST Abcam ab40742 
anti-?Actin-HRP  Mo 1:25000 TBST Sigma A3854 
anti-CHOP Mo 1:1000 5% BSA TBST SCBT sc-7351 
anti-CYP2E1 Rb 1:5000 TBST Abcam ab19140 
anti-GRP78 Rb? 1:1.000 TBST Stressgen SPA-826 
anti-IR [pTyr1162 /1163 ] Rb? 1:1000 5% BSA TBST Calbiochem 407707 
anti-IR? Rb? 1:1000 TBST SCBT sc-711 
anti-IRE1? Rb? 1:1000 5% BSA TBST Cell Signaling 3294 
anti-LAMP2 Rat 1:500 5% BSA TBST Abcam ab13524 
anti-LC3B Rb? 1:1000 5% BSA TBST Cell Signaling 2775 
anti-pAkt1/2/3[Ser473 ] Rb? 1:1000 5% BSA TBST SCBT sc-7985-R 
anti-p62 Rb? 1:100 5% BSA TBST Abgent AP2183b 
anti-PDI Rb? 1:1000 5% BSA TBST Cell Signaling 2446 
anti-pIRE1?[pSer724 ]-HRP Rb? 1:1.000 5% BSA TBST Novus Biologicals NB100-2323H 
anti-rabbit-HRP G 1:20000 TBST Sigma A0545 
anti-rat-HRP G 1:15000 TBST Invitrogen 819520 
anti-mouse-HRP Rb 1:20000 TBST Sigma A9044 
 
Table M4. Primary and secondary antibodies used.  
HRP, horseradish persoxidase conjugated. p, phospho. Rb, rabbit. Mo, mouse. G, goat. 
 
After the overnight incubation: 
• Wash at least 3 times for 10 min with TBST to wash out unspecific binding. 
• Incubate membranes with the corresponding secondary antibodies at the 
indicated dilutions in TBST (Table M4). 
• Wash at least 3 times for 10 min with TBST. 
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10.6. Development, image capturing and analysis: 
Some primary and all secondary antibodies are conjugated with horseradish persoxidase. 
To develop the antibody protein detection we used a peroxidase substrate for enhanced 
chemiluminescence (ECL Western Blotting Substrate. Thermo Scientific, 32106). 
 
Protocol: 
• Warm to RT luminol and peroxide solutions. 
• Mix in a tube, equal volumes of both solutions. 
• Apply on top of the membrane and make sure it is evenly spread.  
• Incubate 1 min at RT. 
• Remove excess liquid. 
 
To obtain the chemiluminescence signal, images were collected with image capturing 
instrument, LAS4000 (GE Healthcare) and analyzed with ImageJ software to quantify 
density of pixels. 
 
 
11. GENE EXPRESSION ANALYSIS: 
 
11.1. mRNA isolation and quantification: 
To isolate mRNA we used a TRIzol-cholorform extraction (Invitrogen, 15596-018). 
TRIzol Reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other 
proprietary components, which facilitate the isolation of a variety of RNA species of large 
or small molecular size. It maintains the integrity of the RNA due to highly effective 
inhibition of RNase activity while disrupting cells and dissolving cell components during 
sample homogenization. After homogenizing the sample with TRIzol, chloroform is 
added, and the homogenate is allowed to separate into a clear upper aqueous layer 
(containing RNA), an interphase, and a red lower organic layer (containing the DNA and 
proteins). RNA is precipitated from the aqueous layer with isopropanol.  
 
RNA is very sensitive to nucleases. All material must be autoclaved and all the solutions 
and organic solvents need to be molecular biology graded, free of DNases and RNase. 
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Protocol: 
• Homogenization: 
o From hepatocytes: add 0,5ml of TRIzol per every 500.000 hepatocytes. 
Lyse the cells by shaking the plates in an orbital shaker at 4ºC. 
o From liver: use 1ml of TRIzol per every 25-50mg of tissue and 
homogenate with a manual pestle. 
• Phase separation: 
o Incubate the homogenized sample for 5 min at RT to allow complete 
dissociation of the nucleoprotein complex. 
o Add 0.2ml of chloroform per 1 ml of TRIzol used for homogenization. 
Cap the tube securely. 
o Shake tube vigorously by hand for 15 sec. 
o Incubate for 2–3 min at RT. 
o Centrifuge the sample at 12,000 × g for 15 min at 4°C. Note: The 
mixture separates into a lower red phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains exclusively 
in the aqueous phase. The upper aqueous phase is ~50% of the total 
volume. 
o Remove the aqueous phase of the sample by angling the tube at 45° and 
pipetting the solution out. Avoid drawing any of the interphase or organic 
layer into the pipette when removing the aqueous phase. 
o Place the aqueous phase into a new tube and proceed to the RNA 
Isolation Procedure. 
• RNA precipitation: 
o Add 0.5ml of 100% isopropanol to the aqueous phase, per each 1ml of 
TRIzol used for homogenization and mix by inversion. 
o Incubate at RT for 10 min. 
o Centrifuge at 12,000 × g for 10 min at 4°C. 
• RNA wash: 
o Remove supernatant from the tube, leaving only the RNA pellet. 
o Wash the pellet, with 1ml of 75% ethanol (in RNase free water) at -20ºC 
per each 1ml of TRIzol Reagent used in the initial homogenization. Note: 
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The RNA can be stored in 75% ethanol at least 1 year at –20°C, or at 
least 1 week at 4°C. 
o Vortex the sample briefly, then centrifuge the tube at 7500 × g for 5 min 
at 4°C. Discard the wash. 
o Air-dry the RNA pellet for 5–10 min. Note: Do not allow the RNA to dry 
completely, because the pellet can lose solubility. Partially dissolved RNA 
samples have an A260/280 ratio <1.6. 
• RNA resuspension: 
o Resuspend the RNA pellet in RNase-free water by passing the solution up 
and down several times through a pipette tip. 
o Incubate at least 30 min at 4ºC to allow complete resuspension. 
• RNA quantification: 
o Load 1μl of resuspended mRNA onto the NanoDrop spectrophotometer 
(Thermo Scientific, NanoDrop 1000). 
o Measure the sample absorbance at 260 nm and 280 nm to calculate 
nucleic acid concentration (260 nm) and the purity of the sample 
(260/280 ratio between 1,7-2,0). 
 
11.2. cDNA synthesis: 
The cDNA synthesis transforms the isolated mRNA into cDNA, which is a more stable 
product. This conversion is carried out by a reverse transcriptase (RT) and random 
primers that bind to non-specific pints along the RNA template. The resulting cDNA can 
be used as a template for a standard PCR.  
 
Protocol: 
• Prepare the cDNA synthesis reaction mix (Applied Biosystems, 4368814): 
 x1 
10x RT Buffer 2μl 
25x dNTP mix (100mM) 0,8μl 
10x RT Random Primers 2μl 
Reverse Transcriptase, 50U/μL 1μl 
RNA 0,25μg/μl (1μg) 4μl 
RNase free H2Od 10,2μl 
Vf 20μl 
 
Table M5. cDNA synthesis reaction mix. 
MATERIALS & METHODS 
?120
• Use 1μg of RNA template per reaction. 
• Thermocycler (ECOGEN, G-Storm) protocol: 10 min at 25ºC; 120 min at 
37ºC; 5 min at 85ºC and forever at 10ºC. 
 
11.3. Real time PCR: 
Real-time polymerase chain reaction (RT-PCR) technique is a refinement of the original 
PCR, which is used to amplify nucleic acids in a cyclic process to generate a large number 
of identical copies. In RT-PCR, the amount of product formed is monitored during the 
course of the reaction by recording the fluorescence of dyes or probes introduced into the 
reaction, which is proportional to the amount of product formed, and the number of 
amplification cycles required to obtain a particular amount of DNA molecules is 
registered. Assuming a certain amplification efficiency, which typically is close to a 
doubling of the number of molecules per amplification cycle, it is possible to calculate the 
number of DNA molecules of the amplified sequence that were initially present in the 
sample (Kubista, Andrade et al. 2006).  
 
In this thesis, we used SYBR-green based RT-PCR as a method for analyzing hepatic 
gene expression changes. SYBR Green (Applied Biosystems, 4368702) is a fluorescent dye 
that binds to double-stranded DNA (i.e., amplicons) and fluoresces when is excited by a 
light source.  
 
One important step in relative quantization is the selection of an endogenous control. 
Normalization to an endogenous control (or housekeeping gene) allows correcting results 
that can be skewed by differing amounts of input nucleic acid template. Any gene 
expressed at the same level in all study samples can potentially be used as an endogenous 
control. In this thesis we used ?-actin and 18S as endogenous controls. 
 
Results were analyzed using the relative quantification method ΔΔCt. Relative 
quantification relates the PCR signal of the target transcript in a treatment group to an 
untreated control. When using the comparative ΔΔCT method, is crucial that the target 
gene and endogenous control have similar or relatively equivalent PCR efficiencies. 
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The Cycle Threshold (Ct) is defined as the number of cycles required for the fluorescent 
signal to cross the threshold (e.g. exceeds background level). Ct levels are inversely 
proportional to the amount of target nucleic acid in the sample, so the lower the Ct level 
the greater the amount of target nucleic acid in the sample. The ΔΔCT Method uses 
arithmetic formulas to achieve the result for relative quantization. The amount of target, 
normalized to an endogenous control and relative to a calibrator (or control experimental 
grup), is given by: 
 
Gene expression = 2 -(ΔΔCt) 
 
Where ΔΔCt stands for:  ΔΔCt = ΔCtexperiment - ΔCtcontrol 
and ΔCt stands for:   ΔCt = Ctgene "X" - Ct?Actin 
 
Protocol: 
• Dilute 1/20 in RNase free water the cDNA synthesis reaction. 
• Prepare as many RT-PCR mixes as number of genes checked (Table M6). 
 
 x1 
RT Fw Primer 10μM 0,5μl 
RT Rev Primer 10μM 0,5μl 
RNase free H2Od 7,5μl 
SYBR green AB 12,5μl 
cDNA 4μl 
Vf 25μl 
 
Table M6. RT-PCR mix. 
 
• Samples followed the indicated PCR protocol in a MyiQ single color real-time 
PCR detection system (Bio-Rad) (Table M7). 
 
 Time Temperature Repetitions 
Step1 10 min 95ºC - 
Step2 15 sec 95ºC   
 30 sec 58ºC x40 cycles 
 30 sec 72ºC   
Step3 1 min 95ºC - 
Step4 10 sec 10ºC x81 
 
Table M7. RT-PCR protocol. 
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11.4. RT-PCR primers: 
 
 
Gene Accession # Forward primer (5'-3') Reverse primer (5'-3') 
18S X00686 AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Abca1 NM_013454 AAAACCGCAGACATCCTTCAG CATACCGAAACTCGTTCACCC 
ACDase NM_019734 TGTTGGATATGTGGGCATGT TTCCTTCCGAACATCCATTC 
ASMase-h NM_000543 CTGACTCTCGGGTTCTCTGG AGGTTGATGGCGGTGAATAG 
ASMase-m NM_011421 TGGGACTCCTTTGGATGGG CGGCGCTATGGCACTGAAT 
Atf4 NM_009716 CCTTCGACCAGTCGGGTTTG CTGTCCCGGAAAAGGCATCC 
Atg7 NM_028835 GCCAGGTACTCCTGAGCTGT ACTTGACCGGTCTTACCCTG 
?actin NM_007393 GACGGCCAGGTCATCACTAT CGGATGTCAACGTCACACTT 
Bhmt NM_016668 ATTCCCCTTTGGATTGGAAC TGTGCATGTCCAAACCACTT 
Caveolin1 NM_007616 TGTACCGTGCATCAAGAGC AAAGAGTGGATCGCAGAAGG 
Cbs NM_178224 CTTCAGGGACATCCCAGTGT AGCTGCCAGGTACATCTGCT 
Cd36 NM_007643 ATGGGCTGTGATCGGAACTG GTCTTCCCAATAAGCATGTCTCC 
CerS2 NM_029789 CCTCTGCTTCTCCTGGTTTG TGAAGAGGTTGTTGCAGGTG 
CerS4 NM_026058 AAGAATGAGGGCCAACTCTG ACCAATGCACCCTCTGTTTC 
CerS5 NM_028015 GATGGCCAATTATGCCAGAC CCAGCTTTCAAAGAGGGTTG 
Chop-m NM_007837 CCACCACACCTGAAAGCAGAA AGGTGAAAGGCAGGGACTCA 
Chop-h NM_001195053 GCGCATGAATTATAAATAAC ACCATTCGGTCAATCCAGAGC 
Dgat2 NM_026384 TGATCTTTGAGGAGGGTTCC AGGGGGCGAAACCAATATAC 
Edem NM_138677  AAGCCCTCTGGA ACTTGCG AACCCA ATGGCCTGTCTGG 
Fabp1 NM_017399 ATGAACTTCTCCGGCAAGTACC CTGACACCCCCTTGATGTCC 
Fas NM_007988 TGATTATGGCCCTCAGTTCC CAGCATTGTGTCCATGAAGG 
Fatp2 NM_011978 TCCTCCAAGATGTGCGGTACT TAGGTGAGCGTCTCGTCTCG 
Grp78-m NM_022310  ACTTGGGGACCACCTATTCCT ATCGCCAATCAGACGCTCC 
Grp78-h NM_005347 AATGACCAGAATCGCCTGAC CGCTCCTTGAGGTTTTTGTC 
Hmgcr NM_008255 GGAACCGTGGGTGGTGGGAC GCCTTCTTGGTGCATGTTCCC 
Lc3b NM_026160  AATCACTGGGATCTTGGTGG  AGTCAGATCGTCTGGCTCG 
Ldlr NM_010700 CTCCTGCATTCACGGTAGCC CCCACTGTGACACTTGAACTTG 
Mat1A NM_133653 GACACCATCAAGCACATTGG ATGCATTCCTCGGTCTCATC 
Mln64 NM_021547 TGCCCATCATTTCATTCATCCTT AAAAGCGGTTTCTCACTCTCC 
Ms NM_001081128 CATCCAAGAGTGTGGTGGTG ATAAACGTGGGCTTCACTGG 
p62 NM_011018 TCTGGGGTAGTGGGTGTCAG AGAATGTGGGGGAGAGTGTG 
Pdi NM_011032  CAAGATCAAGCCCCACCTGAT AGTTCGCCCCAACCAGTACTT 
Ppara NM_011144 AGAGCCCCATCTGTCCTCTC ACTGGTAGTCTGCAAAACCAAA 
Sms1 NM_001168525 ATGATCTCGGTCGTCCATGAA  AAAACGTGTCCGGTAGTGGAG 
Sms2 NM_028943  CCACCAACACTTACACAAGCC GCACCCTTTCGTAACCCGTT 
Srebp1c NM_011480 GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
Srebp2-m NM_033218 CACCTGTGGAGCAGTCTCAA TGGTAGGTCTCACCCAGGAG 
Srebp2-h NM_004599.2 CCCTTCAGTGCAACGGTCATTCAC TGCCATTGGCCGTTTGTGTC 
Star-m NM_011485 AGATGTGGGCAAGGTGTTTC ATGCGGTCCACAAGTTCTTC 
Star-h NM_000349 CTTGGGCATCCTTAGCAAC ATCTTTTCCGATCTTCTGC 
 
 
Table M8. RT-PCR primer sequences. h, stands for human. m, stands for mouse.  
When not indicated, primer sets are for mouse gene detection. 
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All primers were designed in PrimerBank, a public resource for primers designed for gene 
expression quantification (Table M8). The primer design algorithm of PrimerBank tests 
primers for specificity and efficiency and all experimental validation data is available 
online: http://pga.mgh.harvard.edu/primerbank/. All primers were ordered from 
Invitrogen. 
 
 
12. CELL CULTURE: 
 
12.1. Primary mouse hepatocytes:  
12.1.1. Isolation: 
Primary mouse hepatocytes from male mice (6–10 weeks old) were isolated with a 
liver collagenase perfusion followed by a differential centrifugation. 
 
Buffers: prepare HANKS1x and KREBS buffers fresh. 
- HANKS 10x: 1,4M NaCl; 53,6mM KCl; 8,1mM MgSO4·7H2O; 6,7mM 
Na2HPO4·2H2O; 8,8mM KH2HPO4. 
o HANKS 1x: 10% HANKS 10x; 12,6mM Hepes; 25mM NaHCO3. 
? HANKS I (Cleaning Buffer): HANKS1x, 0,5% BSA; 0,9mM 
EGTA. 
? HANKS II (Digestion Buffer): HANKS 1x; 160U/ml 
Collagenase (Sigma, C5138); 4mM CaCl2·2H2O. 
- KREBS: 0,95% Krebs-Henseleit (Sigma, K3753); 16,8mM Hepes; 24mM 
NaHCO3; 2,7mM CaCl2·2H2O, pH 7.4. 
 
Protocol: 
• Gas HANKS1x buffer and KREBS buffer (without the CaCl2) with 95% 
CO2 and 5% O2 for 20 min to stabilize the pH. 
• Add the rest of the components to complete HANKS I-II and KREBS 
buffers. EGTA is crucial in the cleaning buffer to avoid coagulation and 
calcium is necessary for the digestion buffer as a cofactor of the collagenase. 
• Check the pH of Krebs buffer and adjust to 7.4 if needed with NaOH. 
• Filter buffers through a 0.22μm filter.  
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• Allow buffers to reach 37ºC in a water bath. 
• Clean the peristaltic pump tubes with 70% ethanol, distilled water and then 
fill the circuit with warm HANKS I buffer at a speed of 8-10ml/min. 
• Anesthetize the mouse with a dose of 0,1g/Kg Sodium pentobarbital. 
• Prepare two sutures (Lab. Aragó S.A., Seda trenada 2/0 #060), about 12cm 
long. 
• Open the mouse with a laparotomy. 
• Put two sutures under cava and portal vein. 
• Insert the catheter (BD, 381212) into the portal vein and immobilize it with 
the suture around it. If the catheter does not fill with blood, fill it with warm 
HANKS I buffer avoiding bubble formation. 
• Stop the peristaltic pump (Cole-Parmer, MasterFlex L/S #7553-79) and 
connect it to the catheter. Avoid bubble formation. 
• Start the pump and cut the inferior cava vein so the blood can exit the system 
and clean the liver with HANKS I buffer. This will prepare the liver for 
digestion. 
• Open the diaphragm and cut the superior cava vein. Then tie the suture that 
was previously placed around the inferior cava vein so liver circuits are 
cleaned in the other direction. 
• Once the liver is clean, change to HANKS II buffer to start the digestion. It 
will take 2-3 min to digest. The liver will turn slightly white/brown while it 
starts swelling. It is crucial to reach an optimal digestion point. Too much or 
insufficient digestion will result in poor hepatocyte viability. 
• Pour some KREBS buffer in a Petri dish and prepare a small Erlenmeyer with 
a funnel and a sterile maze to filter the non-digested parts of the liver. 
• Take the liver out and with a pair of tweezers disaggregate the tissue in the 
Petri dish with KREBS buffer to liberate the hepatocytes from the digested 
liver. 
• Filter hepatocytes through the maze and adjust to a final volume of 50ml 
with KREBS buffer. 
• Centrifuge at 60 g for 4 min at 4ºC. 
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• Discard the supernatant containing KC, HSC and SEC and resuspend the 
pellet containing the hepatocytes with warm media (twice the volume of the 
pellet). 
• Hepatocyte viability: After the isolation, check viability rate of hepatocytes in 
order to know the starting point of the cells before the experiments. 
Isolations with a viability rate below a 50% were discarded. To check 
viability we used the Trypan Blue staining which allows us to distinguish 
between living and dead cells (See method14.4).  
o Dissolve 50μl of the resuspended cells in 950μl of 0,2% Trypan Blue 
(Sigma, T8154). 
o Wait a minute and start to count for positive and negative cells using a 
Neubauer Chamber. 
o Multiply the number of cells by the Trypan Blue dilution factor (1/20) 
and by the volume of the Neubauer Chamber (104 cells/ml). The sum 
of alive and dead cells will give us the total number of cells that we 
will use to calculate the % of viability: negative cells/total number of 
cells x100. 
 
12.1.2. Culture: 
Primary mouse hepatocytes attach better in collagen-coated plates. For that reason, 
all plates were coated with rat-tail collagen. 
 
Rat-tail collagen isolation protocol: 
• Peal the rat-tail with a scalpel and visualize the four collagen fibers. 
• Dissect the fibers avoiding contamination from the surrounding tissues. 
• Incubate the fibers 24h at RT in 70% ethanol to clean them. 
• Dry the fibers and weigh them.  
• Prepare 300ml of 0,1% acetic acid per each gram of collagen isolated. Cut 
the fibers in pieces and incubate them 48h at 4ºC in 0,1% acetic acid 
agitating. After this incubation, collagen will be dissolved in the acetic acid. 
• Centrifuge at 3000 rpms for 20 min at 4ºC to pull down the non-dissolved 
collagen fibers. 
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• Collect the supernatant in an autoclaved glass bottle and take it to irradiate 
in order to sterilize it (5 min at 1000 rads). 
 
Collagen-coat plates: 
• In the cell culture hood, dilute 1/3 the stock collagen in sterile water. 
• Add 500μl of this dilution to each 6 well plate. 
• Incubate 30 min at RT. 
• Aspirate the collagen. 
• Let it air dry in the hood for 30 min. 
• Keep the plates at 4ºC until used. 
• Before using the plates, wash them with PBS to remove any remaining acetic 
acid. 
 
Media: 
Two different medias were used for the primary hepatocyte culture. The 
supplemented media with fetal bovine serum (FBS) for the first hours post isolation 
and the basic media for the rest of the culture. 
 
- Supplemented media: DMEM:F12 (Gibco, 21331-020) with 10% FBS 
(Gibco, 10-270-106), 10.000U/ml Penicillin-Streptomycin (Gibco, 15140-
122), 200mM L-Glutamine (Gibco, 25030-024), 7,5mM D-Glucose (Sigma, 
G6152), 150mM Hepes pH 7.4 (Sigma,), 1mM Methionine (Sigma, 
M5308). 
- Basic media: is the same media without the FBS. 
 
Seeding: 
• Hepatocytes have a tendency to precipitate at the bottom of the tube very 
quickly due to its size. Make sure to gently homogenize hepatocytes before 
seeding them by pipetting up and down. 
• Seed 0,5x106 cells per well of a 6 well collagen-coated plate for protein 
extracts and 0,25x106 cells per well of a 12 well collagen-coated plate for 
mRNA isolation. 
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Culture: 
• During the first four hours post isolation culture cells with Supplemented 
media. After the first 2h, change the media to remove all non-attached dead 
cells. This will improve the viability of attached cells. 
• 4 hours post isolation, change to the basic media. 
• Keep cells in an incubator at 37ºC with a 5% CO2. 
• Primary mouse hepatocytes keep their phenotype for 36-48h isolation, so 
treatments should be done during this time to avoid artifacts. 
 
12.1.3. Treatments: 
12.1.3.1. Insulin stimulation: 
To examine insulin signaling pathway in primary mouse hepatocytes, cells 
were stimulated with 100nM insulin for 3 minutes. After that, plates were 
flash frozen in liquid nitrogen and their protein extracts were used to analyze 
phosphorylation events of insulin signaling pathway via WB. 
 
12.1.3.2. ER stress induction: 
To see whether ASMase-/- primary mouse hepatocytes were able to sense ER 
stress, cells were challenged with the bacterial AB5 subtilase cytotoxin 
(SubAB) or its mutant inactive form SubAA272B (1 μg/ml). Active SubAB 
rapidly induces ER stress upon proteolytic cleavage of GRP78 (Paton, 
Beddoe et al. 2006). Cells were collected with TRIzol or RIPA buffer for 
mRNA and protein analysis. 
 
12.1.3.3. Autophagic flux: 
Autophagy is a highly dynamic process, which makes challenging to interpret 
results in a steady situation. For that reason, the study of autophagic flux 
requires the use of autophagy inducers and blockers that will help to 
interpret results. 
 
Chloroquine (CHQ): is a lysosomotropic agent that prevents endosomal 
acidification. It accumulates inside the acidic parts of the cell, including 
endosomes and lysosomes. This accumulation leads to inhibition of lysosomal 
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enzymes that require an acidic pH, and prevents fusion of endosomes and 
lysosomes. CHQ inhibits autophagy as it raises the lysosomal pH, which 
leads to inhibition of both fusion of autophagosome with lysosome and 
lysosomal protein degradation. The inhibition of autophagy at this level 
allows us to study the basal autophagic flux when comparing it to a control. 
Primary mouse hepatocytes were treated for 3h with 50μM CHQ (Santa 
Cruz, sc-205629) in basic media. 
 
Rapamycin: is an inhibitor of mTOR, which is a major negative regulatory 
axis of autophagy. Direct inhibitors of mTOR subsequently induce 
autophagy. This treatment allows us to study the cell ability to activate 
autophagy upon mTOR inhibition. Primary mouse hepatocytes were treated 
for 3h with 2μM rapamycin (Santa Cruz, sc-3504A) in basic media. 
 
To study the autophagic flux, cells were processed for protein analysis via 
WB where lipidation of LC3BI to LC3BII and p62 degradation was 
monitored. 
 
12.1.3.4. Lysosomal membrane permeabilization: 
Lysosomotropic detergents, which selectively target lysosomal membranes, 
are compounds that remain predominantly unprotonated and inert in the 
cytosol, but they become protonated, accumulate, and acquire detergent 
properties in the acidic interior of lysosomes. Low concentrations of 
lysomotropic detergents cause translocation of lysosomal contents leading to 
apoptosis.  Lysosomal membrane permeabilization and subsequent release of 
cathepsins is an early event during apoptosis induced by a number of stimuli, 
such as oxidative stress, death receptor ligation, and DNA-damaging drugs.  
 
MSDH (O-methyl-serine dodecylamide hydrochloride) (Appelqvist, Nilsson 
et al. 2011) is lysomotropic detergent kindly gifted by Dr. Hanna Appelqvist 
(Linköping University, Linköping, Sweden).  MSDH was used to induces 
cell death in WT and ASMase-/- primary mouse hepatocytes as well as 
hepatocytes derived from HCD exposed mice. Cells were treated for 24h 
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with 15-20-25μM MSDH. Cell viability was determined by MTT assay (See 
method 13.2). 
 
12.1.3.5. TNF-? stimulation: 
Primary mouse hepatocytes from control and alcoholic mice were incubated 
overnight with recombinant 280ng/ml of human TNF-? (Peprotech EC). Cell 
death was determined by Trypan Blue exclusion (0.2%) (see method 13.2). 
 
12.2. Hep G2 cell line: 
The Hep G2 cell line (ATCC # HB-8065) is a human hepatoma cell line originated from 
a hepatocellular carcinoma from a Caucasian 15 year old male.  Hep G2 is an epithelial-
like adherent cell line that often grows in clusters of multilayer of cells. It has been 
commonly used as a hepatocyte cell line for its good transfection properties. The cells 
express HMG-CoA reductase and hepatic triglyceride lipase activities but they do not 
express ADH.  
 
12.2.1. Culture: 
The base medium for this cell line is DMEM (Invitrogen, 41966-052) with 10% of 
fetal bovine serum and 10.000U/ml Penicillin-Streptomycin. The optimum growing 
are a temperature of 37.0°C in an atmosphere of 95% air and 5% CO2. 
 
Passaging protocol: 
• Remove and discard culture medium. 
• Wash with warm PBS to remove all traces of serum that could inhibit trypsin 
action. 
• Add 2ml of Trypsin-EDTA (Invitrogen, 25200-056) to the flask and observe 
cells under an inverted microscope until cell layer is dispersed (usually within 
5 to 15 min). Note: To avoid clumping do not agitate cells by hitting or 
shaking the flask while waiting for the cells to detach. Cells that are difficult 
to detach may be placed at 37°C to facilitate dispersal. 
• Add 8ml of complete growth medium and collect cells by gently pipetting. 
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• Add appropriate aliquots of the cell suspension to new culture vessels. 
Suggested subcultivation ratio: 1:4 to 1:6 is recommended and a medium 
renewal should be done twice per week. 
 
Preservation: 
Aliquots of low passages should be frozen down in order to have always a source of 
cells in early passages. 
  
• Prepare 5% DMSO growing media.  
• Freeze down 5-10 million cells per cryotube and progressively freeze down by 
first placing the tube on dry ice for 1 hour, then to -80ºC for a week and 
then to liquid nitrogen for definitive storage.  
• Thaw the cells quickly and seed them in a small flask.  
• Switch the media after 4h when cells are attached in order to remove the 
toxic DMSO of the freezing media. 
 
12.2.2. Treatments: 
12.2.2.1. Exogenous sphingomyelinases: 
Hep G2 cells were treated with a dose-response from 0 to 2U/ml of human 
placental ASMase (Sigma, S5283) and 2U/ml Bacillus cereus NSMase (Sigma, 
S9396) for 18h. Cells were processed for RNA isolation and analyzed for ER 
stress markers by gene expression. For Ca2+ ER release studies, cells were 
grown on coverslips and treated with 1U/ml human placental ASMase for 
18h prior to Thapsigargin (Tg) (Sigma, T9033) stimulation (See section 14.4 
for detailed protocol). 
 
12.2.2.2. Thapsigargin-induced Ca2+ release: 
In order to study Ca2+ release from the ER, cells were treated with 1μM Tg. 
Tg is a naturally occurring sesquiterpene lactone isolated from the 
umbelliferous plant Thapsia garganica. This tumor promoter releases Ca2+ 
from intracellular stores by specifically inhibiting the endoplasmic reticulum 
Ca2+-ATPase, SERCA. 
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12.2.2.3. Tunicamycin-TUDCA treatment: 
 Hep G2 cells were challenged with 4μg/ml Tm for 4h in order to induce ER 
stress.  TUDCA (Tauroursodeoxycholic acid) (Sigma, T0266) is a bile acid 
commonly used as a chemical chaperone to release ER stress. Hep G2 cells 
were pre-treated overnight with or without 500μg/ml TUDCA in order to 
prevent Tm-induced ER stress. Cells were processed for RNA isolation and 
gene expression analysis. 
 
 
13. CELL DEATH: 
 
13.1. MTT: 
MTT assay measures the cell proliferation rate and conversely, when metabolic events 
lead to apoptosis or necrosis, the reduction in cell viability. The yellow tetrazolium MTT 
(3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) is reduced by 
metabolically active cells, in part by the action of dehydrogenase enzymes, to generate 
reducing equivalents such as NADH and NADPH. The resulting intracellular purple 
formazan can be solubilized and quantified by spectrophotometric means. 
 
Protocol: 
• Seeding conditions: seed 250.000 hepatocytes per each 12 well. 
• Perform the treatments. 
• MTT reduction: during the last hour of treatment add 0,5mg/ml MTT to the 
medium. During this hour, MTT will be reduced to formazan by metabolically 
active cells. 
• Aspirate the medium and allow plates to completely dry. 
• Solubilize the generated purple formazan with 1ml of 1-propanol per well. 
• Shake the plates until formazan is completely dissolved. 
• In a plate reader spectrophotometer read at an absorbance of 570 nm 
corresponding to the formazan and 630 nm corresponding to the background. 
• The final absorbance will be [Abs570-Abs630]. 
• To express the results in a percentage refer all samples to the controls to obtain a 
fold change. 
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13.2. Trypan blue: 
Cell viability can be assessed by Trypan Blue exclusion. Trypan Blue (Sigma, T8154) is a 
vital stain that selectively stains dead cells. In a viable cell, Trypan Blue does not 
penetrate cell membranes, however, dying or already dead cells have compromised cell 
membranes that allow the entrance of Trypan Blue resulting blue in staining of these 
cells. 0.2% Trypan Blue in PBS was used for the staining and a Neubauer chamber was 
used to count positive and negative stained cells to create a percentage of viability within 
the sample. 
 
 
14. CONFOCAL MICROSCOPY: 
This technique allows visualizing specific components of cells or tissue sections by 
immunofluorescence, binding specific antibodies chemically conjugated with a fluorescent 
dye or by using fluorescent probes with specific targets.  
 
The immunofluorescence direct method uses primary antibodies labeled with a 
fluorescent dye and the indirect method uses a secondary antibody labeled with a 
fluorescent dye that recognizes the primary antibody. This technique can be performed 
on cells fixed on slides and tissue sections. Samples can be examined under a fluorescence 
microscope or a confocal microscope for better resolution. On the other hand, the 
fluorescent probes allow us to specifically stain cellular compartments like mitochondria 
or lysosomes among others. These probes are added to the culture media of living cells 
during the treatments and are incorporated physiologically into the cell. 
 
Confocal microscopy is an optical imaging technique that increases optical resolution and 
contrast of a sample by using point illumination and a spatial pinhole eliminating the out-
of-focus light in specimens that are thicker than the focal plane.  
 
14.1. Mitochondrial cholesterol: 
In order to study whether FC was increased in mitochondrial membranes of ASMase 
deficient primary mouse hepatocytes we immunodetected cytochrome c as a 
mitochondrial marker and filipin, a fluorescent probe, as a FC marker. 
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Protocol: 
• Seeding: 200.000 hepatocytes per 6 well plate containing collagen-coated 
coverslips. 
• Fixation: fix hepatocytes 15 min with 4% paraformaldehyde (PFA) at RT. 
• Washes: wash the cover slips with PBS twice.  
• Blocking and permeabilization: block and permeabilize the cells for 15 min at RT 
using a blocking buffer (PBS +0.5% glycine + 1% FFA-BSA) with 0,025% 
saponinin. 
• Primary antibody: incubate overnight with mouse anti-cytochrome c monoclonal 
antibody (clone 6H2.B4; Pharmingen, 556432) diluted 1:200 in 1x PBS with 1% 
FFA-BSA in a humidity chamber.  
• Washes: wash the cover slips with PBS three times.  
• Secondary antibody and filipin staining: incubate 1h at RT with a secondary anti-
mouse IgG antibody, conjugated with Alexa Fluor 488 (1:1000, Molecular 
Probes, A10684) diluted 1:1000 in PBS + 0,1% FFA-BSA. Filipin was added 
during the secondary antibody incubation at a concentration of 250μg/ml. 
• Washes: wash the cover slips with PBS three times.  
• Mounting: mount the cover slips on glass slides with Dako fluorescent mounting 
medium.  
• Allow mounting media to dry a few hours. 
• Visualize the samples in the Leica SPE confocal laser-scanning microscope. 
(Filipin ?ex340-380nm ; ?em385-470nm. Alexa 488 ?ex488nm ; ?em495-519nm) 
 
14.2. Lysosomal cholesterol: 
In order to study whether FC was increased in lysosomes of ASMase deficient and 
hypercholesterolemic primary mouse hepatocytes we used the fluorescent probe 
Lysotracker (Invitrogen, 7528), which has high tropism towards acidic compartments 
like lysosomes. Filipin was used as a FC marker.  
 
Protocol: 
For these experiments we used 6-10 week old WT and ASMase-/- mice and 48h HCD 
exposed WT mice. 
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• Seeding conditions: 200.000 hepatocytes per 6 well plate containing collagen-
coated coverslips. 
• Lysotracker: 3h post-isolation switch to warm basic media containing 50nM 
Lysotracker. Incubate for 1h at 37ºC in the incubator. 
• Washes: aspirate the media and wash three times with PBS. 
• Fixation: fix cells with 4% PFA for 15 min at RT protecting from the light from 
now on. 
• Washes: wash three times with PBS. 
• Filipin staining: incubate for 15 min at RT with 250μg/ml of filipin in PBS. 
• Washes: wash three times with PBS. 
• Mounting: mount the cover slips on glass slides with 8μl of Dako fluorescent 
mounting medium. 
• Allow mounting media to dry a few hours before visualizing with the microscope. 
• Visualize the samples in the Leica SPE confocal laser-scanning microscope. 
(Filipin ?ex340-380nm ; ?em385-470nm. Lysotracker ?ex577nm ; ?em590nm) 
 
14.3. Autophagosome formation: 
In order to study autophagosome vacuoles in ASMase deficient primary mouse 
hepatocytes we used the fluorescent probe monodansylcadaverine or MDC (Santa Cruz, 
sc-214851) as autophagosome marker and Hoechst 33258 (Molecular Probes) staining 
as cell permeable nucleic acid counterstaining. MDC preferentially accumulates in 
autophagic vacuoles due to a combination of ion trapping and specific interactions with 
membrane lipids. 
 
Protocol: 
For these experiments we used 6-10 week old WT and ASMase-/- mice. 
• Seeding conditions: 200.000 hepatocytes per 6 well plate containing collagen-
coated coverslips. 
• Autophagy induction: 2h post isolation treat cells with 2μM rapamycin for 1h in 
basic media. 
• MDC staining: prepare a fresh stock of 17mg/ml MDC in methanol and perform 
a 1/1000 dilution in PBS. After rapamycin treatment, switch cells to warm PBS 
containing the MDC.  Incubate for 10 min at 37ºC. 
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• Washes: aspirate the media and wash three times with PBS. 
• Fixation: fix cells with 4% PFA for 15 min at RT protecting from the light from 
now on. 
• Washes: wash three times with PBS. 
• Hoechst staining: incubate for 15 min at RT with 2μg/ml Hoechst in PBS. 
• Washes: wash three times with PBS. 
• Mounting: mount the cover slips on glass slides with 8μl of Dako fluorescent 
mounting medium. 
• Allow mounting media to dry a few hours before visualizing with the microscope. 
• Visualize the samples in the Leica SPE confocal laser-scanning microscope. 
(MDC ?ex335nm ; ?em518nm. Hoechst ?ex352nm ; ?em461nm) 
 
14.4. ER Ca2+ release: 
To study the role of ASMase in ER Ca2+ stores, which regulate UPR, we used the 
calcium indicator Fluo-4 AM (Molecular Probes, F-14201) to determine ER Ca2+ 
homeostasis in Hep G2 cells in response to exogenous ASMase. 
 
Protocol: 
• Seeding conditions: seed 300.000 cells per 6 well plate containing glass coverslips. 
• ASMase treatment: pre-treat cells with 1U/ml human placental ASMase for 18h. 
• Calcium indicator: load cells with 4μM of the calcium indicator Fluo-4 AM and 
with 0.08% Pluronic F-127 to facilitate Fluo-4 AM solubilization (Molecular 
Probes, F-127) in DMEM at RT for 30 min.  
• Washes: wash excess Fluo-4 from cells three times with DMEM. 
• Stabilization: let the cells rest in calcium free DMEM for additional 15 min. 
• Washes: wash three more times with calcium free DMEM.  
• Mounting: mount the coverslip on the stage of an inverted confocal Leica TCS-
SL microscope.  
• Life image capturing: fluorescence images were collected every second over a 10 
min period. 1μM Tg was added after two minutes of system stabilization. The 
ratio of basal to peak intensities of individual cells was calculated using Image J, 
and ratios for 10 individual cells were averaged per run. 
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15. HUMAN SAMPLES: 
Human liver samples were obtained from patients with alcoholic hepatitis by 
transyugular biopsies (n=10) or from explanted livers from patients undergoing liver 
transplantation for alcoholic liver disease (n=7). Normal livers were obtained from 
cadaveric liver donors (n=3) or from resection for unrelated liver diseases (metastasis from 
distant organ cancer, n=8). All control donors had normal serum aminotransferase levels 
and normal liver histology.  
 
Samples were immediately frozen in liquid nitrogen and stored at -80°C for mRNA 
analysis. Total RNA was extracted using Nucleospin®RNAII and one microgram of total 
RNA was retro transcribed using the High Capacity cDNA Reverse Transcriptase kit 
(Applied Biosystems) following manufacturer's recommendations. All patients gave 
written informed consent, and the protocol was approved by ethical committees from the 
Hospital Clínic i Provençal de Barcelona and Hospital Huriez, and followed ethical 
guidelines on humans and human samples. Clinical characteristics of patients are included 
in Table M9. 
 
  Control (n=13) Alcoholic Hepatitis (n=17) 
Age (Years) 56 (40-73) 50.14 (38-56) 
AST (U/L) 20.5 (20-22) 104.35 (3-222) 
ALT (U/L) 23.25 (13-32) 38.5 (26-90) 
Bilirrubin (mg/dL) 0.4 (0.3-0.6) 11.71 (4-21) 
?GT (U/L) 101.6 (48-210) 337.75 (123-1100) 
 
Table M9. Clinical and analytical characteristics of patients with acute alcoholic hepatitis. Numeric data is 
shown as median (interquartile range [IQR] 25-75) and categorical/nominal data in count.  AST: Aspartate- 
aminotransferase; ALT: Alanine-aminotransferase; ?GT:  ?-glutamyltransferase. 
 
 
 
16. STATISTICS: 
Results are expressed as mean ±SEM unless otherwise indicated. Statistical significance of 
mean values was assed using Student t-test and one-way ANOVA followed by Bonferroni 
post-test. Statistics were performed using GraphPad Prism 5 software. 
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AIM 1. ROLE OF ACID SPHINGOMYELINASE IN  
NON-ALCOHOLIC STEATOHEPATITIS 
 
1.1. Diet-induced body weight gain, glucose and insulin tolerance in ASMase null 
mice. 
Since obesity and its associated co-morbidities such as insulin resistance and T2DM are 
known to contribute to NAFLD, we first examined the role of ASMase deficiency in body 
weight and systemic glucose homeostasis following HFD intake. On RD ASMase null 
mice were heavier than wild type mice (Figure 1.1). Moreover, while wild type mice 
gained body weight on HFD, as expected, this effect was significantly more pronounced 
in ASMase null mice. 
 
 
   
 
Figure 1.1 Body weight. WT and ASMase-/- mice body weight time course on RD and HFD (n>9). Inside 
figure represents area under the curve of each group. Results are expressed as mean ± SEM (**p<0.01 vs. RD-fed 
WT mice, ##p<0.01 vs. HFD-fed WT mice). 
 
 
Considering that the primary function of adipose tissue is to store fat, we next examined 
whether enhanced adiposity could contribute to the body weight gain of ASMase 
knockout mice following HFD feeding. As expected, wild type mice exhibited increased 
adipose mass, in particular, epididymal (EWAT) and subcutaneous white adipose 
(SCWAT) stores upon HFD feeding (Figure 1.2). However, this effect was blunted in the 
absence of ASMase, as EWAT and SCWAT from ASMase null mice weighted 
significantly less than corresponding tissues from wild type mice (Figure 1.2).  
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Figure 1.2. Tissue weight. Liver, epididymal (EWAT) and subcutaneous (SCWAT) white adipose tissue 
weight of WT and ASMase-/- mice fed either RD or HFD (n>9). Results are expressed as mean ± SEM 
(**p<0.01 vs. RD-fed WT, ##p<0.01 vs. HFD-fed WT). 
 
Furthermore, on RD EWAT from ASMase null mice exhibited more crown-like 
structures than wild type mice, indicating mononuclear cell infiltration (Figure 1.3).  
 
 
 
Figure 1.3. EWAT H&E staining. Epididymal white adipose tissue H&E staining from WT and ASMase-/- 
mice fed either RD or HFD.  
 
Regarding systemic glucose homeostasis, ASMase null mice displayed higher fasting blood 
glucose levels than wild type mice on RD, and this effect worsened upon HFD feeding 
(Figure 1.4).  
  
Figure 1.4. Blood glucose levels. 6h-fasted blood glucose levels of HFD-fed WT and ASMase-/- mice (n>12). 
Results are expressed as mean ± SEM (*p<0.05 vs. RD-fed WT mice, ##p<0.01 vs. HFD-fed WT and ƒp<0.05 
vs. RD-fed ASMase-/- mice). 
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We next performed GTT and ITT to further investigate systemic glucose metabolism 
and insulin action. On RD, there were no major changes except for the moderate glucose 
tolerance of ASMase knockout mice with respect to wild type mice (Figure 1.5. A-C). 
However, upon HFD we observed lower glucose and insulin tolerance in ASMase null 
mice compared to wild type mice following GTT and ITT tests (Figure 1.5 D-F). 
Moreover, body weight gain, glucose homeostasis and tolerance in ASMase+/- mice fed 
HFD were similar to wild type mice (not shown). Since ASMase+/- mice exhibit 40-50% 
residual ASMase activity, these findings suggest that most of ASMase is dispensable in 
regulation of obesity and glucose homeostasis. These findings define a critical role for 
ASMase in the regulation of body weight and insulin sensitivity following HFD intake. 
 
 
 
 
Figure 1.5. Analysis of systemic glucose homeostasis. Glucose tolerance tests of WT and ASMase-/- mice on 
(A) RD and (D) HFD. Insulin tolerance tests of WT and ASMase-/- mice on (B) RD and (E) HFD. Area under 
the curve of GTT and ITT on (C) RD and (F) HFD (n=6). Results are expressed as mean ± SEM (*p<0.05 vs. 
RD-fed WT mice, #p<0.05, ##p<0.01 vs. HFD-fed WT mice). 
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1.2.  Hepatic insulin signaling in ASMase deficiency. 
To specifically address whether hepatic insulin signaling was impaired in ASMase null 
mice, insulin was infused into the portal vein to examine early hepatic insulin signaling 
events. Liver extracts from wild type and ASMase null mice on RD exhibited similar 
phosphorylation of insulin receptor ? (IR?) subunit and Akt (Figure 1.6. A-C).  
Moreover, liver pattern of Akt phosphorylation in wild type and ASMase null mice did 
not change upon HFD feeding. HFD decreased IR? phosphorylation in wild type mice, 
however, this effect was abrogated in ASMase-/- mice-fed HFD (Figure 1.6 A-C). 
 
 
 
Figure 1.6. Hepatic insulin signaling in ASMase deficiency.  (A) Liver insulin-stimulated phosphorylation of 
IR?[pT1162/1163] and Akt[pSer473] after a 3 min portal vein infusion of 1U/Kg insulin or PBS. Each lane represents 
one animal. (B-C) Western blot quantification of panel A. Results are expressed as mean ± SEM (**p<0.01). 
 
Furthermore, to ascertain specific contribution of parenchymal cells to these 
observations, we isolated and cultured primary hepatocytes from wild type and ASMase 
null mice. As observed, insulin induced a similar pattern of IR? phosphorylation in 
hepatocytes from wild type and ASMase knockout mice (Figure 1.7 A-B), consistent with 
the observations in intact liver. Moreover, insulin stimulation of Akt phosphorylation in 
hepatocytes from ASMase-/- mice was increased respect to wild type hepatocytes. Overall, 
these findings indicate that the lack of ASMase does not impair early insulin signaling 
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events in the liver. These findings suggest that systemic effects observed in figure 1.4-5 
likely reflect a role of ASMase in insulin resistance in extra-hepatic tissues. 
 
 
Figure 1.7. Primary mouse hepatocyte insulin signaling. WT and ASMase-/- primary mouse hepatocyte 
insulin stimulation. Representative image of a 3min 100nM insulin-stimulated phosphorylation of IR? and 
Akt. Each lane represents one well. (B) Western blot quantification of three separate experiments of insulin-
stimulated primary mouse hepatocytes (*p<0.05). 
 
1.3.  ASMase ablation prevents diet-induced liver steatosis and regulates lipid 
metabolism. 
Another critical sign of NAFLD is the onset of hepatic macrovesicular steatosis, which is 
characterized by the accumulation of TG, FFA and cholesterol. ASMase null mice 
exhibited hepatomegaly on RD compared to wild type mice (Figure 1.2). Moreover, 
HFD feeding exacerbated this outcome in ASMase null mice. This effect, however, was 
not due to the onset of fatty liver as ASMase-/- mice were protected from HFD-induced 
accumulation of liver TG compared to wild type mice (Figure 1.8 A), which translated in 
lower macrovesicular steatosis, as confirmed by oil-red staining (Figure 1.8 B).  
 
 
Figure 1.8. ASMase deficiency prevents diet-induced liver macrovesicular steatosis. Hepatic (A) 
triglycerides and (B) oil-red staining of RD and HFD-fed WT and ASMase-/- livers (n=5-7). Results are 
expressed as mean ± SEM (*p<0.05 vs. RD-fed WT mice, ##p<0.01 vs HFD-fed WT). 
-     +    +      -     +     +    Insulin
WT ASMase-/-
Akt
p-Akt
95KDa
95KDa
60KDa
60KDa
p-IR?
IR?
p-Akt/Akt
*
-    +    -    +        -    +     -    +    Insulin:
W
B
 q
u
a
n
ti
fi
c
a
ti
o
n
O
.D
. 
u
n
it
s
0
1
2
3 WT pmh
ASMase    pmh -/-
p-IR  /IR ??
A B
A B
RD HFD
0
100
200
300
400
*
##T
ri
g
ly
c
e
ri
d
e
s
(μ
g
/m
g
 p
ro
te
in
)
WT
ASMase-/- W
T
RD HFD
A
S
M
a
s
e
-/
-
RESULTS 
?144
Parallel with these effects, HFD feeding increased levels of liver cholesterol in wild type 
mice (Figure 1.9 A), reflected mainly as free cholesterol accumulation, as indicated by 
filipin staining (Figure 1.9 B). However, ASMase null mice displayed endogenous liver 
free cholesterol accumulation, which further increased upon HFD feeding (Figure 1.9 A-
B).  
 
 
 
Figure 1.9. ASMase deficiency increases hepatic cholesterol deposition. Hepatic (A) total cholesterol and 
(B) filipin staining of RD and HFD-fed WT and ASMase-/- livers (n=5-7). Results are expressed as mean ± SEM 
(**p<0.01 vs. RD-fed WT mice, ##p<0.01 vs HFD-fed WT). 
 
 
Moreover, FFAs slightly accumulated (although not significantly) in wild type mice fed 
HFD, but this trend was not observed in ASMase null mice following HFD intake 
(Figure 1.10). 
  
    
Figure 1.10. Hepatic free fatty acid content of regular and high fat diet-fed wild type and ASMase-/- mice. 
(n=5-7) Results are expressed as mean ± SEM.  
 
Consistent with the observations in the HFD model, feeding a diet deficient in 
methionine and choline also resulted in liver macrovesicular steatosis and marked 
accumulation of TG in wild type mice (Figure 1.11 A-B). However, the increase in 
hepatic TG levels by MCD in ASMase null mice was significantly ameliorated resulting in 
decreased macrovesicular steatosis, indicating that the absence of ASMase prevents the 
induction of fatty liver independently of the nutritional approach used.  
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Figure 1.11. ASMase deficiency protects from of MCD-induced hepatic steatosis. Liver (A) triglycerides 
and (B) H&E staining of RD and MCD-fed WT and ASMase-/- mice (n=5-7).  Results are expressed as mean ± 
SEM (**p<0.01 vs. RD-fed WT mice, ##p<0.01 vs MCD-fed WT and ƒƒp<0.01 vs. RD-fed ASMase-/-). 
 
Analyses of serum cholesterol indicated increased total, HDL and LDL cholesterol levels 
in wild type fed HFD (Figure 1.12 A). ASMase null mice exhibited increased endogenous 
levels of serum cholesterol on RD, which further increased upon HFD feeding. 
Moreover, the effects on cholesterol homeostasis were accompanied by decreased gene 
expression of Hmgcr; the rate-limiting enzyme in cholesterol synthesis, suggesting that 
nutritional accumulation of cholesterol down regulates the de novo cholesterol synthetic 
pathway (Figure 1.12 B). In addition, ASMase null mice fed HFD exhibited decreased 
gene expression of Ldl receptor (Ldlr) and ATP-binding cassette transporter (Abca1) 
compared to wild type mice, suggesting a modulation of major hepatic cholesterol uptake 
and efflux pathways by ASMase (Figure 1.12 B). 
 
 
Figure 1.12. Serum cholesterol and hepatic cholesterol metabolism gene expression. (A) Total, HDL and 
LDL serum cholesterol levels in WT and ASMase-/- mice fed RD or HFD (n= 7-9). (B) Hepatic cholesterol 
metabolism gene expression (n=6). Results are expressed as mean ± SEM (*p<0.05, **p<0.01 vs. RD-fed WT 
mice, #p<0.05, ##p<0.01 vs HFD-fed WT mice and ƒƒp<0.01 vs. RD-fed ASMase-/- mice). 
 
Gene expression of enzymes involved in lipid metabolism indicated increased expression 
of Srebp1c and Dgat2 in wild-type mice fed HFD. However, these effects were negated in 
ASMase-/- mice fed HFD (Figure 1.13), consistent with their resistance to HFD-mediated 
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liver steatosis. Moreover, wild type mice fed HFD increased the expression of fatty acid 
transporters Cd36 and Fatp2 but not Fabp1 (Figure 1.13). However, ASMase-/- mice were 
refractory to diet induced expression of Fatp2 and also showed a decreased expression of 
Fabp1 on HFD (Figure 1.13). Quite intriguingly, Cd36 expression was markedly 
increased in ASMase null mice both on RD and HFD (Figure 1.13). These findings 
underscore an important role for ASMase in fatty liver and indicate that the resistance of 
ASMase null mice to HFD-induced hepatic macrovesicular steatosis is largely due to 
impaired lipogenic pathways and decreased FA sterification. 
 
 
 
Figure 1.13. Hepatic lipogenic gene expression.  Liver gene expression of RD and HFD-fed WT and 
ASMase-/- mice (n=5-6). Results are expressed as mean ± SEM (*p<0.05, **p<0.01 vs. RD-fed WT mice and 
#p<0.05, ##p<0.01 vs. HFD-fed WT mice). 
 
1.4.  HFD-mediated increase in hepatic ceramide levels requires ASMase. 
Ceramide has been shown to regulate multiple cell pathways, including insulin resistance 
and metabolism (Holland, Brozinick et al. 2007; Bikman and Summers 2011). Given the 
above findings on the differential response of ASMase null mice to HFD-induced hepatic 
macrovesicular steatosis and glucose and insulin tolerance, we next explored potential 
alterations in ceramide metabolism. On RD, endogenous hepatic ceramide levels of 
ASMase null mice were lower compared to wild type mice (Figure 1.14 A).  Moreover, in 
addition to the marked TG accumulation, HFD feeding increased hepatic total ceramide 
levels in wild type mice. However, this outcome was markedly defective in ASMase 
knockout mice (Figure 1.14 A), indicating that ASMase is essential for diet-induced liver 
ceramide accumulation. Consistent, with these results, wild-type mice displayed 
increased levels of ASMase mRNA upon HFD feeding (Figure 1.14 B).  
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Figure 1.14. Hepatic total ceramide and ASMase gene expression. (A) Liver total ceramide content in RD 
and HFD-fed WT and ASMase null mice (n=9-10). (B) Liver ASMase gene expression in RD and HFD-fed 
WT mice (n=5-6). Results are expressed as mean ± SEM (*p<0.05, **p<0.01 vs. RD-fed WT mice,  ##p<0.01 
vs HFD-fed  WT mice and ƒp<0.05 vs. RD-fed  ASMase-/-) 
 
Furthermore, on RD ASMase knockout mice exhibited endogenous increased liver SM 
levels that further increased upon HFD feeding (Figure 1.15 A). However, unlike in wild 
type mice fed HFD, this outcome does not reflect increased expression of Sphingomyelin 
synthase 1 and 2 (Sms1 and Sms2) (Figure 1.15 B), suggesting that ASMase plays an 
important role in hepatic SM turnover.  
 
 
 
Figure 1.15. Hepatic sphingomyelin and sphingomyelin synthases gene expression. (A) Hepatic total 
sphingomyelin (n=5-7). Relative gene expression of (B) Sms1 and Sms2 in RD and HFD-fed WT and ASMase-
/- livers (n=5-6).  Results are expressed as mean ± SEM (**p<0.01 vs. RD-fed WT, #p<0.05, ##p<0.01 vs. HFD-
fed WT and ƒƒp<0.01 vs. RD-fed ASMase-/- mice) 
 
In addition, HFD increased hepatic S1P in wild type mice. Surprisingly, ASMase 
knockout mice on RD already showed increased endogenous hepatic S1P compared to 
wild type mice and this effect further increased upon HFD intake (Figure 1.16 A). This 
outcome was accompanied by increased gene expression of ACDase, the lysosomal 
hydrolase that generates sphingosine from ceramide that can be later phosphorylated by 
sphingosine kinases to generate S1P (Figure 1.16 B).  
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Figure 1.16. Hepatic S1P and Acid ceramidase gene expression. (A) Hepatic S1P (n=9-10) and relative gene 
expression of (B) ACDase in RD and HFD-fed WT and ASMase-/- livers (n=5-6).  Results are expressed as mean 
± SEM (*p<0.05, **p<0.01 vs. RD-fed WT, #p<0.05, ##p<0.01 vs HFD-fed WT and ƒƒp<0.01 vs. RD-fed 
ASMase-/-) 
 
We next explored whether ASMase deficiency modulated gene expression of enzymes 
that regulate SL metabolism such as main hepatic ceramide synthases responsible for de 
novo ceramide synthesis. ASMase deficiency resulted in increased gene expression of 
CerS5 that further increased upon HFD intake (Figure 1.17 A). Wild type mice fed HFD 
exhibited increased gene expression of CerS2 and CerS5, while HFD feeding in ASMase 
null mice caused the repression of CerS2 and CerS4. HFD feeding to ASMase knockout 
mice slightly increased liver ceramide levels compared to ASMase null mice fed RD 
(Figure 1.14 A), and this effect likely reflected the increase in the specific ceramide 
species C16:0 and C18:1 (palmitoyl and oleoyl ceramide respectively) (Figure 1.17 B). 
Overall, the above results indicate that ASMase is necessary for diet-induced hepatic 
ceramide accumulation and that ablation of ASMase modulates SL metabolism, resulting 
in SM and S1P accumulation. 
 
 
Figure 1.17. Hepatic ceramide synthases gene expression and ceramide fatty acid chains. (A) Gene 
expression of main hepatic ceramide synthases: CerS2, CerS4 and CerS5 of RD and HFD-fed WT and ASMase-
/- mice (n=5-6). (B) Hepatic lipidomic analysis of ceramide fatty acid chains of RD and HFD-fed WT and 
ASMase-/- mice (n=4-5). Results are expressed as mean ± SEM (*p<0.05, **p<0.01 vs. RD-fed WT mice and 
#p<0.05, ##p<0.01 vs HFD-fed WT). 
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1.5. ASMase deficiency impact on autophagy. 
Since autophagy regulates hepatic lipid metabolism (Singh, Kaushik et al. 2009), we 
analyzed whether stimulation of autophagy contributed to the resistance of ASMase null 
mice to diet-induced steatosis. Autophagy is a complex and dynamic process that 
comprises generation of autophagic double membranes, fusion of autophagosomes with 
lysosomes and degradation of cargo content. Autophagy can be monitored via expression 
of LC3BI, which during autophagy translocates from the cytosol to autophagosome 
membranes by lipidation of the cytosolic LC3BI form resulting in the membrane bound 
LC3BII form.  
 
Analysis of hepatic extracts indicated increased LC3BII/I ratio in ASMase null mice 
compared to wild type mice, both on RD and HFD (Figure 1.18 A). Intriguingly, this 
outcome was accompanied by decreased endogenous expression of ATG7 (Figure 1.18 
A). In order to exclude transcriptional regulation of these markers, their gene expression 
was analyzed by RT-PCR. HFD feeding increased the mRNA levels of Atg7 and Lc3b in 
both wild type and ASMase null mice indicating that the regulation observed by WB was 
not due to changes in gene expression (Figure 1.18 B).   
 
 
 
 
Figure 1.18. Hepatic autophagy in ASMase null mice. (A) Western blotting and immunodetection of 
autophagy-related markers in liver protein extracts and (B) gene expression of autophagy-related markers of RD 
and HFD-fed WT and ASMase null mice (n=5-6). Results are expressed as mean ± SEM (**p<0.01 vs. RD-fed 
WT mice). 
 
Accumulation of LC3BII can result from autophagy induction or reflect a failure of 
autolysosomal degradation. To address autophagic flux, isolated primary mouse 
hepatocytes from wild type and ASMase-/- mice were exposed to chloroquine and/or 
rapamycin, an mTORC1 inhibitor, which promotes autophagy. Consistent with the 
findings in liver extracts, hepatocytes from ASMase null mice displayed increased 
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endogenous LC3BII/I ratio despite decreased ATG7 expression compared to wild type 
hepatocytes. Of interest, this outcome was paired with increased lysosomal proliferation 
as revealed by enhanced LAMP2 levels in ASMase deficient hepatocytes (Figure 1.19). 
However, despite increased basal autophagic flux (LC3BII/?-tubulin in CHQ-CTRL), 
rapamycin-mediated autophagic flux (LC3BII/?-tubulin in [C-R]-RAPA) was lower in 
ASMase null hepatocytes (Figure 1.19). This observation paralleled increased p62 levels 
in ASMase null hepatocytes, indicating decreased autophagic protein degradation upon 
rapamycin stimulation (Figure 1.19). The observation of increased levels of p62 despite 
increased basal autophagic flux in ASMase null hepatocytes is suggestive of impaired 
autophagosome-lysosome fusion or final cargo degradation. 
 
 
 
 
Figure 1.19. Autophagic flux in wild type and ASMase-/- primary mouse hepatocytes. Hepatocytes were 
treated for 3h with 2μM RAPA and 50μM CHQ. Basal and RAPA-induced degradation of LC3BII was 
calculated subtracting LC3BII levels in each condition from its respective CHQ treatment.  Representative 
image of three individual experiments. CTRL, control. CHQ, chloroquine. RAPA, rapamycin. 
 
To confirm these results, we next explored autophagic vacuole formation in primary 
mouse hepatocytes by confocal microscopy using monodansylcadaverine (MDC), a probe 
with high affinity for autophagic vacuoles. Rapamycin treatment increased MDC staining 
in wild type hepatocytes as expected (Figure 1.20). Similar to LC3BII levels, rapamycin 
treatment of ASMase null hepatocytes resulted in further accumulation of autophagic 
vacuoles compared to wild type hepatocytes (Figure 1.20). Taken together, these results 
demonstrate that in the absence of ASMase autophagy is impaired at a lysosomal level 
resulting in accumulation of autophagic vacuoles and delayed p62 degradation.  
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Figure 1.20. Autophagic vacuole formation in primary mouse hepatocytes. Representative image of wild 
type and ASMase-/- hepatocytes treated for 1h with 2μM rapamycin in order to induce autophagic vacuole 
formation. Green represents MDC staining or autophagic vacuoles. Blue represents Hoechst staining or nuclei. 
 
1.6. ASMase deficiency increases lysosomal free cholesterol. 
Since the above findings suggested an impairment of autophagy at a lysosomal level 
(Figure 1.9), we next assessed whether lysosomes accumulate cholesterol in ASMase null 
mice. In particular, FC loading in membranes is known to modulate the physical 
properties of membrane bilayers resulting in decreased membrane dynamics. Hence we 
hypothesized that ASMase deficiency results in lysosomal cholesterol accumulation, 
which in turn impairs autophagosome-lysosome fusion resulting in increased p62 levels. 
To test this hypothesis, we performed confocal imaging experiments in hepatocytes from 
wild type and ASMase null mice stained with filipin and lysotracker. As seen, ASMase-/- 
hepatocytes exhibited increased lysosomal proliferation revealed by increased lysotracker 
staining, consistent with enhanced LAMP2 levels in WB analysis and increased filipin 
staining compared to wild type hepatocytes (Figure 1.21 A). Moreover, lysotracker 
staining colocalized with filipin staining, indicating FC accumulation in lysosomes of 
ASMase null hepatocytes (Figure 1.21 A). Furthermore, ASMase-/- lysosomal phenotype 
can be reproduced in wild type mice fed a high cholesterol diet, as revealed by 
colocalization of lysotracker and filipin in isolated hepatocytes from mice fed HCD for 
two days (Figure 1.21 B). Although qualitatively similar, the degree of lysosomal 
cholesterol accumulation in ASMase-/- hepatocytes was markedly greater than HCD-
exposed hepatocytes (Figure 1.21 A-B). These results indicate that lysosomal FC content 
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increases due to ASMase deficiency, which in turn may impair lysosomal membrane 
function. 
 
 
 
Figure 1.21. Lysosomal free cholesterol in ASMase-/- and HCD primary mouse hepatocytes. (A) 
Representative images and colocalization analysis of lysotracker (green) and filipin (red) staining and merge 
(yellow) of wild type and ASMase-/- primary mouse hepatocytes. (B) Representative images and colocalization 
analysis of lysotracker and filipin staining and merge of RD and HCD-exposed primary mouse hepatocytes.  
Representative images of three individual experiments. 
 
1.7. ASMase deficiency protects hepatocytes from lysosomal membrane 
permeabilization-induced cell death. 
Lysosomal permeabilization has been described as an important mechanism of cell death 
of relevance to NASH. For instance, saturated FA, such as palmitic acid, have been 
shown to induce hepatocellular apoptosis via lysosomal permeabilization-mediated 
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recruitment of mitochondria to activate apoptotic pathways (Li, Berk et al. 2008). Since 
cholesterol is known to regulate membrane physical properties and dynamics and given 
the preceding findings indicating increased lysosomal cholesterol accumulation (Figure 
1.21), we examined the functional relevance in ASMase-/- hepatocytes. To this end, we 
used O-methyl-serinedodecylamide hydrochloride (MSDH, a gift of Dr. Hanna 
Appelqvist), a detergent that specifically permeabilizes lysosomes (Appelqvist, Nilsson et 
al. 2011). As seen, hepatocytes from ASMase null mice were resistant to MSDH-
mediated cell death (Figure 1.22 A). Moreover, in parallel with lysosomal cholesterol 
accumulation induced by HCD-feeding, HCD-exposed hepatocytes were also resistant to 
MSDH-induced cell death (1.22B). These results indicate that increased lysosomal 
membrane FC in ASMase null hepatocytes protects from lysosomal permeabilization-
induced cell death. 
 
 
 Figure 1.22. Lysosomal membrane permeabilization-induced cell death in primary mouse hepatocytes. 
(A) Wild type and ASMase-/- primary mouse hepatocytes cell death assessed by MTT. (B) RD and HCD-
exposed primary mouse hepatocytes cell death assessed by MTT. Data are expressed as percentage vs. control 
and represent the mean of three individual experiments ± SD (##p<0.01 vs. same condition control group). 
 
1.8. Hepatic ER stress in ASMase deficiency. 
Since the preceding findings discard a role for autophagy in ASMase deficiency resistance 
to diet-induced liver steatosis, we next examined the sensitivity of ASMase null mice to 
HFD-induced hepatic ER stress, as this is a critical player in stimulation of lipogenic 
pathways and the onset of fatty liver (Ozcan, Cao et al. 2004; Fu, Yang et al. 2011). 
Liver extracts following HFD feeding were processed for analysis of ER stress markers. As 
seen, HFD induced gene expression of ER stress markers Atf4, Pdi and Edem as well as 
phosphorylation of IRE1? in wild type mice (Figure 1.23 A-D). However, ASMase null 
mice were protected from HFD-induced ER stress (Figure 1.23 A-D).  
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Figure 1.23. Hepatic ER stress in ASMase null mice. Relative gene expression of (A) Atf4, (B) Pdi and (C) 
Edem in RD and HFD-fed WT and ASMase-/- livers (n=5-6).  (D) IRE1? phosphorylation in RD and HFD-
fed WT and ASMase-/- liver protein extracts. Results are expressed as mean ± SEM (*p<0.05, **p<0.01 vs. RD-
fed WT, ##p<0.01 vs. HFD-fed WT). 
 
To address whether resistance of ASMase-/- mice to ER stress was specific to HFD 
feeding, we isolated primary mouse hepatocytes from wild type and ASMase null mice 
and challenged them with SubAB, a bacterial toxin that degrades the ER chaperone 
GRP78 that is essential for the proper glycosylation, folding and assembly of many 
membrane bound and secreted proteins. As expected, SubAB induced the cleavage of 
GRP78 both in wild type and ASMase null hepatocytes, whereas no cleavage was 
induced in the cells treated with the non-active mutant toxin SubA[A727]B (Figure 1.24 A).  
 
 
Figure 1.24. ASMase-/- primary mouse hepatocyte response to SubAB treatment. (A) GRP78 degradation in 
WT and ASMase-/- pmh after 3 and 6h treatment of 1μg/ml SubAB. Relative gene expression of (B) Pdi and 
(C) Edem after SubAB treatments in WT and ASMase-/- pmh (*p<0.05, **p<0.01 vs. SubA[A272]B-treated WT 
pmh, ##p<0.01 vs. SubA[A272]B-treated ASMase-/- pmh and ƒƒp<0.01 vs. SubAB-treated WT pmh). 
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Moreover, in both genotypes, SubAB-mediated Grp78 degradation preceded expression 
of ER stress markers Pdi and Edem after 6h of treatment (Figure 1.24 B-C) compared to 
SubA[A727]B treated cells. These results indicate that the ER from ASMase null 
hepatocytes is capable of sensing ER stress and responding accordingly.  
 
Furthermore, in vivo administration of glycosylation inhibitor tunicamycin (Tm) to 
ASMase-/- mice caused enhanced expression of ER stress markers Atf4 and Pdi (Figure 
1.25 A-B). In addition, Tm increased hepatic TG accumulation to a similar degree in 
wild type and ASMase-/- mice (Figure 1.25 C), indicating that the ER from ASMase-/- 
livers is able to sense Tm-induced stress and cause fat accumulation and hepatic steatosis. 
Although hepatic steatosis and ER stress are reciprocally regulated, these findings indicate 
that resistance of ASMase null mice to HFD-induced hepatic steatosis is likely due to 
defective ER stress response. Overall, these results indicate that the requirement of 
ASMase in nutritional ER stress, and that ER stress is sufficient to induce TG 
accumulation and hepatic steatosis in ASMase null mice. 
 
 
Figure 1.25. Tunicamycin-induced ER stress and lipogenesis in wild type and ASMase-/- mice. Hepatic 
gene expression of (A) Atf4 and (B) Pdi and hepatic (C) triglyceride content in tunicamycin-treated WT and 
ASMase-/- mice (n=3-5). Results are expressed as mean ± SEM (*p< 0.05, **p<0.01 vs. WT Ctrl mice. ƒp<0.05, 
ƒƒp<0.01 vs. ASMase-/- Ctrl mice). 
 
1.9.  ASMase antagonism protects against diet-induced liver injury and LPS 
sensitization. 
As the onset of hepatic steatosis is considered the first hit in the two-hits hypothesis that 
sensitizes to subsequent factors leading to liver damage (Day and James 1998), we next 
examined the degree of hepatocellular injury in ASMase null mice following HFD. Wild 
type mice fed HFD exhibited increased serum ALT levels (Figure 1.26 A), indicating liver 
injury that was confirmed by histological analyses (Figure 1.26 B). Moreover, HFD-fed 
wild type mice displayed increased sensitivity to LPS-mediated liver damage (Figure 1.26 
C-D). However, ASMase null mice were resistant to HFD-induced increased serum ALT 
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levels and liver damage (Figure 1.26 A-B), and more importantly, were refractive to 
HFD-mediated sensitization to LPS-induced liver injury (Figure 1.26 C-D).    
 
 
 
Figure 1.26. ASMase deficiency protects from diet-induced liver damage and LPS susceptibility. (A) 
Serum alanine transaminase levels (n>13) and (B) hepatic H&E staining of RD and HFD-fed WT and 
ASMase-/- mice. (C) Hepatic H&E staining and (E) serum alanine transaminase levels of HFD-fed WT and 
ASMase-/- mice challenged with 5mg/kg LPS for 24h (n=4-5). Results are expressed as mean ± SEM (**p<0.01 
vs. RD-fed WT mice and #p<0.05, ##p<0.01 vs HFD-fed WT mice). 
 
Furthermore, to address the potential relevance of the above findings, we next examined 
whether pharmacological inhibition of ASMase in wild type mice fed HFD would 
reproduce the effects observed in ASMase null mice. Wild type mice were fed HFD for 
16 weeks with or without the tricyclic antidepressant amitriptyline in drinking water to 
functionally inhibit lysosomal ASMase processing and activation (Lang, Schenck et al. 
2007). Amitriptyline treatment significantly inhibited hepatic ASMase activity by 25-
30%, and this effect protected wild type mice against HFD-induced liver injury as seen 
by serum ALT release and histological analyses (Figure 1.27 A-B).  However, unlike 
ASMase null mice, amitriptyline-treated wild type mice did not exhibit further insulin 
insensitivity and glucose intolerance after HFD intake (not shown). Thus, overall these 
findings indicate that ASMase plays a critical role not only in diet induced hepatic 
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macrovesicular steatosis but also in liver injury, and suggest that its pharmacological 
inhibition may be beneficial in diet-mediated NASH. 
 
        
Figure 1.27.  ASMase pharmacological inhibition protects from diet-induced liver damage. (A) Serum 
alanine transaminase levels (n=3) and (B) hepatic H&E staining of RD and HFD-fed control and 1mM 
amitriptyline in drinking water treated mice. Results are expressed as mean ± SEM (**p<0.01 vs. RD-fed WT 
mice and #p<0.05 vs. HFD-fed WT mice). 
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AIM 2. ROLE OF ACID SPHINGOMYELINASE IN  
ALCOHOLIC STEATOHEPATITIS 
 
2.1.  ASMase deficiency increases hepatic SM and cholesterol but prevents alcohol-
induced TG, FFA accumulation and liver macrosteatosis. 
Since fatty liver is one of the earliest symptoms of alcohol intake, we examined the 
hepatic lipid profile of wild type and ASMase knockout mice following chronic alcohol 
feeding. While alcohol administration increased hepatic TG and FFA levels in wild type 
mice, this response was blunted in ASMase knockout mice (Figure 2.1 A-B). In parallel 
with these changes, livers from wild type mice but not ASMase knockout mice exhibited 
macrovesicular steatosis as seen by oil-red staining (Figure 2.1 C).  
 
 
Figure 2.1. ASMase deficiency prevents alcohol-induced macrosteatosis. Hepatic (A) triglyceride and (B) 
free fatty acid content. (C) Oil-red staining in control and ethanol-fed WT and ASMase-/- livers. Results are 
expressed as mean ± SEM (**p<0.01 vs. control-fed WT mice, #p<0.05, vs. ethanol-fed WT mice). 
 
Moreover, ethanol feeding also resulted in increased hepatic SM and cholesterol levels in 
wild type mice (Figure 2.2 A-B) with higher filipin staining (Figure 2.2 C), indicative of 
free cholesterol content. However, ASMase knockout mice fed control diet already 
exhibited increased hepatic SM and cholesterol content compared with wild type mice, 
consistent with recent observations (Prinetti, Prioni et al. 2011). Upon ethanol feeding, 
the hepatic SM and cholesterol levels further increased in ASMase knockout mice (Figure 
2.2 A-C).  
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Figure 2.2. Hepatic cholesterol and sphingomyelin content. Hepatic (A) total cholesterol, and (B) 
sphingomyelin and (C) filipin staining in control and ethanol-fed WT and ASMase-/- livers. Results are 
expressed as mean ± SEM (**p<0.01 vs. control-fed WT mice, and ƒ p<0.05 vs. control-fed ASMase-/- mice). 
 
Consistent with these findings liver to weight ratio increased in ASMase null mice, 
although this increase in response to alcohol feeding was similar between wild type and 
ASMase knockout mice (Figure 2.3 A). Moreover, alcohol induced CYP2E1 up-
regulation was similar in both wild type mice and ASMase null mice (Figure 2.3 B).  
 
 
 
Figure 2.3. Liver to weight ratio and CYP2E1 expression after alcohol intake. (A) Liver vs. body weight 
ratio, and (B) CYP2E1 expression in control and ethanol fed WT and ASMase-/- livers. Results are expressed as 
mean ± SEM (**p<0.01 vs. control-fed WT mice and ƒƒ p< 0.01 vs. control-fed ASMase-/- mice) 
 
Because ASMase is an intermediate in TNF signaling (García-Ruiz, Colell et al. 2003; 
Edelmann, Bertsch et al. 2011), we next examined the response of mice deficient in TNF 
receptors R1 and/or R2 to ethanol feeding. While TNFR1 or TNFR2 ablation exerted 
different effects in alcohol-induced hepatic lipid accumulation, both receptors were 
required for the accumulation of hepatic TG, FFA, SM and cholesterol in response to 
alcohol intake (Figure 2.4 A-D). Unlike ASMase, however, double TNFR1/R2 null mice 
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did not exhibit endogenous accumulation of SM or cholesterol. Thus, these findings 
indicate that the genetic elimination of ASMase prevents alcohol-induced macrosteatosis, 
but results in accumulation of SM and cholesterol. 
 
 
Figure 2.4. Alcohol-induced hepatic lipid accumulation in TNFR1, TNFR2 and TNFR1/2 null mice. 
Hepatic levels of (A) triglycerides, (B) free fatty acids, (C) sphingomyelin, and (D) cholesterol of WT, TNFR1, 
TNFR2 and TNFR1/R2 null mice after chronic ethanol intake. Results are expressed as mean ± SEM (*p<0.05 
vs. control fed WT mice).  
 
2.2. ASMase is required for alcohol-induced lipogenesis. 
Since alcohol-induced lipogenesis contributes to hepatic steatosis, we next explored the 
effect of ASMase deficiency in the gene expression of lipogenic enzymes. As seen in figure 
2.5, alcohol feeding to wild type mice increased the expression of the transcription factor 
Srebp1c and target enzymes including Dgat2 and Fas, as well as Srebp2, which controls 
cholesterol homeostasis (Figure 2.5 A-D), consistent with previous findings (Wang, Yao 
et al. 2010). Interestingly, Srebp1c, Dgat2 and Fas induction was blunted in ASMase-/- 
mice fed ethanol (Figure 2.5 A-C), consistent with the preceding findings in hepatic 
steatosis (Figure 2.1).  However, ASMase null mice fed control diet exhibited increased 
expression of Srebp2, accounting for the intrinsic increase in hepatic cholesterol levels 
(Figure 2.5 D). Thus, these findings indicate that the absence of ASMase prevents the 
alcohol-induced expression of genes involved in lipogenesis, accounting for the observed 
protection from hepatic steatosis. 
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Figure 2.5. ASMase is required for alcohol-induced expression of lipogenic enzymes. Gene expression of 
(A) Srebp1c, (B) Dgat2, (C) Fas, and (D) Srebp2 in control and ethanol-fed WT and ASMase-/- livers. Results are 
expressed as mean ± SEM (*p<0.05 vs. control-fed WT mice, #p<0.05 vs. ethanol-fed WT mice). 
 
2.3. ASMase is required for alcohol-induced ER stress. 
ER stress and UPR are critical adaptive mechanisms to metabolic alterations and stress in 
the liver, especially in the context of lipid metabolism. Alcohol intake has been shown to 
induce ER stress (Kaplowitz and Ji 2006), a mechanism that contributes to liver steatosis 
(Ozcan, Yilmaz et al. 2006). 
 
 
 
Figure 2.6. ASMase is required for alcohol-induced ER stress. Hepatic mRNA expression of (A) Grp78, (B) 
Pdi, (C) Chop, (D) Atf4, and (E) protein expression of IRE1?, phospho-IRE1?, GRP78, PDI and CHOP in 
control and ethanol-fed WT and ASMase-/- livers. Results are expressed as mean ± SEM (*p<0.05 vs. control-fed 
WT mice, #p<0.05 vs. ethanol-fed WT mice). 
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As expected, wild type mice exhibited increased up-regulation of ER stress markers, 
Grp78, Pdi, Chop, Atf4 and IRE1?, both at the mRNA and protein level following 
ethanol feeding (Figure 2.6 A-E). However, these responses were prevented in ASMase-/- 
mice (Figure 2.6 A-E), suggesting a critical role for ASMase in alcohol-induced ER stress.  
Consistent with the resistance of double TNFR1/R2 knockout mice to alcohol-induced 
hepatic steatosis, mice deficient in TNFR1, R2 or double TNFR1/R2 knockout mice did 
not exhibit signs of alcohol-induced ER stress besides Chop in TNFR2-/- mice fed with 
ethanol diet (Figure 2.7 A-D).  
 
 
Figure 2.7. TNFR1, R2 or double TNFR1/R2 null mice do not exhibit alcohol-induced ER stress. Hepatic 
expression of (A) Atf4, (B) Chop, (C) Grp78, and (D) Pdi in WT, TNF-R1, TNF-R2 and TNFR1/R2 null mice 
after chronic ethanol intoxication. Results are expressed as mean ± SEM (*p<0.01 vs. control fed WT mice). 
 
Moreover, in vivo treatment with tunicamycin induced liver ER stress and steatosis 
(Figure 2.8 A-B) both in wild type and ASMase knockout mice.  
 
 
 
Figure 2.8. ASMase null liver responds to tunicamycin-induced ER stress and lipogenesis. (A) Expression 
of IRE1?, PDI and CHOP and (B) Oil-red staining of liver sections after tunicamycin challenge (Tm, 1 mg/kg, 
24 hours) in WT and ASMase-/- mice. 
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Tm-induced steatosis increased by 2.5 the hepatic TG content in both wild type and 
ASMase deficient mice. These results suggest that resistance of ASMase-/- mice to alcohol-
induced ER stress is not due to an inherent defect in ER stress response, and establish a 
cause-and-effect relationship between ER stress and steatosis. Thus, ASMase is critical 
for alcohol-induced ER stress. 
 
2.4. Resistance of ASMase null mice to alcohol-induced ER stress is independent of 
hyperhomocysteinemia. 
 To explore putative mechanisms for the resistance of ASMase null mice to alcohol-
induced ER stress, we analyzed metabolites of methionine cycle, in particular, 
homocysteine, which has been shown to contribute to alcohol-induced ER stress 
(Kaplowitz and Ji 2006). Plasma homocysteine concentration in wild type mice increased 
after ethanol feeding as expected and this increase was also observed in ASMase-/- mice 
(Figure 2.9 A). Moreover, while the hepatic SAM:SAH ratio was moderately lower 
(18%) in control-fed ASMase-/- mice, the decrease in SAM:SAH ratio induced by alcohol 
feeding was similar in wild type and ASMase-/- mice (Figure 2.9 B).  
 
 
 
Figure 2.9. Methinonine metabolism is not altered in ASMase-/- mice. (A) Plasma homocysteine levels, and 
(B) hepatic SAM:SAH ratio in control and ethanol-fed WT and ASMase-/-mice. Results are expressed as mean ± 
SEM (**p<0.01 vs. control-fed WT mice, ƒƒp<0.01 vs. control-fed ASMase-/- mice).  
 
Homocysteine levels are regulated by its remethylation to methionine via methionine 
synthase or betaine homocysteinemethyltransferase. Alcohol feeding decreased Ms mRNA 
levels in both wild type mice and ASMase null mice, but Bhmt expression remained 
unchanged in wild type and ASMase null mice regardless of alcohol feeding (Figure 2.10 
A-B). In addition, expression of liver-specific methionine adenosyltransferase 1A (Mat1A) 
mRNA increased in wild type and ASMase null mice fed alcohol (Figure 2.10 C), and 
cystathionine-?-synthase (Cbs) expression increased in wild type but not in ASMase null 
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alcohol fed mice (Figure 2.10 D). The increase in homocysteine levels by alcohol intake 
was independent of TNFR1 or TNFR2 (Figure 2.10 E).  Thus, these findings indicate 
that alcohol-mediated methionine metabolism disruption is independent of ASMase and 
that hyperhomocysteinemia does not contribute to ER stress induced by oral alcohol 
intake.  
 
 
 
Figure 2.10. Effect of ethanol on the expression of enzymes of the methionine metabolism in wild type and 
ASMase-/- livers. Hepatic mRNA expression of (A) methionine synthase (Ms), (B) betaine-homocysteine 
methyl-transferase (Bhmt), (C) methionine adenosyltransferase 1A (Mat1A) and (C) cystathionine-b-synthase (Cbs) 
in control and ethanol-fed WT and ASMase-/- livers. (E) Plasma homocysteine levels in WT, TNF-R1, TNF-
R2 and TNFR1/R2 null mice after chronic ethanol intoxication. Results are expressed as mean ± SEM 
(**p<0.01 vs. control-fed WT mice). 
 
2.5. ASMase deficiency regulates ceramide metabolism. 
Since ceramide metabolism has been linked to ER stress (Carracedo, Lorente et al. 2006; 
Spassieva, Mullen et al. 2009; Epstein, Kirkpatrick et al. 2012), we next examined 
whether ASMase deficiency was modifying ceramide metabolism. Alcohol feeding 
stimulated ASMase activity and increased total hepatic ceramide levels in wild type mice 
(Figure 2.11 A-B). However, ASMase null mice exhibited lower total ceramide levels 
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compared to wild type mice and were resistant to ceramide increase caused by alcohol 
intake (Figure 2.11 B), suggesting that ASMase is a critical source of alcohol-mediated 
ceramide generation.  
 
 
 
Figure 2.11. Hepatic ASMase activity and total ceramide levels. (A) Representative TLC of hepatic ASMase 
activity in WT ethanol-fed mice, and its inhibition after amitriptyline administration. (B) Total ceramide 
levels in the livers of control and ethanol-fed WT and ASMase-/- mice.  Results are expressed as mean ± SEM 
(**p<0.01 vs. control-fed WT mice).  
 
Moreover, transcriptional up-regulation of Sms1 and Sms2 by alcohol intake was similar 
in both wild type and ASMase null mice (Figure 2.12 A-B), accounting for the increase in 
SM by alcohol in wild type mice despite increased ceramide generation. 
 
 
 
Figure 2.12. Hepatic sphingomyelin synthases gene expression. (A) Sphingomyelin synthase-1 (Sms1), (B) 
sphingomyelin synthase-2 (Sms2) gene expression in livers of control and ethanol-fed WT and ASMase-/- mice. 
Results are expressed as mean ± SEM (**p<0.01 vs. control-fed WT mice, ƒƒp<0.01 vs. control-fed ASMase-/- 
mice).  
 
Because ceramide can be metabolized into S1P, the antiapoptotic SL that promotes cell 
survival, after the consecutive action of ceramidases and sphingosine kinases, we 
determined the mRNA expression of ACDase as well as the S1P levels following alcohol 
feeding. ACDase, was unaffected by ethanol intake in wild type mice, and liver S1P 
concentration was not modified by alcohol consumption. However, ASMase null mice 
displayed increased expression of ACDase and S1P levels compared to wild type mice, and 
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these effects were unaffected following alcohol consumption (Figure 2.13 A-B). Thus, 
these findings indicate that ASMase is an important source of ceramide following alcohol 
intake and its absence modulates ceramide metabolism resulting in S1P generation. 
 
 
 
 
Figure 2.13. ASMase deficiency increases Acid ceramidase mRNA levels and S1P content in liver. (A) 
ACDase gene expression, and (B) S1P levels in the livers of control and ethanol-fed WT and ASMase-/- mice. 
Results are expressed as mean ± SEM (**p<0.01 vs. control-fed WT mice).  
 
 
2.6. Exogenous ASMase induces ER stress and stimulates ER Ca2+ release. 
To investigate the role of ASMase in alcohol-induced ER stress, we cultured human 
hepatocytes with exogenous human ASMase or NSMase from Bacillus cereus and 
determined expression of ER stress markers. Both ASMase and NSMase increase 
ceramide levels by 2 fold peaking by 60 minutes (García-Ruiz, Marí et al. 2000). 
Exposure of Hep G2 cells to human ASMase increased expression of Chop and Grp78, 
indicating the onset of ER stress (Figure 2.14 A-B). Moreover, the exposure of Hep G2 
cells to NSMase from bacillus cereus failed to induce the expression of ER stress markers 
(Figure 2.14 A-B), indicating the specificity of SMases to cause ER stress, suggesting a 
link between endolysosomes and ER. Since ER Ca2+ stores regulate UPR and ER stress, 
we next determined ER Ca2+ homeostasis in Hep G2 cells in response to exogenous 
ASMase. Cells were loaded with the fluorescent calcium indicator Fluo-4 AM, switched 
to calcium-free medium and exposed to thapsigargin, a specific inhibitor of the ER 
calcium pump SERCA. Addition of thapsigargin to control hepatocytes resulted in release 
of ER Ca2+ stores towards the cytosol. However, exposure to exogenous ASMase 
decreased the thapsigargin-stimulated Ca2+ release, indicating lower ER Ca2+ storage 
(Figure 2.14 C-D). Thus, these findings suggest that alcohol-induced ASMase activation 
induces ER stress, at least in part, by disrupting ER Ca2+ homeostasis. 
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Figure 2.14.  Exogenous ASMase induces ER stress.  (A) Chop and (B) Grp78 gene expression of Hep G2 
cells treated for 18h with exogenous human ASMase or bacterial NSMase. (C) Representative fluorescence 
tracings of Fluo4-labeled Hep G2 cells exposed to ASMase (1U/ml) for 18 hours. Thapsigargin (Tg, 1μM) was 
added at the time indicated and fluorescence was recorded by confocal microscopy. (D) Quantification of 
basal to peak Fluo-4 fluorescence ratio after addition of Tg. Results are expressed as mean ± SD of n=4 
individual experiments. *p<0.05 vs control cells. 
 
 
2.7. ASMase knockout mice exhibit defective mitochondrial cholesterol trafficking. 
Since wild type mice and ASMase null mice exhibited increased hepatic free cholesterol 
content upon alcohol feeding (Figure 2.2 A, C), we next examined its trafficking to 
mitochondria, as this process has been shown to regulate cell death and steatohepatitis 
(Marí, Caballero et al. 2006). Mitochondrial cholesterol trafficking was observed in 
cultured hepatocytes from alcohol-fed wild type mice as cholesterol (filipin staining in 
red) and mitochondria (cytochrome c staining in green) colocalized in confocal 
microscopy imaging (Figure 2.15 A); however, this process was defective in hepatocytes 
from ASMase-/- mice fed alcohol (Figure 2.15 B). To account for this unexpected finding, 
we analyzed expression of proteins known to regulate mitochondrial cholesterol 
homeostasis, including StAR and MLN64. While alcohol increased hepatic expression of 
StAR in wild type mice, this response was suppressed in ASMase-/- mice (Figure 2.16 A). 
Mln64 expression was similar in both genotypes regardless of the type of diet (Figure 2.16 
B). Moreover, we determined caveolin-1 expression, as this protein has recently been 
uncovered for its ability to regulate mitochondrial cholesterol (Bosch, Marí et al. 2011). 
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Endogenous expression of caveolin-1 was similar for wild type and ASMase-/- mice, 
however alcohol feeding increased mRNA levels of ASMase-/- mice (Figure 2.16 C).  
 
 
 
 
 
Figure 2.15. Ethanol-induced mitochondrial cholesterol loading is blunted in ASMase-/- primary mouse 
hepatocytes. Fluorescence immunocytochemistry of mitochondria (cytochrome c) and free cholesterol 
(filipin) in hepatocytes from control and ethanol-fed (A) WT, and (B) ASMase-/- mice. 
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Figure 2.16. Gene expression of mitochondrial cholesterol homeostasis related proteins. mRNA 
expression of (A) Star, (B) Mln64, and (C) Caveolin-1 in livers of control and ethanol-fed WT and ASMase-/- 
mice. Results are expressed as mean ± SEM (**p<0.01 vs. control-fed WT mice, ##p<0.01 vs. WT ethanol-fed 
mice). 
 
Consistent with these findings, alcohol feeding increased cholesterol loading in 
mitochondria from wild type but not ASMase null mice, protecting ASMase-/- mice from 
the depletion of mitochondrial GSH pool (Figure 2.17 A-B). These results uncover a 
previously unrecognized role for ASMase in the regulation of mitochondrial cholesterol 
trafficking via StAR expression. 
 
 
 
Figure 2.17. Alcohol-induced mitochondrial cholesterol loading and mGSH depletion does not occur in 
ASMase-/- livers. Hepatic (A) mitochondrial cholesterol and (B) mitochondrial glutathione in control and 
ethanol-fed WT and ASMase-/- mice. Results are expressed as mean ± SEM (*p<0.05 vs. control-fed WT mice). 
 
 
To explore the relationship between ER stress and StAR, we examined the effect of Tm 
in StAR expression in Hep G2 cells. In addition to the induction of ER stress markers, 
Tm up-regulated evels of Srebp2 and StAR (Figure 2.18 A-B). ER stress can be relieved by 
using chemical chaperones like Tauroursodeoxycholic acid (TUDCA) (Ozcan, Yilmaz et 
al. 2006).  TUDCA pretreatment abrogated Tm-induced expression of both Srebp2 and 
StAR in Hep G2 cells (Figure 2.18 A-B).  
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Figure 2.18. ER stress regulation of cholesterol synthesis and trafficking related genes in Hep G2 cells.  
(A) Star and (B) Srebp2 gene expression of Hep G2 cells treated with tunicamycin (Tm) with or without 
TUDCA pre-treatment. Results are expressed as mean ± SD of 4 individual experiments. *p<0.01 vs. control , 
#p<0.01 vs. Tm-treated cells.  
 
Genes involved in cholesterol metabolism are activated by SREBPs, particularly 
SREBP2. In order to confirm that StAR is an ER stress but not SREBP2 regulated gene, 
we fed mice a high cholesterol diet for three days. As expected, HCD feeding decreased 
gene expression of SREBP2 target gene Hgmcr as well as Srebp2 itself but did not affect 
Star expression (Figure 2.19 A-C). Thus, these results uncover a previously unrecognized 
role for ASMase in the regulation of mitochondrial cholesterol trafficking via StAR 
expression. 
 
 
 
Figure 2.19. High cholesterol diet regulation of hepatic Srebp2, Hmgcr and Star gene expression. (A) 
Srebp2, (B) Hmgcr and (C) Star gene expression in livers from wild type mice exposed to either RD or HCD. 
Results are expressed as mean ± SD of 3 individual animals. *p<0.05 vs. WT mice fed RD. 
 
2.8. ASMase ablation blunts alcohol-induced liver injury and susceptibility to LPS 
and ConA. 
Alcohol-induced fatty liver is believed to sensitize to secondary hits, thereby accounting 
for the hepatocellular damage observed in ALD. To examine the contribution of ASMase 
to alcohol-induced liver injury and sensitization to circulating and cell-bound TNF, we 
examined liver damage in wild type and ASMase knockout mice following alcohol feeding 
with or without a low dose LPS or concanavalin-A.  Endogenous liver damage to alcohol 
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intake was modest in wild type mice and reduced in ASMase-/- mice as revealed by lower 
ALT levels and histology analyses (Figure 2.20 A-C). However, alcohol feeding sensitized 
wild type mice to LPS and Con A-mediated liver damage, and this outcome was 
prevented in ASMase-/- mice (Figure 2.20 A-C).  
 
 
 
Figure 2.20. ASMase deficiency prevents alcohol-induced liver injury and susceptibility to LPS and 
Concanavalin A. Serum ATL in control and ethanol-fed WT and ASMase-/- mice challenged with (A) 5mg/Kg 
LPS i.p.  or (B) 0.5mg/Kg ConA i.v. for 24h. (C) H&E staining of liver control and ethanol-fed WT and 
ASMase-/- mice challenged with LPS or Con A. Results are expressed as mean ± SEM (*p<0.05 vs. control-fed 
mice, #p<0.05 vs. same-treatment in WT mice). 
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Moreover, consistent with these findings cultured hepatocytes from wild type but not 
ASMase knockout mice fed alcohol exhibited enhanced susceptibility to TNF-induced 
cell death (Figure 2.21).  
 
 
Figure 2.21. ASMase deficiency protects hepatocytes from alcohol-induced sensitization to TNF-induced 
cell death. Hepatocyte cell death determined by Trypan blue exclusion after TNF challenge (280ng/ml, 16h) in 
control and ethanol-fed WT and ASMase-/- mouse hepatocytes. Results are expressed as mean ± SEM (**p<0.01 
vs. control-fed WT hepatocytes, ##p<0.01 vs. EtOH+TNF  treated WT hepatocytes). 
 
We next addressed the contribution of TNFR1 and TNFR2 to alcohol-induced 
susceptibility to LPS and ConA. In agreement with previous studies reporting the 
sensitization of galactosamine to ConA-induced liver injury (Maeda, Chang et al. 2003), 
TNFR1 knockout mice were resistant while TNFR2 deficiency ameliorated ConA-
mediated liver damage following alcohol feeding, with similar findings observed for LPS 
(Figure 2.22 A-B). Thus, these findings indicate a critical role for ASMase in alcohol-
induced liver damage and sensitization to circulating and cell-bound TNF. 
 
 
Figure 2.22. TNFR1-deficiency prevents alcohol-induced liver injury and susceptibility to LPS and Con 
A. Serum ALT in control and ethanol-fed WT, TNFR1, TNFR2, and TNFR1/R2 null mice challenged with 
(A) LPS (5mg/kg, 24h) or (B) Con A (0.5mg/kg, 24h). Results are expressed as mean ± SEM (**p<0.01 vs. 
control-fed mice). 
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2.9. Pharmacologic ASMase inhibition protects against alcohol-induced hepatic 
ER stress and TNF susceptibility. 
To examine the potential relevance of these findings for ALD, we treated alcohol-fed 
mice with amitriptyline. Mice were fed alcohol for the first week and amitriptyline was 
administered daily i.p. for the last 3 weeks of alcohol intake. As seen, this approach 
significantly inhibited (>80%) the activation of ASMase by alcohol feeding (Figure 2.11 
A). Importantly, compared to control alcohol-fed mice, amitriptyline treatment 
decreased alcohol-induced accumulation of TG as seen in the H&E staining decreased 
hepatic macrosteatosis (Figure 2.23 A). Moreover, amitriptyline ameliorated the alcohol-
induced liver injury and the sensitization LPS (Figure 2.23 B). 
 
 
 
Figure 2.23. ASMase inhibition protects against alcohol-induced liver damage, steatosis and LPS 
susceptibility. (A) Hepatic H&E staining and (B) serum ALT after LPS challenge in control and 
amitriptyline-treated mice. Results are expressed as mean ± SEM (*p<0.05 vs. untreated mice, #p<0.01 vs 
ethanol-fed and LPS-treated mice).  
 
Furthermore, amitriptyline also decreased alcohol-induced activation of ER stress 
markers (Figure 2.24). Thus, these findings indicate that the pharmacologic inhibition of 
ASMase reproduces the effects of genetic ablation of ASMase on symptoms of alcohol-
induced liver injury. 
 
 
 
Figure 2.24. ASMase inhibition protects from alcohol-induced ER stress. Hepatic expression of phospho-
IRE1? and PDI in control WT mice, ethanol-fed WT mice and amitriptyline treated alcohol-fed WT mice. 
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In addition, since liver regeneration can modulate ALD progression, we next asked 
whether the lack of ASMase affects the ability of the liver to regenerate following partial 
hepatectomy (PH). As seen, hepatocyte proliferation examined by PCNA staining and 
final liver mass 10 days after PH were similar between wild type mice and ASMase null 
nice (Figure 2.25 A-B). Thus, these findings show that ASMase deficiency does not 
compromise liver regeneration further supporting the potential relevance of targeting 
ASMase in human ALD. 
 
 
 
Figure 2.25. Liver regeneration in ASMase null mice. (A) PCNA immuno-staining and (B) liver weight of 
WT and ASMase-/- mice after partial hepatectomy. 
 
 
2.10. Alcoholic hepatitis patients exhibit increased expression of ASMase, ER stress 
markers and StAR. 
Given the above results, we next addressed the expression status of ASMase in ALD. For 
this purpose, we compared ASMase mRNA levels in liver biopsies from patients with 
acute alcoholic hepatitis (AH), whose characteristics are shown in Table 2.1.  
 
  Control (n=13) Alcoholic Hepatitis (n=17) 
Age (Years) 56 (40-73) 50.14 (38-56) 
AST (U/L) 20.5 (20-22) 104.35 (3-222) 
ALT (U/L) 23.25 (13-32) 38.5 (26-90) 
Bilirrubin (mg/dL) 0.4 (0.3-0.6) 11.71 (4-21) 
?GT (U/L) 101.6 (48-210) 337.75 (123-1100) 
 
 
Table 2.1. Clinical and analytical characteristics of patients with acute alcoholic hepatitis. Numeric data is 
shown as median (interquartile range [IQR] 25-75) and categorical/nominal data in count.  AST: Aspartate- 
aminotransferase; ALT: Alanine-aminotransferase; ?GT:  ?-glutamyltransferase. 
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Compared to control subjects, patients with AH exhibited a 3-4-fold increase in the 
expression of ASMase as well as ER stress markers (Figure 2.26 A-C). Moreover, StAR 
mRNA levels increased 7 fold in liver biopsies from AH patients with respect to samples 
from control subjects (Figure 2.26 D). Thus, these findings support the potential 
relevance of ASMase in ALD. 
 
 
 
Figure 2.26. ASMase, ER stress markers and StAR expression in liver samples from patients with 
alcoholic hepatitis. Gene expression of (A) ASMase, (B) Grp78, (C) Chop and (D) Star by real time PCR 
analysis. Control group n=13 and AH group n=17 (*p<005 vs. control subjects). 
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Fatty liver disease is one of the most prevalent forms of liver disease worldwide, which 
encompasses both ALD and NAFLD. Although the etiology of both is different they share 
common mechanisms and biochemical features, including hyperglycemia, 
hyperinsulinemia, insulin resistance, hepatic steatosis and liver injury, which can progress 
to more advanced stages characterized by inflammation and fibrosis. The role of ASMase 
in NAFLD and ALD has been only examined in the context of glucose homeostasis and 
hepatic steatosis. The overall goal of the present thesis is to examine the relationship 
between ASMase and ER stress as this is a key mechanism in the regulation of insulin 
signaling and lipid metabolism resulting in activation of lipogenic pathways and hepatic 
steatosis. 
 
 
1. Role of ASMase in NAFLD 
 
Ceramide has been brought to the central stage of insulin resistance and T2DM (Chavez 
and Summers 2012). However, the role of ASMase in NAFLD has been less studied. To 
the best of our knowledge, only two studies focused on the role of ASMase in glucose 
homeostasis and hepatic steatosis (Deevska, Rozenova et al. 2009; Osawa, Seki et al. 
2010). This thesis reports for the first time the role of ASMase in key aspects of diet-
induced NAFLD, such as hepatic ER stress, autophagy, liver injury and LPS 
susceptibility.  
 
An important feature of NAFLD is its association with insulin resistance and hepatic 
steatosis. Unlike the observations in ASMase/LDL receptor double knockout 
(ALDLRDKO) mice (Deevska, Rozenova et al. 2009), findings in this thesis indicate 
that HFD-fed ASMase-/- mice exhibit glucose intolerance and reduced insulin sensitivity 
upon GTT and ITT tests, in line with a recent study using adenoviral ASMase 
overexpression in db/db mice (Osawa, Seki et al. 2010).  The impaired insulin sensitivity 
of ASMase-/- mice did not reflect defective hepatic parenchymal insulin signaling as insulin 
infusion into the portal vein phosphorylated IR? subunit and Akt to a similar degree 
observed in wild type mice. Although, these findings suggest that ASMase is dispensable 
for hepatic insulin-mediated IR? and Akt phosphorylation, they do not discard that 
ASMase may play a role in hepatic glucose transport specially knowing the potential 
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impact of FC and SM accumulation in ASMase-/- membranes that could affect its physic 
properties, specifically microdomains, and as a result influence membrane transporters 
translocation or activity (Liu, Leffler et al. 2004; Yuan, Hong et al. 2007; Sánchez-
Wandelmer, Dávalos et al. 2009; Stancevic and Kolesnick 2010). Nonetheless, it is 
worth considering that ASMase ablation prevents HFD-induced fatty liver and TG 
accumulation, and hence it is conceivable that unimpaired hepatic insulin signaling may 
be due to decreased TG seen in ASMase-/- mice. This possibility suggests that glucose 
intolerance and insulin insensitivity of ASMase-/- mice may reflect defects in extra-hepatic 
tissues (e.g. adipose and muscle). 
 
Another differential feature of our findings in ASMase-/- mice with respect to 
ALDLRDKO mice centers on ceramide homeostasis. While deletion of ASMase in the 
LDL receptor null background increased endogenous hepatic ceramide levels due to de 
novo synthesis in the ER by SPT activation (Deevska, Rozenova et al. 2009), ASMase 
deficiency per se results in decreased endogenous hepatic ceramide content, which is in 
agreement with previous findings (Osawa, Seki et al. 2010). Furthermore, we provide 
evidence that HFD increases liver ceramide via ASMase. Evidence in support for this 
relationship is dual. First, HFD induces gene expression of ASMase; and second,  
ASMase-/- mice are resistant to diet-mediated increase in hepatic ceramide levels. 
Moreover, results presented in this thesis indicate that ASMase is a key enzyme in 
ceramide metabolism since its deficiency affects gene expression of other enzymes of SL 
metabolism including ACDase and modulates hepatic SL profile reflected in 
accumulation of SM and S1P and decreased ceramide content. Cer/S1P ratio has been 
postulated as a biological rheostat, which controls cell fate (Brocklyn and Williams 
2012). ASMase-/- livers display decreased Cer/S1P ratio, which according to Cer/S1P 
rheostat model would be expected to activate survival pathways resulting in protection 
against HFD-mediated liver injury.   
 
The differential mode of ceramide generation between ALDLRDKO mice and our study 
is of relevance. De novo synthesized ceramide has been shown to play a critical role in 
glucocorticoids and diet-induced insulin resistance via inhibition of Akt activation 
(Holland, Brozinick et al. 2007). Moreover, hepatic ASMase-induced ceramide 
generation via adenoviral-mediated overexpression resulted in the activation of Akt and 
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glycogen synthase kinase-3? expression (Osawa, Seki et al. 2010). This outcome was 
accompanied by accumulation of S1P, which is known to activate Akt in hepatocytes 
(Osawa, Seki et al. 2010). Interestingly, we observed that ASMAse ablation also 
increased endogenous hepatic S1P levels, and this event is consistent with our data of 
enhanced insulin-mediated Akt phosphorylation in hepatocytes from ASMase-/- mice. 
Although HFD also increased S1P in wild type mice this response was less dramatic than 
that observed in ASMase-/- mice and suggests a threshold phenomenon for S1P to 
potentiate insulin-induced Akt phosphorylation. In parallel with enhanced hepatic S1P 
levels, ASMase-/- mice also displayed increased expression of ACDase, which is expected 
to provide sphingosine for its phosphorylation by sphingosine kinases, in particular 
Sphk2. Previous findings in C2C12 myotubes showed how ACDase overexpression 
prevented the inhibitory effects of FFAs on insulin signaling by decreasing ceramide 
content and increasing sphingosine levels (Chavez, Holland et al. 2005), thus supporting 
our findings in the liver. Finally, ACDase overexpression in ASMase absence also opens a 
door that invites to speculate about a potential regulation between these two lysosomal 
hydrolases in diet-induced obesity models of disease.  
 
Due to resistance of ASMase null mice to diet-induced hepatic macrovesicular steatosis; 
independently of the nutritional approach used (e.g. HFD or MCD feeding), we 
investigated potential underlying mechanisms. While ER stress stimulates lipogenesis via 
activation of ER-based transcription factor SREBP1c, autophagy has emerged as an 
alternative mechanism regulating intracellular lipid stores (macrolipophagy). 
Consequently, impaired hepatic autophagy could contribute to intracellular lipid 
accumulation and hepatic steatosis (Singh, Kaushik et al. 2009).  
 
Hepatic autophagy markers of ASMase null mice showed decreased levels of ATG7, 
suggesting that ASMase regulates proximal autophagic events. ATG7 is a critical gene in 
the organization of the autophagic process, including the conjugation of LC3B to PE at 
autophagosomal membranes (Ravikumar, Sarkar et al. 2010). However, decreased ATG7 
levels were accompanied by a paradoxical increased lipidation of LC3BII. Whether 
increased basal LC3BII/LC3BI reflects an adaptive mechanism to decreased ATG7 
expression remains to be further explored. Nevertheless, to establish if increased LC3BII 
levels in ASMase null mice reflect increased autophagic flux or decreased processing and 
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degradation at a lysosomal level, we incubated hepatocytes with autophagy inducer 
rapamycin and/or autophagy inhibitor chloroquine. Estimation of LC3BII levels in these 
conditions indicated that rapamycin-induced LC3BII degradation in the absence of 
ASMase reflects decreased lysosomal degradation and not increased autophagic flux. As a 
potential mechanism contributing to these observations, we examined lysosomal 
cholesterol content, and hypothesized that its accumulation may impair 
autophagosome/lysosome fusion and hence overall autophagy. Consistent with this 
possibility, we observed increased p62 levels in ASMase deficient hepatocytes compared 
to wild type hepatocytes. In line with this, confocal microscopy confirmed colocalization 
of FC with lysosomes in ASMase null hepatocytes, a key factor of autophagy impairment 
due to defective lysosome-autophagosome fusion, acidification and final proteolysis 
(Elrick, Yu et al. 2012). ASMase phenotype resembles Niemann Pick C fibroblasts 
phenotype, where unsterified cholesterol and SLs accumulate within lysosomes and 
regulate autophagy by increasing Beclin1 and LC3B II expression, thus promoting 
autophagosome maturation, while inhibiting autophagy at a lysosomal level due to 
impaired proteolysis (Lieberman, Puertollano et al. 2012).  In addition, findings in a cell 
model of NPC induced by U18666A, which causes lysosomal cholesterol accumulation, 
results in increased LC3BII levels due to decreased autophagosome degradation 
(Appelqvist, Nilsson et al. 2011). All together, these results indicate that increased 
autophagy is not the mechanism responsible for ASMase deficiency protection from 
hepatic steatosis.  
 
As an alternative mechanism involved in regulation of hepatic steatosis in ASMase null 
mice fed HFD, we next focused on hepatic ER stress. We observed that ASMase-/- mice 
are resistant to HFD-induced ER stress, accounting for the decreased expression of 
lipogenic pathways and transcription factor Srebp1c. Importantly, we also discarded that 
the defective ability of ASMase-/- mice to increase ER stress by HFD is mediated by an 
inherent defect of the ER, as ASMase-/- mice undergo the expected ER stress induced by 
tunicamycin or the bacterial AB5 subtilase cytotoxin (Paton, Beddoe et al. 2006). Thus, 
these results strongly suggest that ASMase is required for HFD-induced liver 
macrosteatosis by stimulating ER stress and subsequent activation of lipogenesis 
pathways (Figure D1). Since hepatic steatosis and ER stress are reciprocally regulated, it 
is conceivable that the reduced diet-induced ER stress in ASMase null mice may be a 
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consequence rather than a cause of decreased hepatic steatosis. However, exploiting the 
fact that ASMase null mice ER appear functional and able to sense stress, we treated 
ASMase null mice with Tm in vivo. As expected, Tm induced ER stress markers up-
regulation as well as hepatic steatosis in ASMase-/- mice, arguing that resistance to diet-
induced ER stress is the primary mechanism of decreased hepatic steatosis in ASMase 
null mice. 
 
 
Figure D1. ASMase role in NAFLD model. 
 
Finally, we focused on the role of ASMase in hepatocellular injury during HFD.  Our 
data indicate a critical role for ASMase in this cardinal feature of NAFLD, as ASMase-/- 
mice exhibit less liver injury compared to wild-type mice, and become resistant to HFD-
mediated sensitization to LPS-induced liver damage. These data are consistent with the 
role of ASMase as a critical intermediate in death receptor-induced cell death (García-
Ruiz, Colell et al. 2003; Marí, Colell et al. 2004; Dumitru and Gulbins 2006), and 
suggest that targeting ASMase may be of relevance in NAFLD. Moreover, this thesis 
demonstrated that a good portion of increased FC of ASMase-/- hepatocytes resides within 
lysosomes. Recent data demonstrated that changes in lysosomal membrane FC confer 
lysosomal stability, thus protecting from lysosomal membrane permeabilization-induced 
cell death (Appelqvist, Nilsson et al. 2011). Results presented in this thesis show that 
ASMase deficient primary mouse hepatocytes are protected from lysomotropic agent, 
MSDH-induced apoptosis. This protection is of relevance since it has been described 
that saturated FFA lipotoxicity in hepatocytes act upon lysosomal membrane 
permeabilization-induced cell death (Li, Berk et al. 2008). Hence, in addition to the 
decreased Cer/S1P ratio, lysosomal permeabilization-mitochondrial axis is a second 
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mechanism of protection against liver injury in NAFLD regulated by ASMase (Figure 
D1). 
 
Of interest, pharmacological ASMase inhibition is able to protect wild-type mice against 
HFD-mediated liver damage. Moreover, the correlation of ASMase expression and 
disease progression in NAFLD patients (Moles, Tarrats et al. 2010), lends further 
support for targeting ASMase in NAFLD. Thus, the findings suggest that targeting 
ASMase pharmacologically may be of benefit not only to prevent the action of major 
players in NAFLD, such as ER stress, but also to protect against diet-induced 
hepatocellular injury and liver dysfunction (Figure D1). 
?
?
2. Role of ASMase in ALD: 
 
To address the role of ASMase in ALD, this thesis characterized the response of ASMase 
knockout mice to in vivo alcohol intake. The observations in this thesis indicate that 
genetic ablation of ASMase prevents the adverse effects of chronic alcohol consumption 
including lipogenesis, fatty liver, ER stress, mitochondrial cholesterol trafficking, and 
hepatocellular susceptibility to cell-bound and circulating TNF.  
 
Of significance, this thesis shows that ASMase null mice are refractory to alcohol-induced 
ER stress. The resistance is specific for alcohol-induced ER stress and not due to an 
inherent defect in ER stress response, as ASMase null mice exhibit signs of ER stress 
following tunicamycin challenging. Moreover, tunicamycin treatment in ASMase null 
mice resulted in increased TG levels and steatosis, thus establishing a cause-and-effect 
relationship between ER stress and fatty liver. Therefore, the mechanism whereby 
ASMase null mice are resistant to alcohol-induced steatosis is their insensitivity to 
alcohol-induced ER stress.  
 
Interestingly, findings in this thesis indicate that the role of ASMase in alcohol-induced 
ER stress is independent of homocysteine, and that ASMase does not modulate alcohol-
induced hyperhomocysteinemia. In contrast with Lieber-DeCarli oral administration of 
alcohol model, previous studies using intragastric alcohol infusion model in mice 
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indicated a role for homocysteine in hepatic ER stress. Compared to our observations of 
3 fold higher plasma homocysteine in mice fed alcohol orally with respect to control 
mice, this effect was more pronounced (7-10 fold) in mice fed alcohol intragastrically (Ji 
and Kaplowitz 2003; Ji, Deng et al. 2004), suggesting a threshold phenomenon for 
homocysteine to mediate alcohol-induced hepatic ER stress. However, recent findings 
have reported that supplementing MCD diet with homocysteine attenuated MCD diet-
induced hepatic ER stress and protected mice against MCD-induced steatohepatitis 
despite a 7-10 fold increase in homocysteine levels (Henkel, Elias et al. 2009). Moreover, 
mice fed a control diet supplemented with homocysteine had a 3-6-fold elevation in 
plasma homocysteine but demonstrated no pathophysiologic changes (Henkel, Elias et al. 
2009). Thus, based on these findings it could be argued that alcohol-induced hepatic ER 
stress can be caused independently by increased homocysteine and ASMase activation, 
suggesting that the participation of the former might be determined by the severity of 
hyperhomocysteinemia (Figure D2).  
 
Based on the link between ceramide and ER stress (Carracedo, Lorente et al. 2006; 
Spassieva, Mullen et al. 2009; Epstein, Kirkpatrick et al. 2012), we hypothesized that 
ASMase activation per se could induce ER stress, accounting for the resistance of ASMase 
null mice to both NAFLD and ALD. To test this hypothesis, we exposed Hep G2 cells to 
human placenta ASMase, previously characterized for its acid pH optimum to generate 
ceramide (García-Ruiz, Marí et al. 2000). While exogenous ASMase increased expression 
of ER stress markers, incubation of cells with NSMase from Bacillus cereus failed to 
induce these changes. These findings fit with the notion that the effects of ceramide may 
depend on the site of intracellular generation and imply that the activation of ASMase in 
acidic endolysosomal compartments is functionally linked to ER homeostasis. Previous 
findings in HeLa cells reported the ability of ceramide to release Ca2+ from the ER to the 
cytosol (Pinton, Ferrari et al. 2001). Consistent with the key role of Ca2+ to maintain ER 
homeostasis and that ER Ca2+ loss results in ER stress (Feng, Yao et al. 2003), we 
provide evidence that ASMase-induced ceramide leads to ER stress by stimulating ER 
Ca2+ release. Indeed, we observed that the stimulation of ER Ca2+ release by thapsigargin 
was decreased in cells exposed to exogenous ASMase. Of interest, stimulation of Ca2+ 
release from ER by exogenous ASMase preceded the expression of ER stress markers. 
Overall, our findings fit with the concept that aberrant lipid composition in the ER 
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regulates SERCA and hence ER Ca2+ homeostasis (Fu, Yang et al. 2011). Whether 
ASMase activation modulates SERCA activity in the ER by perturbing ER membrane 
physical properties remains to be examined. In support for endolysosomal/ER 
relationship, previous findings in NPC1 disease have shown that stimulation of ER Ca2+ 
release via SERCA by thapsigargin or curcumin to the cytosol overcomes reduced 
lysosomal Ca2+ in NPC1 null cells, correcting endocytic transport (Lloyd-Evans, Morgan 
et al. 2008). Further work remains to be done to fully understand the mechanism 
whereby ASMase-induced ceramide generation in endolysosomes stimulates ER Ca2+ 
release. Since NPC1 disease is characterized by increased accumulation of endolysosomal 
cholesterol and sphingolipids, it is conceivable that NPC1, whose physiological role is to 
transfer cholesterol from lysosomes to ER, may contribute to the transfer of ceramide 
from endolysosomes to ER. 
 
The findings on cholesterol homeostasis in ASMase null mice deserve further 
consideration. In addition to the intrinsic liver phenotype characterized by increased SM 
levels, ASMase knockout mice exhibit high endogenous cholesterol content in liver. This 
finding is in agreement with recent reports relating cholesterol up-regulation in ASMase 
null mice with aging (Prinetti, Prioni et al. 2011).  Although SM and cholesterol are 
functionally associated (Ridgway 2000), the mechanism whereby cholesterol accumulates 
secondary to the build up of SM in ASMase null mice has remained incompletely 
characterized.  Results of this thesis showed increased expression of SREBP2 activation 
in the knockout mice, indicating that a potential source for the increase of cholesterol in 
the absence of ASMase derives from de novo cholesterol synthesis via the mevalonate 
pathway. Regardless of the source of hepatic cholesterol content we observed a defective 
trafficking of cholesterol to mitochondria in ASMase null mice that was associated with 
impaired expression of StAR, a mitochondrial cholesterol transporting polypeptide 
(Miller and Bose 2011). Given the increased basal cholesterol levels in ASMase null mice 
and the normal expression of StAR, it is conceivable that the trafficking of cholesterol to 
mitochondria may depend on stimulated up-regulation of StAR, which implies that the 
pre-existing StAR pool in basal ASMase null mice may be saturated with cholesterol.  
 
Moreover, this thesis provides evidence that StAR is an ER stress target gene. First, 
tunicamycin induces the expression of StAR, which is blunted by the ER stress inhibitor 
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TUDCA (Ozcan, Yilmaz et al. 2006). Second, the outcome in mice fed a high 
cholesterol diet demonstrates repression of SREBP2 and its regulated gene HMG-CoA 
reductase but not StAR, indicating that StAR regulation is independent from SREBP2. 
Our findings are consistent with previous data in NIH-3T3 cells showing that ER stress 
stimulated expression of StARD5 but not of StARD4 or MLN64 (Soccio, Adams et al. 
2005), implying a differential sensitivity of the individual members of the StART family of 
lipid transporting proteins to ER stress. Our findings, however, suggest a functional link 
between ER stress and mitochondrial cholesterol trafficking due to StAR up-regulation 
(Figure D2).  
 
 
Figure D2. ASMase role in ALD model. 
 
To address the potential relevance and applicability of the findings with the genetic 
ablation of ASMase, we addressed the effects of alcohol feeding in wild type mice treated 
in vivo with a pharmacological ASMase inhibitor. Although recent studies reported that 
ASMase inhibition by imipramine ameliorated alcohol-induced hepatic steatosis and 
insulin resistance (Liangpunsakul, Rahmini et al. 2012), the role of imipramine on 
alcohol-induced hepatic ER stress, lipogenesis, liver injury and TNF susceptibility was 
not investigated. Here, we show that amitriptyline treatment reduced alcohol-induced 
ER stress markers, fatty liver and protected against the sensitization to LPS-induced liver 
injury. Consistent with the functional relationship between TNF and ASMase, the 
resistance of ASMase null mice to the deleterious effects of alcohol was reproduced in 
mice deficient in TNFR1/R2. However, unlike TNF, which is critical for liver 
regeneration (Yamada, Webber et al. 1998; Tarrats, Moles et al. 2011), the deficiency of 
ASMase did not impair the recovery of the liver mass after partial hepatectomy. This 
feature is of significant clinical relevance as defects in liver regeneration is a serious 
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concern that can contribute to the fatal outcome in patients with acute alcoholic 
hepatitis. Moreover, consistent with the observations in the experimental model, our 
data indicate enhanced expression of ASMase, StAR and ER stress markers in liver 
biopsies from patients with alcoholic hepatitis. StAR up-regulation suggests increased 
mitochondrial cholesterol trafficking, however confirmation at this level in patients 
would require larger size samples to determine cholesterol content in isolated 
mitochondria.   
 
Overall, our study defines a previously unrecognized role of ASMase in ALD by inducing 
ER stress and suggests that targeting ASMase may be a novel and therapeutic option for 
the treatment of ALD without compromising liver regeneration. 
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The conclusions from this thesis are: 
 
1. ASMase is necessary for alcohol and diet-induced hepatic ceramide generation 
and its ablation results in a shift of hepatic SL content resulting in SM and S1P 
accumulation.  
 
2. ASMase counteracts diet-induced body weight gain and is required for diet-
mediated lipid storage in adipose tissue. 
 
3. ASMase contributes to maintenance of whole body glucose homeostasis but it is 
dispensable for early hepatic insulin signaling events. 
 
4. ASMase is essential for both nutritional and alcohol-induced hepatic steatosis. 
 
5. Although ASMase is important for appropriate hepatic autophagic flux, its 
impairment in the absence of ASMase plays a minimal role in resistance to diet-
induced hepatic steatosis. 
 
6. ASMase-mediated autophagy regulation likely resides at the lysosomal level by 
modulating lysosomal cholesterol homeostasis. 
 
7. ASMase-induced ceramide generation promotes ER stress. This role accounts for 
the resistance of ASMase null mice to both diet and alcohol-induced ER stress. 
 
8. ASMase is dispensable for alcohol-induced hyperhomocysteinemia. 
 
9. ASMase-mediated ER stress causes cholesterol trafficking to mitochondria 
contributing to alcohol-induced mitochondrial GSH depletion. 
 
10. The regulation of lysosomal and mitochondrial cholesterol by ASMase are 
important mechanisms involved in nutritional and alcohol-mediated liver injury 
and sensitization to circulating and cell-bound TNF. 
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11. ASMase targeting does not impair liver regeneration. 
 
12. Pharmacological ASMase inhibitors emerge as novel and promising agents in the 
treatment of both NAFLD and ALD. 
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